<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":3.288294,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpYCQ4EBUYPBUIeVlcQRwkRAg9WDQdVHFlAEVwFDgQVHElLVl1VXQkbVFJQUR1TVAEAAB0DQAoO","queueTime":0,"ttGuid":"0bb6c176ba2f48bf"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full">
<meta property="description" name="description" content="Hereditary ATTR V30M amyloidosis is a lethal autosomal dominant sensorimotor and autonomic neuropathy caused by deposition of aberrant transthyretin (TTR). I...">
<meta property="og:title" name="title" content="Frontiers | Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy">
<meta property="og:description" name="description" content="Hereditary ATTR V30M amyloidosis is a lethal autosomal dominant sensorimotor and autonomic neuropathy caused by deposition of aberrant transthyretin (TTR). I...">
<meta name="keywords" content="Amyloidosis,TTR,C5a receptor,Macrophages,amyloid clearance">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="10">
<meta name="citation_journal_title" content="Frontiers in Molecular Neuroscience">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Mol. Neurosci.">
<meta name="citation_issn" content="1662-5099">
<meta name="citation_doi" content="10.3389/fnmol.2017.00138">
<meta name="citation_firstpage" content="266403">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy">
<meta name="citation_keywords" content="Amyloidosis; TTR; C5a receptor; Macrophages; amyloid clearance">
<meta name="citation_abstract" content="Hereditary ATTR V30M amyloidosis is a lethal autosomal dominant sensorimotor and autonomic neuropathy caused by deposition of aberrant transthyretin (TTR). Immunohistochemical examination of sural nerve biopsies in patients with amyloidotic neuropathy show co-aggregation of TTR with several proteins; including apolipoprotein E, serum amyloid P and components of the complement cascade. Complement activation and macrophages are increasingly recognized to play a crucial role in amyloidogenesis at the tissue bed level. In the current study we test the effect of two C5a receptor agonists and a C5a receptor antagonist (PMX53) on disease phenotype in ATTR V30M mice. Our results indicate that amyloid deposition was significantly reduced following treatment with the C5a receptor agonists, while treatment with the antagonist resulted in a significant increase of amyloid load. Administration of the C5a receptor agonists triggered increased recruitment of phagocytic cells resulting in clearance of amyloid deposits.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2017/04/21">
<meta name="citation_publication_date" content="2017/05/10">
<meta name="citation_author" content="Fella, Eleni ">
<meta name="citation_author_institution" content="Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus">
<meta name="citation_author" content="Sokratous, Kleitos ">
<meta name="citation_author_institution" content="Electron Microscopy and Molecular Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus">
<meta name="citation_author" content="Papacharalambous, Revekka ">
<meta name="citation_author_institution" content="Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus">
<meta name="citation_author" content="Kyriacou, Kyriacos ">
<meta name="citation_author_institution" content="Cyprus School of Molecular Medicine, Nicosia, Cyprus">
<meta name="citation_author" content="Phillips, Joy ">
<meta name="citation_author_institution" content="Donald P. Shiley Bioscience Center, San Diego State University, San Diego, CA, USA">
<meta name="citation_author" content="Sanderson, Sam ">
<meta name="citation_author_institution" content="Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA">
<meta name="citation_author" content="Panayiotou, Elena ">
<meta name="citation_author_institution" content="Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus">
<meta name="citation_author" content="Kyriakides, Theodoros ">
<meta name="citation_author_institution" content="Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus">
<meta name="dc.identifier" content="doi:10.3389/fnmol.2017.00138">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy","author":[{"@type":"Person","name":"Eleni Fella","affiliation":["Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus","Cyprus School of Molecular Medicine, Nicosia, Cyprus"]},{"@type":"Person","name":"Kleitos Sokratous","affiliation":["Electron Microscopy and Molecular Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus","Bioinformatics Group, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus"]},{"@type":"Person","name":"Revekka Papacharalambous","affiliation":["Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus"]},{"@type":"Person","name":"Kyriacos Kyriacou","affiliation":["Cyprus School of Molecular Medicine, Nicosia, Cyprus","Electron Microscopy and Molecular Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus"]},{"@type":"Person","name":"Joy Phillips","affiliation":["Donald P. Shiley Bioscience Center, San Diego State University, San Diego, CA, USA"]},{"@type":"Person","name":"Sam Sanderson","affiliation":["Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA"]},{"@type":"Person","name":"Elena Panayiotou","affiliation":["Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus"]},{"@type":"Person","name":"Theodoros Kyriakides","affiliation":["Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus","Cyprus School of Molecular Medicine, Nicosia, Cyprus"]}],"datePublished":"2017-05-10","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2017","isPartOf":{"@type":"PublicationVolume","volumeNumber":"10","isPartOf":{"@type":"Periodical","name":"Frontiers in Molecular Neuroscience"}}},"citation":["https://doi.org/10.3389/fnmol.2017.00138"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/molecular-neuroscience" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Molecular Neuroscience</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=171&amp;specialtyid=0&amp;entitytype=2&amp;entityid=2031" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/molecular-neuroscience" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Molecular Neuroscience</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/brain-disease-mechanisms" data-event="iBarJournal-sections-a_id_2032">Brain Disease Mechanisms</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/methods-and-model-organisms" data-event="iBarJournal-sections-a_id_2034">Methods and Model Organisms</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/molecular-neuroscience-archive" data-event="iBarJournal-sections-a_id_2">Molecular Neuroscience Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/molecular-signalling-and-pathways" data-event="iBarJournal-sections-a_id_2033">Molecular Signalling and Pathways</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/neuroplasticity-and-development" data-event="iBarJournal-sections-a_id_2036">Neuroplasticity and Development</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/pain-mechanisms-and-modulators" data-event="iBarJournal-sections-a_id_2035">Pain Mechanisms and Modulators</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=171&amp;specialtyid=0&amp;entitytype=2&amp;entityid=2031" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/molecular-neuroscience" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Molecular Neuroscience</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/brain-disease-mechanisms" data-event="iBarJournal-sections-a_id_2032">Brain Disease Mechanisms</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/methods-and-model-organisms" data-event="iBarJournal-sections-a_id_2034">Methods and Model Organisms</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/molecular-neuroscience-archive" data-event="iBarJournal-sections-a_id_2">Molecular Neuroscience Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/molecular-signalling-and-pathways" data-event="iBarJournal-sections-a_id_2033">Molecular Signalling and Pathways</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/neuroplasticity-and-development" data-event="iBarJournal-sections-a_id_2036">Neuroplasticity and Development</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/pain-mechanisms-and-modulators" data-event="iBarJournal-sections-a_id_2035">Pain Mechanisms and Modulators</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/molecular-neuroscience" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Molecular Neuroscience</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/brain-disease-mechanisms" data-event="iBarJournal-sections-a_id_2032">Brain Disease Mechanisms</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/methods-and-model-organisms" data-event="iBarJournal-sections-a_id_2034">Methods and Model Organisms</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/molecular-neuroscience-archive" data-event="iBarJournal-sections-a_id_2">Molecular Neuroscience Archive</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/molecular-signalling-and-pathways" data-event="iBarJournal-sections-a_id_2033">Molecular Signalling and Pathways</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/neuroplasticity-and-development" data-event="iBarJournal-sections-a_id_2036">Neuroplasticity and Development</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/molecular-neuroscience/sections/pain-mechanisms-and-modulators" data-event="iBarJournal-sections-a_id_2035">Pain Mechanisms and Modulators</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/molecular-neuroscience/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=1&amp;fieldid=171&amp;specialtyid=0&amp;entitytype=2&amp;entityid=2031" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Mol. Neurosci.</span><span>, 10 May 2017</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Brain Disease Mechanisms</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 10 - 2017 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fnmol.2017.00138">https://doi.org/10.3389/fnmol.2017.00138</a></p><!----></div><!----><!----></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract">
<a id="h1" name="h1"></a>
<div class="authors"><span class="author-wrapper notranslate">
<img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="
Eleni Fella," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Eleni Fella<sup>1,2</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Kleitos Sokratous," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Kleitos Sokratous<sup>3,4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Revekka Papacharalambous" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Revekka Papacharalambous<sup>1</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Kyriacos Kyriacou," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Kyriacos Kyriacou<sup>2,3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Joy Phillips" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Joy Phillips<sup>5</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Sam Sanderson" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Sam Sanderson<sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Elena Panayiotou&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Elena Panayiotou<sup>1&#x02020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/83140" class="user-id-83140"><img class="pr5" src="https://loop.frontiersin.org/images/profile/83140/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Theodoros Kyriakides,*&#x;">Theodoros Kyriakides</a><sup>1,2*&#x02020;</sup></span></div>
<ul class="notes">
<li><span><sup>1</sup></span>Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</li>
<li><span><sup>2</sup></span>Cyprus School of Molecular Medicine, Nicosia, Cyprus</li>
<li><span><sup>3</sup></span>Electron Microscopy and Molecular Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</li>
<li><span><sup>4</sup></span>Bioinformatics Group, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus</li>
<li><span><sup>5</sup></span>Donald P. Shiley Bioscience Center, San Diego State University, San Diego, CA, USA</li>
<li><span><sup>6</sup></span>Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA</li>
</ul> 
<p>Hereditary ATTR V30M amyloidosis is a lethal autosomal dominant sensorimotor and autonomic neuropathy caused by deposition of aberrant transthyretin (TTR). Immunohistochemical examination of sural nerve biopsies in patients with amyloidotic neuropathy show co-aggregation of TTR with several proteins; including apolipoprotein E, serum amyloid P and components of the complement cascade. Complement activation and macrophages are increasingly recognized to play a crucial role in amyloidogenesis at the tissue bed level. In the current study we test the effect of two C5a receptor agonists and a C5a receptor antagonist (PMX53) on disease phenotype in ATTR V30M mice. Our results indicate that amyloid deposition was significantly reduced following treatment with the C5a receptor agonists, while treatment with the antagonist resulted in a significant increase of amyloid load. Administration of the C5a receptor agonists triggered increased recruitment of phagocytic cells resulting in clearance of amyloid deposits.</p> 
<div class="clear"></div>
</div>
<div class="JournalFullText">
<a id="h2" name="h2"></a><h2>Introduction</h2>
<p class="mb15">Hereditary ATTR V30M amyloidosis is a life-threatening progressive sensory-motor and autonomic peripheral neuropathy. ATTR V30M amyloidosis is caused by extracellular accumulation of misfolded transthyretin (TTR), subsequently creating insoluble aggregates of amyloid fibrils (<a href="#B50">Saraiva et al., 1984</a>). Even though there are more than a 100 mutations causing ATTR amyloidoses, the first discovered and by far the most common is ATTR V30M, which is due to a substitution of a valine with methionine in position 30 (Val30Met) of the TTR protein (<a href="#B2">Ando et al., 2005</a>).</p>
<p class="mb15">There is considerable variability in the age of onset and penetrance of hereditary ATTR V30M in different countries. Epigenetic and genetic factors are believed to contribute to this variability. Complement cascade components have been shown to co-precipitate with amyloid in various forms of amyloidotic neuropathy (<a href="#B21">Hafer-Macko et al., 2000</a>). Our group has previously identified polymorphisms in C1q to correlate with age of onset in a Cypriot cohort of ATTR V30M patients suggesting that complement C1q may be a modifier gene (<a href="#B12">Dardiotis et al., 2009</a>). We have recently demonstrated that C1q deficient ATTR V30M mice exhibit a 60% increase in amyloid deposition compared to their C1q efficient counterparts (<a href="#B43">Panayiotou et al., 2017</a>). C1q has also been shown to modulate beta-amyloid induced complement activation and neuronal loss in Alzheimer&#x02019;s disease (<a href="#B17">Fonseca et al., 2011</a>) as well as modulating phagocytosis of soluble pre-amyloid aggregates (<a href="#B46">Pisalyaput and Tenner, 2008</a>). A dual role for complement has been proposed, a protective effect from early components of complement (C1q opsonizes foreign material and phagocytes) and a detrimental effect from late components such as C3a and C5a exarcebating neuroinflammation (<a href="#B17">Fonseca et al., 2011</a>). Late component C5a is produced following the activation of any of the three pathways of the complement cascade system. The C5 complement system factor is cleaved by C5 convertases producing the C5a and C5b molecules. C5a acts as an anaphylactic molecule by attracting C5a receptor bearing cells including macrophages and neutrophils leading to a pro-inflammatory response (<a href="#B35">Mathern and Heeger, 2015</a>). Activation of the C5a receptor in the CNS could have a detrimental role leading to neurotoxicity or a neuroprotective role through phagocytosis (<a href="#B16">Fonseca et al., 2009</a>). However, the effects of C5a receptor activation by the C5a anaphylatoxin in ATTRV30M amyloidosis have not been elucidated yet.</p>
<p class="mb15">More recently it has been shown that anti-serum amyloid P antibodies admnistered to AA amyloidotic mice resulted in an extensive &#x0201C;complement-dependent, macrophage-derived&#x0201D; response which reduced the amount of amyloid deposition (<a href="#B6">Bodin et al., 2010</a>). This observation has been extended successfully in a Phase 1 study in humans (<a href="#B48">Richards et al., 2015</a>).</p>
<p class="mb0">The objective of the current study was to elucidate further the role of the complement in the pathogenesis of ATTR V30M amyloidosis and investigate the possibilty of therapeutically manipulating complement to eliminate amyloid deposit. We have administered two C5a receptor agonists, a full C5a receptor agonist and EP67 (a response-selective C5a receptor agonist deprived of C5a-like anaphylatoxin activity), and a C5a receptor antagonist (PMX53) and examined disease phenotype in ATTR V30M mice after 1 week. We show that treatment with the C5a receptor agonists significantly ameliorated amyloid deposition while C5a receptor antagonist PMX53 exacerbated amyloid deposits. We have also carried out mass spectrometry-based proteomic analysis, comparing the proteome of animals with the highest amount of amyloid and the lowest amount of amyloid. This analysis has shown substantial phagocytic cell activation, as well as the increased expression of proteolytic peptidases accompanying the reduction in amyloid deposition.</p>
<a id="h3" name="h3"></a><h2>Materials and Methods</h2>
<h3 class="pt0">Animals and Tissue Handling</h3>
<p class="mb15">The previously published mouse model of ATTR V30M neuropathy (<a href="#B28">Kohno et al., 1997</a>) was kindly donated by Dr. M. Saraiva. These animals are knockouts for murine TTR and have been bred to carry the human V30M mutated cDNA in the form of a transgene in a homozygous state (mTTR<sup>&#x02212;/&#x02212;</sup>hTTR<sup>Met30+/+</sup>). Real time PCR was used to ensure that all animals included in the experiments had the same copy number of human TTR transgenes. All animals used for the experiments were 13&#x02013;14 months old since at this age amyloid deposits are well established.</p>
<p class="mb15">All animals were kept in a regular 12-h light-12 h dark cycle and were given free access to water and food, under SPF conditions. Animals were separated in cages depending on the molecule they were treated with. Four groups of animals were included for study; one group was treated with PMX53 (kindly provided by Cephalon USA), one group with the full C5a receptor agonist molecule (purchased from Anaspec), one group with the modified C5a receptor agonist, EP67 (<a href="#B49">Sanderson et al., 2012</a>) and finally there was a control group. Each group was comprised of six animals while the treatment period lasted for 1 week, during which each molecule was added to the animals&#x02019; water source at 20 &#x003BC;g/ml. The control group animals only received water without the addition of any other compound. All animal involving experiments were carried out in accordance to the 86/609/EEC Directive. Also, a project license was obtained from the Cyprus Veterinary Services approving the project and methodology (License Number: CY/EXP/P.L6/2010).</p>
<p class="mb0">Mice were anesthetized and then euthanized using Tribromoethanol (Avertin) through IP injection at a dose of 250 mg/Kg. The animals were then exsanguinated via PBS perfusion to reduce the contribution of plasma in tissue measurements. Tissues were processed for immunohistochemistry by carrying out overnight 4% PFA fixation followed by wax embedding or were frozen and kept at &#x02212;80&#x000B0;C for immunoblotting. Amyloid deposition assessment was confined to stomach tissue since this tissue is heavily involved in amyloid deposition at an early age in this particular mouse model of ATTR V30M neuropathy.</p>
<h3>Genotyping</h3>
<p class="mb0">Animals were genotyped using the PCR method. Primers for the mouse TTR gene (mTTR F 5&#x02032;&#x02013;CTG ACC CAT TTC ACT GAC ATT T&#x02013;3&#x02032; &#x00026; mTTR R 5&#x02032;&#x02013;CAA ATG GGA ACC TGG AAC C&#x02013;3&#x02032;); the human mutated transgene (hMET30 F 5&#x02032;&#x02013;TGCTGATGACACCTGGGAGC&#x02013;3&#x02032; and hMET30 R 5&#x02032;TCAGGTTCCTGGTCACTTCC&#x02013;3&#x02032;) were utilized for screening with annealing temperature at 58&#x000B0;C.</p>
<h3>Amyloid Plaque Visualization and Quantification</h3>
<p class="mb0">Thioflavin S staining combined with TTR immunofluorescence were used to identify TTR specific amyloid deposits in paraffin sections obtained from stomach tissue. Paraffin sections were deparaffinized and hydrated to distilled water. Sections were then stained with Mayer&#x02019;s hemeatoxylin for 5 min, washed further with distilled water and then stained with aqueous 1% Thioflavin S solution (T1892-25G) for a further 5 min and finally differentiated in 50% ethanol before been rinsed with distilled water and then mounted using the DAKO Fluorescence Mounting Medium (S3023). Thioflavin S positive deposits were further confirmed to be amyloid by Congo Red (Figures <a href="#F1">1Bi,ii</a>). Plaques positive for both Thioflavin S and hTTR were measured using the ImageJ software set to measure yellow (570&#x02013;585 nm; Figures <a href="#F1">1Biii&#x02013;Bvi</a>). TTR amyloid plaques were measured over the entire area of stomach section, a percentage of the surface area occupied by plaques was calculated and an average percentage obtained over five serial sections.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 1</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg" name="figure1" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg" alt="www.frontiersin.org" id="F1" loading="lazy">
  </picture>
</a>
<p><strong>Figure 1. Amyloid deposition: amyloid plaques were quantified through Thioflavin-S staining (A).</strong> All groups exhibited significant difference from one another, with the PMX53 treated mice having the greatest amount of deposition and the full agonist treated group having the lowest recorded amount. <i>n</i> = 6/group, data presented as mean &#x000B1; 1 SD. *<i>p</i> &#x0003C; 0.05, **<i>p</i> &#x0003C; 0.01, ***<i>p</i> &#x0003C; 0.001. <strong>(B)</strong> Amyloid plaque in the stomach that stains with Congo red and exhibits apple green birefringence <strong>(Bi,ii)</strong>. The same plaque stains Thioflavin-S positive <strong>(Biii)</strong> and is composed of human transthyretin (TTR; <strong>Biv</strong>). The area of co-localization of Thioflavin-S and TTR labeling appears yellow <strong>(Bv)</strong> and morphometric measurements are carried out with the ImageJ software <strong>(Bvi)</strong>. Scale bar = 150 &#x003BC;m.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<h3>Serum Elisa Method</h3>
<p class="mb0">Serum human TTR was measured using enzyme-linked immunosorbent assay (ELISA) from four animals from each of the four groups. Blood samples were collected, without sacrificing any of the animals, from the orbital sinus in the absence of anticoagulant. The samples were allowed to stand at room temperature for approximately 30 min to coagulate. They were then centrifuged at 3500 rpm for 10 min and the top layer was collected in order to obtain the serum. Samples were diluted 1/50,000 using the supplied mix diluent from the kit used (Abnova TTR Human ELISA Kit KA0495) and the procedure was carried out as outlined by the supplier. Absorbance was measured at 450 nm using a microplate reader.</p>
<h3>Western Blots and Densitometry</h3>
<p class="mb15">Stomach homogenate (tissue lysed with RIPA buffer and protease inhibitors under sonication) was separated via reducing SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% BSA for 1 h at room temperature. The membranes were then incubated overnight at 4&#x000B0;C with the appropriate primary antibody. Specific antibodies were then visualized using the Super Signal West Femto Maximum Sensitivity Substrate (Thermo Fisher 34095) after incubating with the required HRP conjugated secondary antibody for 1 h at room temperature. Blots were repeated in triplicates and were visualized using the UVP bio-imaging system.</p>
<p class="mb15">The antibodies used for immunoblotting were against: BiP (anti-rabbit Santa Cruz sc-13968 1/350), C1q (anti-rabbit Santa Cruz sc-27661 1/100), Caspase-3 (anti-rabbit Enzo Life Sciences ALX-210-806-C100 1/1000), CD68 (anti-rabbit Santa Cruz sc-9139 1/150), CD88 (anti-mouse Santa Cruz sc-53795 1/100), ELANE (anti-rabbit Abcam ab68672 1/1000), F4/80 (anti-rabbit Santa Cruz sc-25830 1/100), IL-36&#x003B3; (anti-goat Santa Cruz sc-168163 1/100), Ly6G (anti-mouse Antibodies online ABIN361224 1/1000) and Properdin (anti-rabbit Santa Cruz sc-68367 1/100). The appropriate HRP conjugated secondary antibodies were used, anti-mouse (Santa Cruz SC-2031 1/5000), anti-rabbit (Santa Cruz SC-2004 1/5000).</p>
<p class="mb0">ImageJ was used to carry out densitometry calculations, while all bands were normalized against a GAPDH loading control (Santa Cruz sc-25778 1/1000), while the same reference sample was in all westerns to allow cross-gel comparison).</p>
<h3>Immunohistochemistry</h3>
<p class="mb15">Paraffin sections from animals&#x02019; stomachs were deparaffinized and hydrated to distilled water. Sections were then blocked with 5% BSA solution in PBS for 1 h at room temperature and then incubated with the appropriate primary antibody overnight at 4&#x000B0;C. The slides were then washed and incubated with the appropriate secondary antibody for 1 h at room temperature. Finally, DAPI staining was used to label the cells&#x02019; nuclei (Sigma Aldrich D9542) before been mounted using the DAKO Fluorescence Mounting Medium (S3023). Pictures were taken using a Zeiss AXIOIMAGER M2 fluorescence microscope.</p>
<p class="mb0">The primary antibodies used were against: BiP (anti-rabbit Santa Cruz sc-13968 1/100), Caspase-3 (anti-rabbit Santa Cruz sc-7148 1/500), CD68 (anti-goat Santa Cruz sc-7084 1/50), ELANE (anti-rabbit Abcam ab68672 1/100), Lamp-1 (anti-rabbit Cell signaling 8653 1/800) and human TTR (anti rabbit DAKO A000202 1/500). The appropriate Invitrogen Alexa Fluor 555 and 488 fluorescence secondary antibodies were used, anti-rabbit (A-21428 and A-11008 1/2000) and anti-goat (A-21432 and A-11055 1/2000).</p>
<h3>Mass Spectrometry-Based Proteomics</h3>
<p class="mb0">Frozen stomach tissue samples from three animals from two groups of animals (full agonist treated and PMX53 treated) were incubated in lysis buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% (v/v) SDS, 1X protease inhibitors) for 30 min on ice, followed by sonication for 30 s (50% pulse) using Model 150VT (Biologics Inc., Virginia, USA). Lysates were clarified by centrifugation at 12,000 rpm for 20 min at 4&#x000B0;C. The supernatant was collected and proteins were precipitated in tenfold excess volume of ice-cold acetone overnight at &#x02212;20&#x000B0;C and subsequently resuspended in urea buffer (8 M urea, 50 mM ammonium bicarbonate). Protein concentration was determined using BCA protein assay. For each sample, 100 &#x003BC;g of protein was transferred to a new tube, reduced with DTT (10 mM final concentration) for 30 min at 60&#x000B0;C and alkylated with iodoacetamide (15 mM final concentration) for 15 min in dark at room temperature followed by fourfold dilution in 50 mM ammonium bicarbonate. Proteins were digested with 2 &#x003BC;g of proteomics grade trypsin (Roche Diagnostics GmbH, Mannheim, Germany) at 37&#x000B0;C for 18 h. Digestion was quenched by addition of TFA to a final concentration of 0.5%. Peptides were desalted and purified using reverse phase solid phase extraction cartridges (Sep-Pak C18, Waters, Vienna, Austria) and eluates were lyophilized using a centrifugal vacuum concentrator. Peptide pellets were re-dissolved in 1% acetonitrile, 0.1% formic acid (mobile phase A) to yield an approximate concentration of 200 ng/&#x003BC;L (determined by NanoDrop measurement at 280 nm). The peptide separation was performed on a Waters nanoAcquity UPLC system (Waters Co., Wilmslow, UK). Peptides were loaded onto a C18 column (Acquity UPLC M-Class, Peptide CSH, 75 &#x003BC;m &#x000D7; 250 mm, 1.7 &#x003BC;m, 130 &#x000C5;) and eluted with a linear gradient from 5% mobile phase B (0.1% formic acid in acetonitrile) to 40% mobile phase B over 175-min. Peptides were analyzed on a Waters Synapt G2Si HDMS instrument (Waters Co., Wilmslow, UK) operated in ion mobility mode using the UDMS<sup>E</sup> approach (<a href="#B14">Distler et al., 2014</a>). Each sample analyzed in triplicate. Raw mass spectrometry data were analyzed using Progenesis QI for proteomics software (version 3.0) and were subjected to protein identification against the SwissProt mouse reference proteome database (version July 2016, 16761 sequences plus human TTR, P02766) using the MS<sup>e</sup> peptide identification method. The searching parameters used were: trypsin digestion, 1 missed cleavage, FDR &#x0003C;4%. The identifications were refined using the following parameters: score &#x02265;5, hits &#x02265;2, sequence length &#x02265;6, description not containing probable, predictive, potential or putative.</p>
<h3>Statistical Analyses</h3>
<p class="mb0">Statistical analysis was performed using GraphPad Prism version 5.00 for Windows (GraphPad software, San Diego, CA, USA) where one-way analysis of variance (ANOVA) followed by Tukey&#x02019;s <i>post hoc</i> test was carried out. Using this information, graphical charts representing the data were prepared.</p>
<a id="h4" name="h4"></a><h2>Results</h2>
<h3 class="pt0">Amyloid Deposition in the Stomach</h3>
<p class="mb0">Following administration of all three agents for 1 week, all animals were sacrificed (including untreated, age-matched control hTTRV30M animals) and amyloid deposition was examined by combined Thioflavin S staining and TTR immunofluorescence (Figure <a href="#F1">1A</a>). There was a 160% increase in amyloid load following the administration of PMX53 for a week when compared to the control hTTRV30M mice. Administration of the C5a receptor agonist EP67 resulted in a 42% decrease in deposited amyloid. Further amyloid reduction was recorded following administration of the full receptor agonist (65%).</p>
<h3>hTTR Levels in Serum and Stomach</h3>
<p class="mb0">The levels of human V30M TTR were measured in the serum of all mice participating in the study using the ELISA at the end of the treatment period. Our results indicate that the amount of hTTR found in the serum remains unaffected for all four groups (Figure <a href="#F2">2A</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 2</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg" name="figure2" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg" alt="www.frontiersin.org" id="F2" loading="lazy">
  </picture>
</a>
<p><strong>Figure 2. Amount of hTTR found in the serum and stomach: (A)</strong> TTR in the serum was quantified using enzyme-linked immunosorbent assay (ELISA). Results show that no statistical difference in the amount of circulating TTR was recorded between the four groups of mice. <i>n</i> = 4/group, data presented as mean &#x000B1; 1 SD. <strong>(B)</strong> hTTR levels in the stomach were measured via immunoblotting. Significant decrease was observed in the mice treated with the two agonist molecules when compared to the untreated control mice. <i>n</i> = 6/group. Data presented as mean &#x000B1; 1 SD. Indicative images from each group shown in <strong>(Bi&#x02013;iv)</strong>. *<i>p</i> &#x0003C; 0.05, **<i>p</i> &#x0003C; 0.01, ***<i>p</i> &#x0003C; 0.001.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb0 w100pc float_left mt15">The amount of pre-fibrillar hTTR was measured in stomach tissue of all animals (Figure <a href="#F2">2B</a>). Our results indicated significantly less hTTR between the two groups treated with the agonists and the control animals. The PMX53 group did not significantly differ from the control group.</p>
<h3>Phagocytic Cell Markers in Stomach Tissue</h3>
<p class="mb15">The PMX53 molecule is a known C5a receptor (CD88) inhibitor, while the other two molecules used are agonists for the receptor. Even though C5a receptors (C5R1, CD88) are ubiquitously expressed on a variety of cells, they are most prominently expressed on the surface of neutrophils and macrophages (<a href="#B40">Monk et al., 2007</a>), therefore, identifying markers for these two cell types were used to establish their presence in the experimental animals.</p>
<p class="mb0">CD88, the ubiquitous C5a receptor was found to be significantly elevated in both the full agonist and EP67 groups when compared to the control animals, whereas the receptor was severely decreased in the animals treated with PMX53 (Figure <a href="#F3">3A</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 3</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg" name="figure3" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg" alt="www.frontiersin.org" id="F3" loading="lazy">
  </picture>
</a>
<p><strong>Figure 3. Expression of phagocytic cell markers in stomach tissue: (A)</strong> The expression of CD88 was measured by immunoblotting indicating a decrease in the marker in both the untreated group and the group treated with the PMX53 antagonist, while the two groups treated with the agonists exhibited the greatest level of expression. Similar effects were observed with Neutrophil elastase <strong>(B)</strong>, Ly6G <strong>(C)</strong> and IL-36&#x003B3; <strong>(D)</strong>. Immunoblots for the macrophage specific markers F4/80 <strong>(E)</strong> and CD68 <strong>(F)</strong> however indicate their overexpression in the group of mice treated with the modified agonist molecule EP67, while the group treated with the PMX53 antagonist exhibited the lowest levels of expression for both markers. <i>n</i> = 6/group data presented as mean &#x000B1; 1 SD. *<i>p</i> &#x0003C; 0.05, **<i>p</i> &#x0003C; 0.01, ***<i>p</i> &#x0003C; 0.001.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Neutrophil elastase (ELANE) and Ly6G are both well characterized markers of neutrophils (<a href="#B57">Talukdar et al., 2012</a>; <a href="#B1">Amsalem et al., 2014</a>). ELANE is a chymotrypsin like serine proteinase which is mainly secreted by neutrophils during inflammation in order to induce the clearance of bacteria and host tissue (<a href="#B5">Belaaouaj et al., 2000</a>). ELANE is also very similar to other immune system cytotoxic serine proteases such as granzymes and cathepsin G (<a href="#B59">Thomas et al., 2014</a>). Our results show that ELANE is highest in the group of mice treated with the full agonist molecule, which retains its anaphylactic properties, while it is lower in the group treated with the agonist EP67 which activates C5aR receptors on macrophages but less so on neutrophils (Figure <a href="#F3">3B</a>). The PMX53 treated animals were found to express the lowest levels of ELANE even though the change was not statistically significant when compared to the untreated control group.</p>
<p class="mb15">Ly6G is s neutrophil specific marker which has been previously used to deplete neutrophils in mice (<a href="#B45">Pillay et al., 2013</a>). Our data indicate a similar pattern as with ELANE, where the groups treated with the agonist molecules exhibit the highest level of Ly6G, while the mice treated with the PMX53 antagonist molecule exhibit the lowest amount of Ly6G detected (Figure <a href="#F3">3C</a>).</p>
<p class="mb15">Interleukin 36&#x003B3; (IL-36&#x003B3;) has been found to be up-regulated in a number of inflammatory diseases and is believed to be expressed by both neutrophils and macrophages (<a href="#B7">Bozoyan et al., 2015</a>; <a href="#B29">Kovach et al., 2016</a>; <a href="#B33">Macleod et al., 2016</a>). Our results also indicate that IL-36&#x003B3; is highest in the group of mice treated with the full agonist and the lowest in the group treated with the PMX53 molecule (Figure <a href="#F3">3D</a>).</p>
<p class="mb15">The murine F4/80 (EGF-like module-containing mucin-like hormone receptor-like 1, Emr1 homolog) is a well-known marker of murine macrophage populations (<a href="#B3">Austyn and Gordon, 1981</a>), while CD68 is found to be expressed on all macrophages (<a href="#B41">Murray and Wynn, 2011</a>). The PMX53 treated mice exhibited the lowest levels of both macrophage markers, while both groups of mice treated with the agonist molecules displayed greater expression of the two markers when compared to the untreated control (Figures <a href="#F3">3E,F</a>). However, the mice treated with EP67 display the greatest levels of macrophages, even when compared to the group treated with the full agonist.</p>
<p class="mb0">Results yielded from the liquid chromatography&#x02014;tandem mass spectrometry (LC-MS/MS) analysis comparison between the group with the highest amyloid deposition (PMX53 treated) and the group with the lowest amount of amyloid (full agonist treated) revealed a number of macrophage and neutrophil related markers which were highly expressed in the animals with the lowest amount of amyloid (Supplementary Table S1).</p>
<h3>Immunofluorescence with Neutrophil and Macrophage Markers</h3>
<p class="mb15">In order to examine the co-expression of the macrophage and neutrophil markers with the amyloid plaques serial deparaffinized stomach sections were immunostained with antibodies specific for CD68, neutrophil elastase/ELANE, hTTR and Thioflavin-S.</p>
<p class="mb0">The untreated group displays minimal co-localization of &#x003B1;-CD68 with the Thioflavin-S/hTTR positive plaques, while there is no co-localization with &#x003B1;-ELANE (Figure <a href="#F4">4A</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 4</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg" name="figure4" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg" alt="www.frontiersin.org" id="F4" loading="lazy">
  </picture>
</a>
<p><strong>Figure 4. Amyloid plaque infiltration by macrophages and neutrophils: serial sections stomach sections from mice representing the four groups of mice were stained with Thioflavin-S, &#x003B1;-TTR, the pan-macrophage marker &#x003B1;-CD68 and the neutrophil marker &#x003B1;-Neutrophil elastase (ELANE).</strong> Immunofluorescence on the stomach tissue from the untreated mouse indicates the complete absence of neutrophils from the plaque, while there is some co-expression with CD68 <strong>(A)</strong>. A similar pattern was observed with the mouse treated with the PMX53 antagonist molecule <strong>(B)</strong>, while complete co-localization with both CD68 and ELANE was observed in the mouse treated with the full agonist molecule <strong>(C)</strong>. Immunofluorescence on the mouse treated with the modified agonist EP67 however revealed complete plaque co-localization with CD68 and the complete absence of ELANE from the region <strong>(D)</strong>. Scale bar = 75 &#x003BC;m.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">The sections from the mice treated with the C5a antagonist PMX53 exhibit an even lower level of &#x003B1;-CD68 co-localization, probably indicative of the fact that there&#x02019;s a decreased recruitment due to inhibition of the receptor (Figure <a href="#F4">4B</a>).</p>
<p class="mb0">In the group treated with the full agonist there was complete plaque co-localization with both &#x003B1;-CD68 and &#x003B1;-ELANE (Figure <a href="#F4">4C</a>). The EP67 treated group however exhibited mainly co-localization with &#x003B1;-CD68 positivity with a much less neutrophil recruitment (Figure <a href="#F4">4D</a>).</p>
<h3>Complement Markers in Stomach Tissue</h3>
<p class="mb15">The complement system has been previously shown to be involved with amyloidogenesis and the pathogenesis of the disease. Therefore, markers for both the classical and alternative complement system were analyzed using immunoblotting.</p>
<p class="mb0">The classical complement pathway is initiated through the C1q molecule. C1q itself is produced by peripheral tissue phagocytic cells (<a href="#B44">Petry et al., 1991</a>). The group of mice treated with the full agonist molecule express the greatest amount of C1q; even though the mice treated with the EP67 molecule also exhibit elevated amounts of C1q when compared to the untreated control animals. On the contrary, the animals treated with the C5aR inhibitor, PMX53; do not display any significant difference from the control animals (Figure <a href="#F5">5A</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 5</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg" name="figure5" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg" alt="www.frontiersin.org" id="F5" loading="lazy">
  </picture>
</a>
<p><strong>Figure 5. Expression of complement markers: the expression of the classical complement pathway protein C1q was measured by immunoblotting in stomach tissues of all the animals from the four groups of mice (A).</strong> The group treated with the full agonist molecule exhibited the highest levels of C1q which was statistically significant when compared to the rest of the groups, while the mice with the modified agonist also exhibited a significant increase when compared to the untreated control group. Similar effects were observed via immunofluorescence. Properdin, the alternative complement pathway marker, also presented an analogous pattern so that the group of mice treated with the two agonists also expressed the greatest amount of the protein <strong>(B)</strong>. <i>n</i> = 6/group, data presented as mean &#x000B1; 1 SD. B&#x00026;D Scale bar = 150 &#x003BC;m. *<i>p</i> &#x0003C; 0.05, **<i>p</i> &#x0003C; 0.01, ***<i>p</i> &#x0003C; 0.001.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Properdin (factor P) is a unique positive regulator of complement activation which functions by stabilizing the alternative pathway convertases (<a href="#B53">Smith et al., 1984</a>) so that it may be used as an alternative complement pathway marker.</p>
<p class="mb15">Our results indicate the greatest amount of properdin in the animals treated with the full agonist, followed by the EP67 treated group (Figure <a href="#F5">5B</a>). The PMX53 treated mice express the same amount of properdin as the control group.</p>
<p class="mb0">These results were also corroborated through the LC-MS/MS analysis, where the complement cascade proteins, along with properdin, were found to be higher in the group of mice treated with the full agonist molecule when compared to the group of mice treated with the PMX53 molecule (Supplementary Table S1).</p>
<h3>Stress and Apoptosis Markers in Stomach Tissue</h3>
<p class="mb0">The presence of extracellular amyloid deposits and pre-fibrillar hTTR species have been shown to increase endoplasmic reticulum stress through the activation of the classical unfolded protein response pathways in tissues not specialized in hTTR synthesis (<a href="#B58">Teixeira et al., 2006</a>; <a href="#B32">Macedo et al., 2007</a>). Our results indicate that the mice treated with PMX53 possess the highest levels of BiP which is in accordance with the high levels of amyloid deposits. The groups treated with the agonists exhibit significantly less amount of BiP than the PMX53 mice even though they do not appear to be lower than the control untreated mice (Figure <a href="#F6">6A</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 6</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg" name="figure6" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg" alt="www.frontiersin.org" id="F6" loading="lazy">
  </picture>
</a>
<p><strong>Figure 6. Expression of stress markers: the expression of BiP was measured by immunoblotting (A)</strong> in the stomach tissues of all animals from the four groups. While the animals from the groups treated with the two agonists and the untreated group displayed comparable levels of BiP, the group treated with the PMX53 antagonist exhibited significantly greater amounts of the cellular stress marker. Comparable effects were observed via immunostaining. Similarly, immunoblotting using the apoptotic marker Caspase-3 displayed a significantly increased expression in the group of mice treated with PMX53 <strong>(B)</strong>. <i>n</i> = 6/group, data presented as mean &#x000B1; 1 SD. B&#x00026;D Scale bar = 150 mm. *<i>p</i> &#x0003C; 0.05, **<i>p</i> &#x0003C; 0.01, ***<i>p</i> &#x0003C; 0.001.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<p class="mb15 w100pc float_left mt15">Immunostaining of nerve biopsies from hereditary V30M patients carried out with an activated caspase-3 specific antibody has shown that expression of this apoptotic marker increases as the disease progresses (<a href="#B54">Sousa et al., 2001</a>). We have also observed a significant increase in Caspase-3 in the group with the highest amyloid load (PMX53 treated) as compared to the other groups, even though no significant difference was recorded between the agonists treated groups and the control group (Figure <a href="#F6">6B</a>).</p>
<p class="mb0">The LC-MS/MS analysis has revealed a great number of ER related stress markers which appear greatly increased in the PMX53 treated group of mice, as well as a number of Caspases and apoptotic markers (Supplementary Table S2).</p>
<h3>Lysosomal Marker in Stomach Tissue</h3>
<p class="mb0">Lysosomal-associated membrane protein 1 (Lamp-1) is a glycoprotein known to primarily reside across lysosomal membranes (<a href="#B11">Carlsson and Fukuda, 1989</a>), also Lamp-1 may be expressed on the cell surface following lysosomal fusion with the cell membrane during phagocytosis (<a href="#B27">Kima et al., 2000</a>). During the formation and maturation of the phagosome, Lamp-1 will specifically become localized on the phagosomes (<a href="#B56">Sugaya et al., 2011</a>), so that, expression of Lamp-1 signifies the final steps of activated phagocytosis. Serial deparaffinized stomach sections from a mouse treated with the full agonist and EP67 exhibit the complete co-localization of &#x003B1;&#x02013;Lamp-1 with &#x003B1;&#x02013;CD68 and &#x003B1;&#x02013;ELANE. On the contrary, the PMX53 treated mouse does not exhibit any co-localization with ELANE, CD68, or LAMP-1(Figure <a href="#F7">7A</a>). On the contrary, sections from an animal treated with PMX53 display no plaque co-localization with Lamp-1 (Figure <a href="#F7">7B</a>).</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 7</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg" name="figure7" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg" alt="www.frontiersin.org" id="F7" loading="lazy">
  </picture>
</a>
<p><strong>Figure 7. Amyloid plaque co-localization with the lysosomal marker: immunofluorescence of serial stomach sections from the group treated with the full agonist molecule (A)</strong> and the PMX53 antagonist <strong>(B)</strong> show the complete co-expression of the amyloid plaque with Lamp-1 <strong>(Ai)</strong> in the mouse treated with the agonist as opposed to the antagonist treated mouse which presents complete absence of the lysosomal marker in the vicinity of the plaque <strong>(Bi)</strong>. Sections were co-stained with Thioflavin-S, a-Lamp-1 and a-CD68 <strong>(Ai-iv and Bi-iv)</strong> and Thioflavin-S, a-hTTR and a-ELANE <strong>(Av-viii and Bv-viii)</strong>. Scale bar = 75 &#x003BC;m.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<h3>Liquid Chromatography&#x02013;Tandem Mass Spectrometry Analysis</h3>
<p class="mb0">Considering that the animals treated with the full agonist molecule exhibited the least amount of deposited amyloid, and the animals treated with the PMX53 molecule had the highest amount of amyloid recorded, these two groups were compared using label-free mass spectrometry-based proteomic approach. Overall, a total of 3154 quantifiable proteins were identified. The expression of most of the markers examined using immunoblotting, as well as other related markers, was also confirmed through this technique (Supplementary Tables S1, S2). Furthermore, the data obtained through the LC-MS/MS technique was further analyzed using the Panther tool in order to identify clusters of proteins involved with specific functions in the two extreme groups of mice (<a href="#B60">Thomas et al., 2003</a>; <a href="#B38">Mi et al., 2010</a>). The most relevant results from this analysis have been summarized in Figure <a href="#F8">8</a>, while the specific proteins can be found in Supplementary Tables S3&#x02013;S7. Also, the full list of obtained proteins along with their confidence scores can be found in Supplementary Data Sheet 1. A greater number of proteins involved with macrophage and complement activation were found to be highly expressed in the mice treated with the full agonist molecule. Similarly, a greater number of proteins associated with inflammation mediated by cytokines and chemokines, as well as peptidases were also found in the group treated with the full agonist molecule. However, the animals treated with PMX53 appeared to express a greater number of apoptosis related proteins when compared to the full agonist treated group.</p>
<div class="DottedLine"></div>
<div class="Imageheaders">FIGURE 8</div>
<div class="FigureDesc">
<a href="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg" name="figure8" target="_blank">

  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg" alt="www.frontiersin.org" id="F8" loading="lazy">
  </picture>
</a>
<p><strong>Figure 8. LC-MS/MS clustering: protein functional clustering was carried out through the Panther tool between the group of mice treated with the full agonist molecule and the PMX53 antagonist.</strong> The group of mice treated with the full agonist displayed an increase in the expression of markers related with macrophage and complement system activation. Furthermore, an upsurge in the expression of peptidases and factors involved with inflammation was observed. The group treated with the antagonist exhibited a greater expression of caspases and other proteins involved in the apoptosis pathways.</p></div> 
<div class="clear"></div>
<div class="DottedLine"></div>
<a id="h5" name="h5"></a><h2>Discussion</h2>
<p class="mb15">Currently there is a variety of approaches, either in the clinic or in clinical trials, for treating ATTR V30M amyloidotic neuropathy; liver transplantation, TTR stabilizers (Tafamidis, Diflunisal), inhibitors of TTR translation (anti-sense oligonucleotides, silencing RNAs), drugs that interfere with amyloid dynamics at the tissue level (doxycycline/TUDCA). There is however an unmet need that arises from the fact that already formed amyloid deposits continue to form foci for further deposition of normal TTR giving rise to further organ damage such as the heart and the kidneys. In addition, amyloidogenesis in certain tissue beds such as the eye and the brain has not yet been effectively addressed partly due to issues of access of the various treatments to the relevant tissue beds. More recently, antibodies against serum amyloid P or in the case of ATTR V30M amyloidosis, a cryptic TTR epitope visible only when TTR is in its monomeric form, are beginning to be explored as possible treatments (<a href="#B48">Richards et al., 2015</a>; <a href="#B25">Hosoi et al., 2016</a>). Both of these antibodies appear to enhance phagocytosis by macrophages. Complement participation has also been demonstrated with the anti-serum amyloid P antibody <i>in vivo</i>. In the current study we provide evidence that amyloid phagocytosis can be modulated by pharmacological manipulation of the C5a receptor and in the absence of any antibodies perhaps offering a more generic and convenient treatment option for the amyloidoses.</p>
<p class="mb15">Agonist and antagonists of the C5a receptor molecule are constructed based on the C terminus of the C5a molecule (<a href="#B24">Higginbottom et al., 2005</a>). Agonists can be used to activate the C5a receptor bearing cells such as macrophages and neutrophils in order to induce the release of proinflammatory agents, thus activating an inflammatory response (<a href="#B52">Short et al., 1999</a>). The C5a molecule is considered an anaphylatoxin based on its propensity to induce mast cell, basophil and neutrophil degranulation (<a href="#B30">Lee et al., 2008</a>).</p>
<p class="mb15">The full agonist molecule of the C5a receptor used here ((N-Methyl-Phe)-Lys-Pro-d-Cha-Cha-d-Arg-CO<sub>2</sub>H) is a peptide analog of the last six C-terminal residues of the C5a molecule (<a href="#B24">Higginbottom et al., 2005</a>). In essence, this molecule retains its anaphylactic activity by not only activating macrophages but also neutrophils. EP67 (Thr-Ser-Phe-Lys-Asp-Met-Pro-(MeLeu)-D-Ala-Arg), a conformationally-restricted decapeptide of the last ten amino acids of the C5a molecule contains an altered structure, which is accommodated by C5a receptors expressed on antigen presenting cells such as macrophages (<a href="#B49">Sanderson et al., 2012</a>; <a href="#B22">Hanke et al., 2013</a>). The C5a receptor antagonist PMX53 (AcF-[OP(D Cha) WR]) is a small cyclic peptide molecule which binds the C5a receptor suspending its downstream function (<a href="#B61">Woodruff et al., 2006</a>; <a href="#B31">Lobato and Rocha, 2012</a>).</p>
<p class="mb15">Our results show that while administering the PMX53 compound results in a 160% increase of fibrillar amyloid deposition (both the full agonist and EP67 result in the decrease of amyloid deposition by 65% and 42%, respectively) following 1 week of oral administration through the animals&#x02019; drinking water. Therefore, inhibition of the C5a receptor (CD88) results in an increase in amyloid deposition, whereas enhancing the action of the receptor induces a considerable decrease. This decrease is even more substantial following the administration of the full agonist molecule which recruits both macrophages and neutrophils (<a href="#B4">Baik et al., 2014</a>).</p>
<p class="mb15">The fact that the amount of circulating hTTR protein in the serum remains unchanged in all four groups is expected since liver production of TTR is not expected to be affected, while the changes in tissue handling of TTR as a result of the administration of the three types of molecules for only a week would be too short to influence serum levels. However, there was a significant decrease in the amount of prefibrillar hTTR detected in the stomach tissue of animals receiving the C5 receptor agonists when compared to control presumably due to increased phagocytosis of prefibrillar hTTR. The PMX53 group mice exhibited no significant rise in prefibrillar hTTR, compared to control, as might be expected due to reduced phagocytosis of prefibrillar hTTR (<a href="#B39">Misumi et al., 2013</a>; <a href="#B55">Suenaga et al., 2016</a>). This is most likely explained by a shift to a higher rate of amyloid formation driven by higher prefibrillar hTTR.</p>
<p class="mb15">The marked decrease in amyloid load observed with the animals treated with the C5a receptor agonists is accompanied by a remarkable increase in neutrophil and macrophage markers. EP67 predominantly targets the macrophage populations, while the full agonist, which also targets neutrophils, produces significantly more IL-36&#x003B3; perhaps indicative of phagocytic capacity (<a href="#B49">Sanderson et al., 2012</a>; <a href="#B22">Hanke et al., 2013</a>). The extra 23% decrease in amyloid observed in the full agonist treated mice is probably a direct effect of neutrophil activation and recruitment. Immunofluorescence labeling of the plaques shows no co-localization with neutrophils except in mice treated with the full C5a receptor agonist (Figure <a href="#F4">4C</a>). Interestingly, this is the group which exemplifies the greatest reduction in amyloid load, indicating a capacity of neutrophils to clear amyloid (<a href="#B4">Baik et al., 2014</a>). Moreover, amyloid plaques in animals treated with the two C5a receptor agonists exhibit increased expression of the lysosomal marker Lamp-1, signifying that the recruitment of macrophages and neutrophils does ultimately lead to activated phagocytosis of the amyloid plaque. Additionally, the PMX53 treated group of animals exhibited the lowest expression of both neutrophil and macrophage markers as might be expected due to the inhibition of the C5a receptor (<a href="#B8">Brennan et al., 2015</a>; <a href="#B20">Gupta and Kaplan, 2016</a>).</p>
<p class="mb15">The complement pathway is involved in innate immunity and C5a is one of the final effector molecules produced. C5a is imperative in tissue clearance through the recruitment of inflammatory cells. Mice treated with the C5a receptor agonists express a greater amount of C1q than both the control and the PMX53 treated mice. Neutrophils are known to possess C1q receptors which in turn enhance the expression of the CR3 receptor (<a href="#B15">Eggleton et al., 1994</a>), an integral part of the innate immune response. Therefore, the significant increase in C1q, observed especially in the group treated with the full C5a receptor agonist, is probably due to the presence of neutrophils. Neutrophils also activate the alternative complement pathway and release C5 fragments, which further amplify the neutrophil pro-inflammatory response, acting in a positive feedback loop (<a href="#B10">Camous et al., 2011</a>). Furthermore, macrophages have also been shown to activate the alternative complement pathway by activating C3 (<a href="#B51">Schorlemmer et al., 1977</a>), explaining the increase in properdin in the groups treated with the C5a receptor agonists. The PMX53 treated mice however did not appear to produce less properdin than the control group of animals, probably a response to the increased amyloid deposition where several complement components co-localize (<a href="#B47">Reichwald et al., 2009</a>). This evidence is also corroborated by the LC-MS/MS analysis, which indicates the massive up-surge of both the classical and alternative complement cascade in relation to the PMX53 treated group (Supplementary Table S1).</p>
<p class="mb15">The LC-MS/MS data reveal that a greater number of peptidases, and more specifically serine proteases, become up-regulated in the full agonist treated group when compared to the PMX53 treated animals which exhibit the greatest amyloid load. Evidence from work carried out on amyloid &#x003B2; peptides in Alzheimer&#x02019;s brains, identifies peptidase and protease mediated cleavage as a possible clearance mechanism in the catabolism of amyloid plaques (<a href="#B36">Matsumoto et al., 1995</a>; <a href="#B42">Ogawa et al., 2000</a>; <a href="#B23">Hersh, 2003</a>; <a href="#B34">Malito et al., 2008</a>). Neutrophils are known to release a number of serine proteases which induce chemokine and cytokine release as well as proteolytic cleavage (<a href="#B26">Kessenbrock et al., 2011</a>; <a href="#B37">Meyer-Hoffert and Wiedow, 2011</a>). Furthermore, neutrophil elastase (ELANE), a serine protease secreted by neutrophils has been shown to preferentially activate IL-36 yielding the three by-products IL-36&#x003B1;, IL-36&#x003B2; and IL-36&#x003B3; triggering further inflammatory response. We present data, via immunoblotting and LC-MS/MS analysis demonstrating the significant increase of IL-36&#x003B3; in animals treated with the C5a receptor agonists vs. the animals treated with the PMX53 inhibitor.</p>
<p class="mb15">Both apoptosis and cellular stress have been shown to increase along with extracellular TTR amyloid deposition (<a href="#B32">Macedo et al., 2007</a>). We observe both by immunoblotting and LC-MS/MS analysis, that the groups of animals treated with the C5a receptor agonists do not have lower levels of apoptosis or cellular stress when compared to the control despite a reduction in amyloid load. This is perhaps partly due to the presence of macrophages and neutrophils <i>per se</i> since both are involved in inflammatory pathways which do evoke the ER stress response pathway (<a href="#B18">Gotoh et al., 2011</a>). Similarly, macrophages have the ability to release Fas ligands, thus increasing extrinsic-signal triggered apoptosis (<a href="#B9">Brown and Savill, 1999</a>) but also the ability to induce chronic inflammation leading to further apoptosis (<a href="#B13">Diez-Roux and Lang, 1997</a>; <a href="#B19">Gregory and Devitt, 2004</a>).</p>
<p class="mb15">In summary our data show that while inhibition of the C5a receptor results in the significant increase of amyloid load, activation of the C5a receptor results in a substantial reduction of amyloid deposits. Measurable effects were seen with only 1 week oral intake and with no visible side-effects on the mice. The full C5a receptor agonist molecule, retaining its full ability to activate neutrophils, had a greater impact in reducing the amyloid load. The long term safety of the of both C5a receptor agonists will need to be assessed in the mouse model whether on a continuous or intermittent basis.</p>
<p class="mb15">The role that neutrophils and macrophages may hold in activating amyloid clearance mechanisms also needs to be addressed in the context of other amyloidoses models. It appears that migration towards the plaque may not be determined by the plaque inducing peptide <i>per se</i>, but rather on the generic amyloid fibrillar formation since experiments have shown that individual &#x003B1;&#x003B2; monomers do not have the ability to attract peripheral phagocytic cells (<a href="#B4">Baik et al., 2014</a>). Therefore, activating the phagocytic immune response through the complement cascade may target generic amyloidoses.</p>
<p class="mb0">The therapeutic exploitation of these small molecules as generic treatment in the amyloidoses will no doubt be both more challenging and rewarding.</p>
<a id="h6" name="h6"></a><h2>Author Contributions</h2>
<p class="mb0">EF: data acquisition, data analysis and interpretation. KS: data acquisition and data analysis. RP: sample preparation, data acquisition. KK: study conception, manuscript critical revision. JP and SS: study design, manuscript critical revision. EP: study conception and design, data acquisition, data analysis and interpretation, drafting of manuscript. TK: study conception and design, data interpretation, drafting of manuscript.</p>
<a id="h7" name="h7"></a><h2>Funding</h2>
<p class="mb0">This study was funded by the Cyprus Institute of Neurology and Genetics under the Telethon grants (Code: 33173126).</p>
<a id="h8" name="h8"></a><h2>Conflict of Interest Statement</h2>
<p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<a id="h9" name="h9"></a><h2>Acknowledgments</h2>
<p class="mb0">We acknowledge Professor Maria Saraiva for kindly donating the mTTR<sup>&#x02212;/&#x02212;</sup>hMET30<sup>+/+</sup> transgenic mice.</p>
<a id="h10" name="h10"></a><h2>Supplementary Material</h2>
<p class="mb0">The Supplementary Material for this article can be found online at: <a href="http://journal.frontiersin.org/article/10.3389/fnmol.2017.00138/full&#x00023;supplementary-material">http://journal.frontiersin.org/article/10.3389/fnmol.2017.00138/full&#x00023;supplementary-material</a></p>
<a id="h11" name="h11"></a><h2>References</h2>
<div class="References">
<p class="ReferencesCopy1"><a name="B1" id="B1"></a>Amsalem, H., Kwan, M., Hazan, A., Zhang, J., Jones, R. L., Whittle, W., et al. (2014). Identification of a novel neutrophil population: proangiogenic granulocytes in second-trimester human decidua. <i>J. Immunol.</i> 193, 3070&#x02013;3079. doi: 10.4049/jimmunol.1303117</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25135830" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4049/jimmunol.1303117" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Identification+of+a+novel+neutrophil+population%3A+proangiogenic+granulocytes+in+second-trimester+human+decidua&#x00026;author=Amsalem+H.&#x00026;author=Kwan+M.&#x00026;author=Hazan+A.&#x00026;author=Zhang+J.&#x00026;author=Jones+R.+L.&#x00026;author=Whittle+W.&#x00026;+&#x00026;publication_year=2014&#x00026;journal=J.+Immunol.&#x00026;volume=193&#x00026;pages=3070-3079" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B2" id="B2"></a>Ando, Y., Nakamura, M., and Araki, S. (2005). Transthyretin-related familial amyloidotic polyneuropathy. <i>Arch. Neurol.</i> 62, 1057&#x02013;1062. doi: 10.1001/archneur.62.7.1057</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16009758" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/archneur.62.7.1057" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Transthyretin-related+familial+amyloidotic+polyneuropathy&#x00026;author=Ando+Y.&#x00026;author=Nakamura+M.&#x00026;author=Araki+S.&#x00026;publication_year=2005&#x00026;journal=Arch.+Neurol.&#x00026;volume=62&#x00026;pages=1057-1062" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B3" id="B3"></a>Austyn, J. M., and Gordon, S. (1981). F4/80, a monoclonal antibody directed specifically against the mouse macrophage. <i>Eur. J. Immunol.</i> 11, 805&#x02013;815. doi: 10.1002/eji.1830111013</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=7308288" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/eji.1830111013" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=F4%2F80,+a+monoclonal+antibody+directed+specifically+against+the+mouse+macrophage&#x00026;author=Austyn+J.+M.&#x00026;author=Gordon+S.&#x00026;publication_year=1981&#x00026;journal=Eur.+J.+Immunol.&#x00026;volume=11&#x00026;pages=805-815" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B4" id="B4"></a>Baik, S. H., Cha, M. Y., Hyun, Y. M., Cho, H., Hamza, B., Kim, D. K., et al. (2014). Migration of neutrophils targeting amyloid plaques in Alzheimer&#x02019;s disease mouse model. <i>Neurobiol. Aging</i> 35, 1286&#x02013;1292. doi: 10.1016/j.neurobiolaging.2014.01.003</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24485508" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.neurobiolaging.2014.01.003" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Migration+of+neutrophils+targeting+amyloid+plaques+in+Alzheimer's+disease+mouse+model&#x00026;author=Baik+S.+H.&#x00026;author=Cha+M.+Y.&#x00026;author=Hyun+Y.+M.&#x00026;author=Cho+H.&#x00026;author=Hamza+B.&#x00026;author=Kim+D.+K.&#x00026;+&#x00026;publication_year=2014&#x00026;journal=Neurobiol.+Aging&#x00026;volume=35&#x00026;pages=1286-1292" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B5" id="B5"></a>Belaaouaj, A., Kim, K. S., and Shapiro, S. D. (2000). Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. <i>Science</i> 289, 1185&#x02013;1188. doi: 10.1126/science.289.5482.1185</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=10947984" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1126/science.289.5482.1185" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Degradation+of+outer+membrane+protein+A+in+Escherichia+coli+killing+by+neutrophil+elastase&#x00026;author=Belaaouaj+A.&#x00026;author=Kim+K.+S.&#x00026;author=Shapiro+S.+D.&#x00026;publication_year=2000&#x00026;journal=Science&#x00026;volume=289&#x00026;pages=1185-1188" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B6" id="B6"></a>Bodin, K., Ellmerich, S., Kahan, M. C., Tennent, G. A., Loesch, A., Gilbertson, J. A., et al. (2010). Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. <i>Nature</i> 468, 93&#x02013;97. doi: 10.1038/nature09494</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20962779" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature09494" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Antibodies+to+human+serum+amyloid+P+component+eliminate+visceral+amyloid+deposits&#x00026;author=Bodin+K.&#x00026;author=Ellmerich+S.&#x00026;author=Kahan+M.+C.&#x00026;author=Tennent+G.+A.&#x00026;author=Loesch+A.&#x00026;author=Gilbertson+J.+A.&#x00026;+&#x00026;publication_year=2010&#x00026;journal=Nature&#x00026;volume=468&#x00026;pages=93-97" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B7" id="B7"></a>Bozoyan, L., Dumas, A., Patenaude, A., and Valli&#x000E9;res, L. (2015). Interleukin-36&#x003B3; is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis. <i>J. Neuroinflammation</i> 12:173. doi: 10.1186/s12974-015-0392-7</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26377915" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12974-015-0392-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Interleukin-36&#x003B3;+is+expressed+by+neutrophils+and+can+activate+microglia,+but+has+no+role+in+experimental+autoimmune+encephalomyelitis&#x00026;author=Bozoyan+L.&#x00026;author=Dumas+A.&#x00026;author=Patenaude+A.&#x00026;author=Valli&#x000E9;res+L.&#x00026;publication_year=2015&#x00026;journal=J.+Neuroinflammation&#x00026;volume=12&#x00026;pages=173" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B8" id="B8"></a>Brennan, F. H., Gordon, R., Lao, H. W., Biggins, P. J., Taylor, S. M., Franklin, R. J., et al. (2015). The complement receptor c5ar controls acute inflammation and astrogliosis following spinal cord injury. <i>J. Neurosci.</i> 35, 6517&#x02013;6531. doi: 10.1523/JNEUROSCI.5218-14.2015</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25904802" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1523/JNEUROSCI.5218-14.2015" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=The+complement+receptor+c5ar+controls+acute+inflammation+and+astrogliosis+following+spinal+cord+injury&#x00026;author=Brennan+F.+H.&#x00026;author=Gordon+R.&#x00026;author=Lao+H.+W.&#x00026;author=Biggins+P.+J.&#x00026;author=Taylor+S.+M.&#x00026;author=Franklin+R.+J.&#x00026;+&#x00026;publication_year=2015&#x00026;journal=J.+Neurosci.&#x00026;volume=35&#x00026;pages=6517-6531" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B9" id="B9"></a>Brown, S. B., and Savill, J. (1999). Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. <i>J. Immunol.</i> 162, 480&#x02013;485. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9886423" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Phagocytosis+triggers+macrophage+release+of+Fas+ligand+and+induces+apoptosis+of+bystander+leukocytes&#x00026;author=Brown+S.+B.&#x00026;author=Savill+J.&#x00026;publication_year=1999&#x00026;journal=J.+Immunol.&#x00026;volume=162&#x00026;pages=480-485" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B10" id="B10"></a>Camous, L., Roumenina, L., Bigot, S., Brachemi, S., Fr&#x000E9;meaux-Bacchi, V., Lesavre, P., et al. (2011). Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. <i>Blood</i> 117, 1340&#x02013;1349. doi: 10.1182/blood-2010-05-283564</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21063021" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1182/blood-2010-05-283564" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Complement+alternative+pathway+acts+as+a+positive+feedback+amplification+of+neutrophil+activation&#x00026;author=Camous+L.&#x00026;author=Roumenina+L.&#x00026;author=Bigot+S.&#x00026;author=Brachemi+S.&#x00026;author=Fr&#x000E9;meaux-Bacchi+V.&#x00026;author=Lesavre+P.&#x00026;+&#x00026;publication_year=2011&#x00026;journal=Blood&#x00026;volume=117&#x00026;pages=1340-1349" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B11" id="B11"></a>Carlsson, S. R., and Fukuda, M. (1989). Structure of human lysosomal membrane glycoprotein 1. Assignment of disulfide bonds and visualization of its domain arrangement. <i>J. Biol. Chem.</i> 264, 20526&#x02013;20531. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=2584229" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Structure+of+human+lysosomal+membrane+glycoprotein+1.+Assignment+of+disulfide+bonds+and+visualization+of+its+domain+arrangement&#x00026;author=Carlsson+S.+R.&#x00026;author=Fukuda+M.&#x00026;publication_year=1989&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=264&#x00026;pages=20526-20531" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B12" id="B12"></a>Dardiotis, E., Koutsou, P., Zamba-Papanicolaou, E., Vonta, I., Hadjivassiliou, M., Hadjigeorgiou, G., et al. (2009). Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. <i>J. Neurol. Sci.</i> 284, 158&#x02013;162. doi: 10.1016/j.jns.2009.05.018</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19493541" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.jns.2009.05.018" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Complement+C1Q+polymorphisms+modulate+onset+in+familial+amyloidotic+polyneuropathy+TTR+Val30Met&#x00026;author=Dardiotis+E.&#x00026;author=Koutsou+P.&#x00026;author=Zamba-Papanicolaou+E.&#x00026;author=Vonta+I.&#x00026;author=Hadjivassiliou+M.&#x00026;author=Hadjigeorgiou+G.&#x00026;+&#x00026;publication_year=2009&#x00026;journal=J.+Neurol.+Sci.&#x00026;volume=284&#x00026;pages=158-162" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B13" id="B13"></a>Diez-Roux, G., and Lang, R. A. (1997). Macrophages induce apoptosis in normal cells <i>in vivo</i>. <i>Development</i> 124, 3633&#x02013;3638. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9342055" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Macrophages+induce+apoptosis+in+normal+cells+in+vivo&#x00026;author=Diez-Roux+G.&#x00026;author=Lang+R.+A.&#x00026;publication_year=1997&#x00026;journal=Development&#x00026;volume=124&#x00026;pages=3633-3638" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B14" id="B14"></a>Distler, U., Kuharev, J., Navarro, P., Levin, Y., Schild, H., and Tenzer, S. (2014). Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. <i>Nat. Methods</i> 11, 167&#x02013;170. doi: 10.1038/nmeth.2767</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24336358" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nmeth.2767" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Drift+time-specific+collision+energies+enable+deep-coverage+data-independent+acquisition+proteomics&#x00026;author=Distler+U.&#x00026;author=Kuharev+J.&#x00026;author=Navarro+P.&#x00026;author=Levin+Y.&#x00026;author=Schild+H.&#x00026;author=Tenzer+S.&#x00026;publication_year=2014&#x00026;journal=Nat.+Methods&#x00026;volume=11&#x00026;pages=167-170" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B15" id="B15"></a>Eggleton, P., Ghebrehiwet, B., Coburn, J. P., Sastry, K. N., Zaner, K. S., and Tauber, A. I. (1994). Characterization of the human neutrophil C1q receptor and functional effects of free ligand on activated neutrophils. <i>Blood</i> 84, 1640&#x02013;1649. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=8068954" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Characterization+of+the+human+neutrophil+C1q+receptor+and+functional+effects+of+free+ligand+on+activated+neutrophils&#x00026;author=Eggleton+P.&#x00026;author=Ghebrehiwet+B.&#x00026;author=Coburn+J.+P.&#x00026;author=Sastry+K.+N.&#x00026;author=Zaner+K.+S.&#x00026;author=Tauber+A.+I.&#x00026;publication_year=1994&#x00026;journal=Blood&#x00026;volume=84&#x00026;pages=1640-1649" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B16" id="B16"></a>Fonseca, M. I., Ager, R. R., Chu, S. H., Yazan, O., Sanderson, S. D., LaFerla, F. M., et al. (2009). Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer&#x02019;s disease. <i>J. Immunol.</i> 183, 1375&#x02013;1383. doi: 10.4049/jimmunol.0901005</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19561098" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4049/jimmunol.0901005" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Treatment+with+a+C5aR+antagonist+decreases+pathology+and+enhances+behavioral+performance+in+murine+models+of+Alzheimer's+disease&#x00026;author=Fonseca+M.+I.&#x00026;author=Ager+R.+R.&#x00026;author=Chu+S.+H.&#x00026;author=Yazan+O.&#x00026;author=Sanderson+S.+D.&#x00026;author=LaFerla+F.+M.&#x00026;+&#x00026;publication_year=2009&#x00026;journal=J.+Immunol.&#x00026;volume=183&#x00026;pages=1375-1383" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B17" id="B17"></a>Fonseca, M. I., Chu, S. H., Berci, A. M., Benoit, M. E., Peters, D. G., Kimura, Y., et al. (2011). Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer&#x02019;s disease. <i>J. Neuroinflammation</i> 8:4. doi: 10.1186/1742-2094-8-4</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21235806" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1742-2094-8-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Contribution+of+complement+activation+pathways+to+neuropathology+differs+among+mouse+models+of+Alzheimer's+disease&#x00026;author=Fonseca+M.+I.&#x00026;author=Chu+S.+H.&#x00026;author=Berci+A.+M.&#x00026;author=Benoit+M.+E.&#x00026;author=Peters+D.+G.&#x00026;author=Kimura+Y.&#x00026;+&#x00026;publication_year=2011&#x00026;journal=J.+Neuroinflammation&#x00026;volume=8&#x00026;pages=4" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B18" id="B18"></a>Gotoh, T., Endo, M., and Oike, Y. (2011). Endoplasmic reticulum stress-related inflammation and cardiovascular diseases. <i>Int. J. Inflam.</i> 2011:259462. doi: 10.4061/2011/259462</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21755026" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4061/2011/259462" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Endoplasmic+reticulum+stress-related+inflammation+and+cardiovascular+diseases&#x00026;author=Gotoh+T.&#x00026;author=Endo+M.&#x00026;author=Oike+Y.&#x00026;publication_year=2011&#x00026;journal=Int.+J.+Inflam.&#x00026;volume=2011&#x00026;pages=259462" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B19" id="B19"></a>Gregory, C. D., and Devitt, A. (2004). The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? <i>Immunology</i> 113, 1&#x02013;14. doi: 10.1111/j.1365-2567.2004.01959.x</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=15312130" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1365-2567.2004.01959.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=The+macrophage+and+the+apoptotic+cell%3A+an+innate+immune+interaction+viewed+simplistically%3F&#x00026;author=Gregory+C.+D.&#x00026;author=Devitt+A.&#x00026;publication_year=2004&#x00026;journal=Immunology&#x00026;volume=113&#x00026;pages=1-14" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B20" id="B20"></a>Gupta, S., and Kaplan, M. J. (2016). The role of neutrophils and NETosis in autoimmune and renal diseases. <i>Nat. Rev. Nephrol.</i> 12, 402&#x02013;413. doi: 10.1038/nrneph.2016.71</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27241241" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrneph.2016.71" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=The+role+of+neutrophils+and+NETosis+in+autoimmune+and+renal+diseases&#x00026;author=Gupta+S.&#x00026;author=Kaplan+M.+J.&#x00026;publication_year=2016&#x00026;journal=Nat.+Rev.+Nephrol.&#x00026;volume=12&#x00026;pages=402-413" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B21" id="B21"></a>Hafer-Macko, C. E., Dyck, P. J., and Koski, C. L. (2000). Complement activation in acquired and hereditary amyloid neuropathy. <i>J. Peripher. Nerv. Syst.</i> 5, 131&#x02013;139. doi: 10.1046/j.1529-8027.2000.00018.x</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11442169" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1046/j.1529-8027.2000.00018.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Complement+activation+in+acquired+and+hereditary+amyloid+neuropathy&#x00026;author=Hafer-Macko+C.+E.&#x00026;author=Dyck+P.+J.&#x00026;author=Koski+C.+L.&#x00026;publication_year=2000&#x00026;journal=J.+Peripher.+Nerv.+Syst.&#x00026;volume=5&#x00026;pages=131-139" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B22" id="B22"></a>Hanke, M. L., Heim, C. E., Angle, A., Sanderson, S. D., and Kielian, T. (2013). Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. <i>J. Immunol.</i> 190, 2159&#x02013;2168. doi: 10.4049/jimmunol.1202348</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=23365077" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4049/jimmunol.1202348" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Targeting+macrophage+activation+for+the+prevention+and+treatment+of+Staphylococcus+aureus+biofilm+infections&#x00026;author=Hanke+M.+L.&#x00026;author=Heim+C.+E.&#x00026;author=Angle+A.&#x00026;author=Sanderson+S.+D.&#x00026;author=Kielian+T.&#x00026;publication_year=2013&#x00026;journal=J.+Immunol.&#x00026;volume=190&#x00026;pages=2159-2168" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B23" id="B23"></a>Hersh, L. B. (2003). Peptidases, proteases and amyloid &#x003B2;-peptide catabolism. <i>Curr. Pharm. Des.</i> 9, 449&#x02013;454. doi: 10.2174/1381612033391676</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=12570808" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.2174/1381612033391676" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Peptidases,+proteases+and+amyloid+&#x003B2;-peptide+catabolism&#x00026;author=Hersh+L.+B.&#x00026;publication_year=2003&#x00026;journal=Curr.+Pharm.+Des.&#x00026;volume=9&#x00026;pages=449-454" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B24" id="B24"></a>Higginbottom, A., Cain, S. A., Woodruff, T. M., Proctor, L. M., Madala, P. K., Tyndall, J. D., et al. (2005). Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. <i>J. Biol. Chem.</i> 280, 17831&#x02013;17840. doi: 10.1074/jbc.M410797200</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=15661745" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1074/jbc.M410797200" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Comparative+agonist%2Fantagonist+responses+in+mutant+human+C5a+receptors+define+the+ligand+binding+site&#x00026;author=Higginbottom+A.&#x00026;author=Cain+S.+A.&#x00026;author=Woodruff+T.+M.&#x00026;author=Proctor+L.+M.&#x00026;author=Madala+P.+K.&#x00026;author=Tyndall+J.+D.&#x00026;+&#x00026;publication_year=2005&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=280&#x00026;pages=17831-17840" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B25" id="B25"></a>Hosoi, A., Su, Y., Torikai, M., Jono, H., Ishikawa, D., Soejima, K., et al. (2016). Novel antibody for the treatment of transthyretin amyloidosis. <i>J. Biol. Chem.</i> 291, 25096&#x02013;25105. doi: 10.1074/jbc.M116.738138</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27758856" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1074/jbc.M116.738138" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Novel+antibody+for+the+treatment+of+transthyretin+amyloidosis&#x00026;author=Hosoi+A.&#x00026;author=Su+Y.&#x00026;author=Torikai+M.&#x00026;author=Jono+H.&#x00026;author=Ishikawa+D.&#x00026;author=Soejima+K.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=291&#x00026;pages=25096-25105" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B26" id="B26"></a>Kessenbrock, K., Dau, T., and Jenne, D. E. (2011). Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. <i>J. Mol. Med.</i> 89, 23&#x02013;28. doi: 10.1007/s00109-010-0677-3</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20809089" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00109-010-0677-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Tailor-made+inflammation%3A+how+neutrophil+serine+proteases+modulate+the+inflammatory+response&#x00026;author=Kessenbrock+K.&#x00026;author=Dau+T.&#x00026;author=Jenne+D.+E.&#x00026;publication_year=2011&#x00026;journal=J.+Mol.+Med.&#x00026;volume=89&#x00026;pages=23-28" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B27" id="B27"></a>Kima, P. E., Burleigh, B., and Andrews, N. W. (2000). Surface-targeted lysosomal membrane glycoprotein-1 (Lamp-1) enhances lysosome exocytosis and cell invasion by Trypanosoma cruzi. <i>Cell. Microbiol.</i> 2, 477&#x02013;486. doi: 10.1046/j.1462-5822.2000.00071.x</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11207602" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1046/j.1462-5822.2000.00071.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Surface-targeted+lysosomal+membrane+glycoprotein-1+(Lamp-1)+enhances+lysosome+exocytosis+and+cell+invasion+by+Trypanosoma+cruzi&#x00026;author=Kima+P.+E.&#x00026;author=Burleigh+B.&#x00026;author=Andrews+N.+W.&#x00026;publication_year=2000&#x00026;journal=Cell.+Microbiol.&#x00026;volume=2&#x00026;pages=477-486" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B28" id="B28"></a>Kohno, K., Palha, J. A., Miyakawa, K., Saraiva, M. J., Ito, S., Mabuchi, T., et al. (1997). Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. <i>Am. J. Pathol.</i> 150, 1497&#x02013;1508. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9095004" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Analysis+of+amyloid+deposition+in+a+transgenic+mouse+model+of+homozygous+familial+amyloidotic+polyneuropathy&#x00026;author=Kohno+K.&#x00026;author=Palha+J.+A.&#x00026;author=Miyakawa+K.&#x00026;author=Saraiva+M.+J.&#x00026;author=Ito+S.&#x00026;author=Mabuchi+T.&#x00026;+&#x00026;publication_year=1997&#x00026;journal=Am.+J.+Pathol.&#x00026;volume=150&#x00026;pages=1497-1508" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B29" id="B29"></a>Kovach, M. A., Singer, B. H., Newstead, M. W., Zeng, X., Moore, T. A., White, E. S., et al. (2016). IL-36&#x003B3; is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components. <i>J. Leukoc. Biol.</i> 100, 413&#x02013;421. doi: 10.1189/jlb.4A0315-087R</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26864267" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1189/jlb.4A0315-087R" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=IL-36&#x003B3;+is+secreted+in+microparticles+and+exosomes+by+lung+macrophages+in+response+to+bacteria+and+bacterial+components&#x00026;author=Kovach+M.+A.&#x00026;author=Singer+B.+H.&#x00026;author=Newstead+M.+W.&#x00026;author=Zeng+X.&#x00026;author=Moore+T.+A.&#x00026;author=White+E.+S.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=J.+Leukoc.+Biol.&#x00026;volume=100&#x00026;pages=413-421" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B30" id="B30"></a>Lee, H., Whitfeld, P. L., and Mackay, C. R. (2008). Receptors for complement C5a. <i>Immunol. Cell Biol.</i> 86, 153&#x02013;160. doi: 10.1038/sj.icb.7100166</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18227853" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.icb.7100166" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Receptors+for+complement+C5a&#x00026;author=Lee+H.&#x00026;author=Whitfeld+P.+L.&#x00026;author=Mackay+C.+R.&#x00026;publication_year=2008&#x00026;journal=Immunol.+Cell+Biol.&#x00026;volume=86&#x00026;pages=153-160" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B31" id="B31"></a>Lobato, L., and Rocha, A. (2012). Transthyretin amyloidosis and the kidney. <i>Clin. J. Am. Soc. Nephrol.</i> 7, 1337&#x02013;1346. doi: 10.2215/CJN.08720811</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22537653" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.2215/CJN.08720811" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Transthyretin+amyloidosis+and+the+kidney&#x00026;author=Lobato+L.&#x00026;author=Rocha+A.&#x00026;publication_year=2012&#x00026;journal=Clin.+J.+Am.+Soc.+Nephrol.&#x00026;volume=7&#x00026;pages=1337-1346" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B32" id="B32"></a>Macedo, B., Batista, A. R., do Amaral, J. B., and Saraiva, M. J. (2007). Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. <i>Mol. Med.</i> 13, 584&#x02013;591. doi: 10.2119/2007-00068.Macedo</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=17932549" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.2119/2007-00068.Macedo" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Biomarkers+in+the+assessment+of+therapies+for+familial+amyloidotic+polyneuropathy&#x00026;author=Macedo+B.&#x00026;author=Batista+A.+R.&#x00026;author=do+Amaral+J.+B.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2007&#x00026;journal=Mol.+Med.&#x00026;volume=13&#x00026;pages=584-591" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B33" id="B33"></a>Macleod, T., Doble, R., McGonagle, D., Wasson, C. W., Alase, A., Stacey, M., et al. (2016). Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist. <i>Sci. Rep.</i> 6:24880. doi: 10.1038/srep24880</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27101808" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/srep24880" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Neutrophil+Elastase-mediated+proteolysis+activates+the+anti-inflammatory+cytokine+IL-36+Receptor+antagonist&#x00026;author=Macleod+T.&#x00026;author=Doble+R.&#x00026;author=McGonagle+D.&#x00026;author=Wasson+C.+W.&#x00026;author=Alase+A.&#x00026;author=Stacey+M.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=Sci.+Rep.&#x00026;volume=6&#x00026;pages=24880" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B34" id="B34"></a>Malito, E., Hulse, R. E., and Tang, W. J. (2008). Amyloid &#x003B2;-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. <i>Cell. Mol. Life Sci.</i> 65, 2574&#x02013;2585. doi: 10.1007/s00018-008-8112-4</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18470479" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00018-008-8112-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Amyloid+&#x003B2;-degrading+cryptidases%3A+insulin+degrading+enzyme,+presequence+peptidase,+and+neprilysin&#x00026;author=Malito+E.&#x00026;author=Hulse+R.+E.&#x00026;author=Tang+W.+J.&#x00026;publication_year=2008&#x00026;journal=Cell.+Mol.+Life+Sci.&#x00026;volume=65&#x00026;pages=2574-2585" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B35" id="B35"></a>Mathern, D. R., and Heeger, P. S. (2015). Molecules great and small: the complement system. <i>Clin. J. Am. Soc. Nephrol.</i> 10, 1636&#x02013;1650. doi: 10.2215/CJN.06230614</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25568220" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.2215/CJN.06230614" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Molecules+great+and+small%3A+the+complement+system&#x00026;author=Mathern+D.+R.&#x00026;author=Heeger+P.+S.&#x00026;publication_year=2015&#x00026;journal=Clin.+J.+Am.+Soc.+Nephrol.&#x00026;volume=10&#x00026;pages=1636-1650" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B36" id="B36"></a>Matsumoto, A., Matsumoto, R., Baba, H., and Fujiwara, Y. (1995). A serine protease in Alzheimer&#x02019;s disease cells cleaves a 16K-peptide with flanking residues upstream to &#x003B2;-amyloid-N-terminus as natural substrate. <i>Neurosci. Lett.</i> 195, 171&#x02013;174. doi: 10.1016/0304-3940(95)11810-j</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=8584202" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/0304-3940(95)11810-j" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=A+serine+protease+in+Alzheimer's+disease+cells+cleaves+a+16K-peptide+with+flanking+residues+upstream+to+&#x003B2;-amyloid-N-terminus+as+natural+substrate&#x00026;author=Matsumoto+A.&#x00026;author=Matsumoto+R.&#x00026;author=Baba+H.&#x00026;author=Fujiwara+Y.&#x00026;publication_year=1995&#x00026;journal=Neurosci.+Lett.&#x00026;volume=195&#x00026;pages=171-174" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B37" id="B37"></a>Meyer-Hoffert, U., and Wiedow, O. (2011). Neutrophil serine proteases: mediators of innate immune responses. <i>Curr. Opin. Hematol.</i> 18, 19&#x02013;24. doi: 10.1097/MOH.0b013e32834115d1</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21042214" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1097/MOH.0b013e32834115d1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Neutrophil+serine+proteases%3A+mediators+of+innate+immune+responses&#x00026;author=Meyer-Hoffert+U.&#x00026;author=Wiedow+O.&#x00026;publication_year=2011&#x00026;journal=Curr.+Opin.+Hematol.&#x00026;volume=18&#x00026;pages=19-24" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B38" id="B38"></a>Mi, H., Dong, Q., Muruganujan, A., Gaudet, P., Lewis, S., and Thomas, P. D. (2010). PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. <i>Nucleic Acids Res.</i> 38, D204&#x02013;D210. doi: 10.1093/nar/gkp1019</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20015972" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkp1019" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=PANTHER+version+7%3A+improved+phylogenetic+trees,+orthologs+and+collaboration+with+the+Gene+Ontology+Consortium&#x00026;author=Mi+H.&#x00026;author=Dong+Q.&#x00026;author=Muruganujan+A.&#x00026;author=Gaudet+P.&#x00026;author=Lewis+S.&#x00026;author=Thomas+P.+D.&#x00026;publication_year=2010&#x00026;journal=Nucleic+Acids+Res.&#x00026;volume=38&#x00026;pages=D204-D210" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B39" id="B39"></a>Misumi, Y., Ando, Y., Gon&#x000E7;alves, N. P., and Saraiva, M. J. (2013). Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis. <i>Lab. Invest.</i> 93, 911&#x02013;920. doi: 10.1038/labinvest.2013.83</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=23817086" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/labinvest.2013.83" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Fibroblasts+endocytose+and+degrade+transthyretin+aggregates+in+transthyretin-related+amyloidosis&#x00026;author=Misumi+Y.&#x00026;author=Ando+Y.&#x00026;author=Gon&#x000E7;alves+N.+P.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2013&#x00026;journal=Lab.+Invest.&#x00026;volume=93&#x00026;pages=911-920" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B40" id="B40"></a>Monk, P. N., Scola, A. M., Madala, P., and Fairlie, D. P. (2007). Function, structure and therapeutic potential of complement C5a receptors. <i>Br. J. Pharmacol.</i> 152, 429&#x02013;448. doi: 10.1038/sj.bjp.0707332</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=17603557" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.bjp.0707332" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Function,+structure+and+therapeutic+potential+of+complement+C5a+receptors&#x00026;author=Monk+P.+N.&#x00026;author=Scola+A.+M.&#x00026;author=Madala+P.&#x00026;author=Fairlie+D.+P.&#x00026;publication_year=2007&#x00026;journal=Br.+J.+Pharmacol.&#x00026;volume=152&#x00026;pages=429-448" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B41" id="B41"></a>Murray, P. J., and Wynn, T. A. (2011). Protective and pathogenic functions of macrophage subsets. <i>Nat. Rev. Immunol.</i> 11, 723&#x02013;737. doi: 10.1038/nri3073</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21997792" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nri3073" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Protective+and+pathogenic+functions+of+macrophage+subsets&#x00026;author=Murray+P.+J.&#x00026;author=Wynn+T.+A.&#x00026;publication_year=2011&#x00026;journal=Nat.+Rev.+Immunol.&#x00026;volume=11&#x00026;pages=723-737" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B42" id="B42"></a>Ogawa, K., Yamada, T., Tsujioka, Y., Taguchi, J., Takahashi, M., Tsuboi, Y., et al. (2000). Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease. <i>Psychiatry Clin. Neurosci.</i> 54, 419&#x02013;426. doi: 10.1046/j.1440-1819.2000.00731.x</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=10997858" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1046/j.1440-1819.2000.00731.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Localization+of+a+novel+type+trypsin-like+serine+protease,+neurosin,+in+brain+tissues+of+Alzheimer's+disease+and+Parkinson's+disease&#x00026;author=Ogawa+K.&#x00026;author=Yamada+T.&#x00026;author=Tsujioka+Y.&#x00026;author=Taguchi+J.&#x00026;author=Takahashi+M.&#x00026;author=Tsuboi+Y.&#x00026;+&#x00026;publication_year=2000&#x00026;journal=Psychiatry+Clin.+Neurosci.&#x00026;volume=54&#x00026;pages=419-426" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B43" id="B43"></a>Panayiotou, E., Fella, E., Papacharalambous, R., Malas, S., Saraiva, M. J., and Kyriakides, T. (2017). C1q ablation exacerbates amyloid deposition: a study in a transgenic mouse model of ATTRV30M amyloid neuropathy. <i>PLoS One</i> 12:e0175767. doi: 10.1371/journal.pone.0175767</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28407005" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0175767" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=C1q+ablation+exacerbates+amyloid+deposition%3A+a+study+in+a+transgenic+mouse+model+of+ATTRV30M+amyloid+neuropathy&#x00026;author=Panayiotou+E.&#x00026;author=Fella+E.&#x00026;author=Papacharalambous+R.&#x00026;author=Malas+S.&#x00026;author=Saraiva+M.+J.&#x00026;author=Kyriakides+T.&#x00026;publication_year=2017&#x00026;journal=PLoS+One&#x00026;volume=12&#x00026;pages=e0175767" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B44" id="B44"></a>Petry, F., Reid, K. B., and Loos, M. (1991). Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. <i>J. Immunol.</i> 147, 3988&#x02013;3993. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=1940381" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Gene+expression+of+the+A-+and+B-chain+of+mouse+C1q+in+different+tissues+and+the+characterization+of+the+recombinant+A-chain&#x00026;author=Petry+F.&#x00026;author=Reid+K.+B.&#x00026;author=Loos+M.&#x00026;publication_year=1991&#x00026;journal=J.+Immunol.&#x00026;volume=147&#x00026;pages=3988-3993" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B45" id="B45"></a>Pillay, J., Tak, T., Kamp, V. M., and Koenderman, L. (2013). Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. <i>Cell Mol. Life Sci.</i> 70, 3813&#x02013;3827. doi: 10.1007/s00018-013-1286-4</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=23423530" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00018-013-1286-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Immune+suppression+by+neutrophils+and+granulocytic+myeloid-derived+suppressor+cells%3A+similarities+and+differences&#x00026;author=Pillay+J.&#x00026;author=Tak+T.&#x00026;author=Kamp+V.+M.&#x00026;author=Koenderman+L.&#x00026;publication_year=2013&#x00026;journal=Cell+Mol.+Life+Sci.&#x00026;volume=70&#x00026;pages=3813-3827" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B46" id="B46"></a>Pisalyaput, K., and Tenner, A. J. (2008). Complement component C1q inhibits &#x003B2;-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. <i>J. Neurochem.</i> 104, 696&#x02013;707. doi: 10.1111/j.1471-4159.2007.05012.x</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=17986223" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/j.1471-4159.2007.05012.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Complement+component+C1q+inhibits+&#x003B2;-amyloid-+and+serum+amyloid+P-induced+neurotoxicity+via+caspase-+and+calpain-independent+mechanisms&#x00026;author=Pisalyaput+K.&#x00026;author=Tenner+A.+J.&#x00026;publication_year=2008&#x00026;journal=J.+Neurochem.&#x00026;volume=104&#x00026;pages=696-707" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B47" id="B47"></a>Reichwald, J., Danner, S., Wiederhold, K. H., and Staufenbiel, M. (2009). Expression of complement system components during aging and amyloid deposition in APP transgenic mice. <i>J. Neuroinflammation</i> 6:35. doi: 10.1186/1742-2094-6-35</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19917141" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1742-2094-6-35" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Expression+of+complement+system+components+during+aging+and+amyloid+deposition+in+APP+transgenic+mice&#x00026;author=Reichwald+J.&#x00026;author=Danner+S.&#x00026;author=Wiederhold+K.+H.&#x00026;author=Staufenbiel+M.&#x00026;publication_year=2009&#x00026;journal=J.+Neuroinflammation&#x00026;volume=6&#x00026;pages=35" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B48" id="B48"></a>Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., et al. (2015). Therapeutic clearance of amyloid by antibodies to serum amyloid P component. <i>N. Engl. J. Med.</i> 373, 1106&#x02013;1114. doi: 10.1056/NEJMoa1504942</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26176329" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa1504942" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Therapeutic+clearance+of+amyloid+by+antibodies+to+serum+amyloid+P+component&#x00026;author=Richards+D.+B.&#x00026;author=Cookson+L.+M.&#x00026;author=Berges+A.+C.&#x00026;author=Barton+S.+V.&#x00026;author=Lane+T.&#x00026;author=Ritter+J.+M.&#x00026;+&#x00026;publication_year=2015&#x00026;journal=N.+Engl.+J.+Med.&#x00026;volume=373&#x00026;pages=1106-1114" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B49" id="B49"></a>Sanderson, S. D., Thoman, M. L., Kis, K., Virts, E. L., Herrera, E. B., Widmann, S., et al. (2012). Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a. <i>PLoS One</i> 7:e40303. doi: 10.1371/journal.pone.0040303</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22792270" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0040303" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Innate+immune+induction+and+influenza+protection+elicited+by+a+response-selective+agonist+of+human+C5a&#x00026;author=Sanderson+S.+D.&#x00026;author=Thoman+M.+L.&#x00026;author=Kis+K.&#x00026;author=Virts+E.+L.&#x00026;author=Herrera+E.+B.&#x00026;author=Widmann+S.&#x00026;+&#x00026;publication_year=2012&#x00026;journal=PLoS+One&#x00026;volume=7&#x00026;pages=e40303" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B50" id="B50"></a>Saraiva, M. J., Birken, S., Costa, P. P., and Goodman, D. S. (1984). Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. <i>J. Clin. Invest.</i> 74, 104&#x02013;119. doi: 10.1172/jci111390</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=6736244" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1172/jci111390" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Amyloid+fibril+protein+in+familial+amyloidotic+polyneuropathy,+Portuguese+type&#x00026;author=Saraiva+M.+J.&#x00026;author=Birken+S.&#x00026;author=Costa+P.+P.&#x00026;author=Goodman+D.+S.&#x00026;publication_year=1984&#x00026;journal=J.+Clin.+Invest.&#x00026;volume=74&#x00026;pages=104-119" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B51" id="B51"></a>Schorlemmer, H. U., Bitter-Suermann, D., and Allison, A. C. (1977). Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. <i>Immunology</i> 32, 929&#x02013;940. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=328387" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Complement+activation+by+the+alternative+pathway+and+macrophage+enzyme+secretion+in+the+pathogenesis+of+chronic+inflammation&#x00026;author=Schorlemmer+H.+U.&#x00026;author=Bitter-Suermann+D.&#x00026;author=Allison+A.+C.&#x00026;publication_year=1977&#x00026;journal=Immunology&#x00026;volume=32&#x00026;pages=929-940" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B52" id="B52"></a>Short, A. J., Paczkowski, N. J., Vogen, S. M., Sanderson, S. D., and Taylor, S. M. (1999). Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat. <i>Br. J. Pharmacol.</i> 128, 511&#x02013;514. doi: 10.1038/sj.bjp.0702847</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=10516626" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.bjp.0702847" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Response-selective+C5a+agonists%3A+differential+effects+on+neutropenia+and+hypotension+in+the+rat&#x00026;author=Short+A.+J.&#x00026;author=Paczkowski+N.+J.&#x00026;author=Vogen+S.+M.&#x00026;author=Sanderson+S.+D.&#x00026;author=Taylor+S.+M.&#x00026;publication_year=1999&#x00026;journal=Br.+J.+Pharmacol.&#x00026;volume=128&#x00026;pages=511-514" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B53" id="B53"></a>Smith, C. A., Pangburn, M. K., Vogel, C. W., and M&#x000FC;ller-Eberhard, H. J. (1984). Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. <i>J. Biol. Chem.</i> 259, 4582&#x02013;4588. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=6707020" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Molecular+architecture+of+human+properdin,+a+positive+regulator+of+the+alternative+pathway+of+complement&#x00026;author=Smith+C.+A.&#x00026;author=Pangburn+M.+K.&#x00026;author=Vogel+C.+W.&#x00026;author=M&#x000FC;ller-Eberhard+H.+J.&#x00026;publication_year=1984&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=259&#x00026;pages=4582-4588" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B54" id="B54"></a>Sousa, M. M., Du Yan, S., Fernandes, R., Guimaraes, A., Stern, D., and Saraiva, M. J. (2001). Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. <i>J. Neurosci.</i> 21, 7576&#x02013;7586. </p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11567048" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?title=Familial+amyloid+polyneuropathy%3A+receptor+for+advanced+glycation+end+products-dependent+triggering+of+neuronal+inflammatory+and+apoptotic+pathways&#x00026;author=Sousa+M.+M.&#x00026;author=Du+Yan+S.&#x00026;author=Fernandes+R.&#x00026;author=Guimaraes+A.&#x00026;author=Stern+D.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2001&#x00026;journal=J.+Neurosci.&#x00026;volume=21&#x00026;pages=7576-7586" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B55" id="B55"></a>Suenaga, G., Ikeda, T., Komohara, Y., Takamatsu, K., Kakuma, T., Tasaki, M., et al. (2016). Involvement of macrophages in the pathogenesis of familial amyloid polyneuropathy and efficacy of human ips cell-derived macrophages in its treatment. <i>PLoS One</i> 11:e0163944. doi: 10.1371/journal.pone.0163944</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27695122" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1371/journal.pone.0163944" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Involvement+of+macrophages+in+the+pathogenesis+of+familial+amyloid+polyneuropathy+and+efficacy+of+human+ips+cell-derived+macrophages+in+its+treatment&#x00026;author=Suenaga+G.&#x00026;author=Ikeda+T.&#x00026;author=Komohara+Y.&#x00026;author=Takamatsu+K.&#x00026;author=Kakuma+T.&#x00026;author=Tasaki+M.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=PLoS+One&#x00026;volume=11&#x00026;pages=e0163944" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B56" id="B56"></a>Sugaya, K., Seto, S., Tsujimura, K., and Koide, Y. (2011). Mobility of late endosomal and lysosomal markers on phagosomes analyzed by fluorescence recovery after photobleaching. <i>Biochem. Biophys. Res. Commun.</i> 410, 371&#x02013;375. doi: 10.1016/j.bbrc.2011.06.023</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21683685" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.bbrc.2011.06.023" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Mobility+of+late+endosomal+and+lysosomal+markers+on+phagosomes+analyzed+by+fluorescence+recovery+after+photobleaching&#x00026;author=Sugaya+K.&#x00026;author=Seto+S.&#x00026;author=Tsujimura+K.&#x00026;author=Koide+Y.&#x00026;publication_year=2011&#x00026;journal=Biochem.+Biophys.+Res.+Commun.&#x00026;volume=410&#x00026;pages=371-375" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B57" id="B57"></a>Talukdar, S., Oh, D. Y., Bandyopadhyay, G., Li, D., Xu, J., McNelis, J., et al. (2012). Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. <i>Nat. Med.</i> 18, 1407&#x02013;1412. doi: 10.1038/nm.2885</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22863787" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nm.2885" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Neutrophils+mediate+insulin+resistance+in+mice+fed+a+high-fat+diet+through+secreted+elastase&#x00026;author=Talukdar+S.&#x00026;author=Oh+D.+Y.&#x00026;author=Bandyopadhyay+G.&#x00026;author=Li+D.&#x00026;author=Xu+J.&#x00026;author=McNelis+J.&#x00026;+&#x00026;publication_year=2012&#x00026;journal=Nat.+Med.&#x00026;volume=18&#x00026;pages=1407-1412" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B58" id="B58"></a>Teixeira, P. F., Cerca, F., Santos, S. D., and Saraiva, M. J. (2006). Endoplasmic reticulum stress associated with extracellular aggregates. <i>J. Biol. Chem.</i> 281, 21998&#x02013;22003. doi: 10.1074/jbc.M602302200</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16751191" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1074/jbc.M602302200" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Endoplasmic+reticulum+stress+associated+with+extracellular+aggregates&#x00026;author=Teixeira+P.+F.&#x00026;author=Cerca+F.&#x00026;author=Santos+S.+D.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2006&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=281&#x00026;pages=21998-22003" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B60" id="B60"></a>Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., et al. (2003). PANTHER: a library of protein families and subfamilies indexed by function. <i>Genome Res.</i> 13, 2129&#x02013;2141. doi: 10.1101/gr.772403</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=12952881" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1101/gr.772403" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=PANTHER%3A+a+library+of+protein+families+and+subfamilies+indexed+by+function&#x00026;author=Thomas+P.+D.&#x00026;author=Campbell+M.+J.&#x00026;author=Kejariwal+A.&#x00026;author=Mi+H.&#x00026;author=Karlak+B.&#x00026;author=Daverman+R.&#x00026;+&#x00026;publication_year=2003&#x00026;journal=Genome+Res.&#x00026;volume=13&#x00026;pages=2129-2141" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B59" id="B59"></a>Thomas, M. P., Whangbo, J., McCrossan, G., Deutsch, A. J., Martinod, K., Walch, M., et al. (2014). Leukocyte protease binding to nucleic acids promotes nuclear localization and cleavage of nucleic acid binding proteins. <i>J. Immunol.</i> 192, 5390&#x02013;5397. doi: 10.4049/jimmunol.1303296</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24771851" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4049/jimmunol.1303296" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Leukocyte+protease+binding+to+nucleic+acids+promotes+nuclear+localization+and+cleavage+of+nucleic+acid+binding+proteins&#x00026;author=Thomas+M.+P.&#x00026;author=Whangbo+J.&#x00026;author=McCrossan+G.&#x00026;author=Deutsch+A.+J.&#x00026;author=Martinod+K.&#x00026;author=Walch+M.&#x00026;+&#x00026;publication_year=2014&#x00026;journal=J.+Immunol.&#x00026;volume=192&#x00026;pages=5390-5397" target="_blank">Google Scholar</a></p>
</div>
<div class="References">
<p class="ReferencesCopy1"><a name="B61" id="B61"></a>Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A. B., de Vos, K., et al. (2006). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. <i>FASEB J.</i> 20, 1407&#x02013;1417. doi: 10.1096/fj.05-5814com</p>
<p class="ReferencesCopy2"><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16816116" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1096/fj.05-5814com" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?title=Therapeutic+activity+of+C5a+receptor+antagonists+in+a+rat+model+of+neurodegeneration&#x00026;author=Woodruff+T.+M.&#x00026;author=Crane+J.+W.&#x00026;author=Proctor+L.+M.&#x00026;author=Buller+K.+M.&#x00026;author=Shek+A.+B.&#x00026;author=de+Vos+K.&#x00026;+&#x00026;publication_year=2006&#x00026;journal=FASEB+J.&#x00026;volume=20&#x00026;pages=1407-1417" target="_blank">Google Scholar</a></p>
</div>
</div>
<div class="thinLineM20"></div>
<div class="AbstractSummary">
<p><span>Keywords:</span> amyloidosis, TTR, C5a receptor, macrophages, amyloid clearance</p> 
<p><span>Citation:</span> Fella E, Sokratous K, Papacharalambous R, Kyriakou K, Phillips J, Sanderson S, Panayiotou E and Kyriakides T (2017) Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy. Front. Mol. Neurosci. 10:138. doi: 10.3389/fnmol.2017.00138</p>
<p id="timestamps"><span>Received:</span> 13 March 2017; <span>Accepted:</span> 21 April 2017;<br> <span>Published:</span> 10 May 2017.</p>
<div><p>Edited by:</p> <a href="http://loop.frontiersin.org/people/75238/overview">Detlev Boison</a>, Legacy Health, USA</div>
<div><p>Reviewed by:</p> <a href="http://loop.frontiersin.org/people/82207/overview">Ursula Susan Sandau</a>, Oregon Health &#x00026; Science University, USA<br> <a href="http://loop.frontiersin.org/people/124888/overview">David Blum</a>, Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale (INSERM), France</div>
<p><span>Copyright</span> &#x000A9; 2017 Fella, Sokratous, Papacharalambous, Kyriakou, Phillips, Sanderson, Panayiotou and Kyriakides. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
<p><span>*Correspondence:</span> Theodoros Kyriakides, <a id="encmail">dGhlb2RvcmVAY2luZy5hYy5jeQ==</a></p>
<p><span><sup>&#x02020;</sup></span> These authors have contributed equally to this work.</p>
<div class="clear"></div>
</div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fnmol.2017.00138" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">6,8K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,8K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">8</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/266403#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fnmol.2017.00138" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fnmol.2017.00138" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/75238/overview" data-event="editorInfo-a-detlevBoison" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">D</span><span class="notranslate">B</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Detlev  Boison</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Department of Neurosurgery, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, United States</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/82207/overview" data-event="editorInfo-a-ursulaSSandau" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">U</span><span class="notranslate">S</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Ursula  S Sandau</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Oregon Health and Science University, United States</div></div></a><a href="https://loop.frontiersin.org/people/124888/overview" data-event="editorInfo-a-davidBlum" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">D</span><span class="notranslate">B</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">David  Blum</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">INSERM U1172 Centre de Recherche Jean Pierre Aubert, France</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal">
<li><a href="#h1">Abstract</a></li>
<li><a href="#h2">Introduction</a></li>
<li><a href="#h3">Materials and Methods</a></li>
<li><a href="#h4">Results</a></li>
<li><a href="#h5">Discussion</a></li>
<li><a href="#h6">Author Contributions</a></li>
<li><a href="#h7">Funding</a></li>
<li><a href="#h8">Conflict of Interest Statement</a></li>
<li><a href="#h9">Acknowledgments</a></li>
<li><a href="#h10">Supplementary Material</a></li>
<li><a href="#h11">References</a></li>
</ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fnmol.2017.00138" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full",["Reactive",16],{"main":17,"user":502,"article":503,"articleHub":802,"mainHeader":806},{"ibar":18,"footer":212,"newsletterComponent":-1,"snackbarItem":294,"toggleShowSnackbar":295,"contentfulJournal":296,"graphJournal":402,"settingsFeaturesSwitchers":406,"templateToggleBanner":407,"tenantConfig":467},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":143,"aboutJournal":144,"mainLinks":193,"journalLinks":200,"helpCenterLink":209},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=1&fieldid=171&specialtyid=0&entitytype=2&entityid=2031",{"id":115,"name":116,"slug":117,"sections":118},2031,"Frontiers in Molecular Neuroscience","molecular-neuroscience",[119,123,127,131,135,139],{"id":120,"name":121,"slug":122},2032,"Brain Disease Mechanisms","brain-disease-mechanisms",{"id":124,"name":125,"slug":126},2034,"Methods and Model Organisms","methods-and-model-organisms",{"id":128,"name":129,"slug":130},2,"Molecular Neuroscience Archive","molecular-neuroscience-archive",{"id":132,"name":133,"slug":134},2033,"Molecular Signalling and Pathways","molecular-signalling-and-pathways",{"id":136,"name":137,"slug":138},2036,"Neuroplasticity and Development","neuroplasticity-and-development",{"id":140,"name":141,"slug":142},2035,"Pain Mechanisms and Modulators","pain-mechanisms-and-modulators","Sections",[145,169],{"title":146,"links":147},"Scope",[148,151,154,157,160,163,166],{"text":149,"url":150,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/molecular-neuroscience/about#about-editors",{"text":152,"url":153,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/molecular-neuroscience/about#about-scope",{"text":155,"url":156,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/molecular-neuroscience/about#about-facts",{"text":158,"url":159,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/molecular-neuroscience/about#about-submission",{"text":161,"url":162,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/molecular-neuroscience/about#about-open",{"text":164,"url":165,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/molecular-neuroscience/about#copyright-statement",{"text":167,"url":168,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/molecular-neuroscience/about#about-quality",{"title":170,"links":171},"For authors",[172,175,178,181,184,187,190],{"text":173,"url":174,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/why-submit",{"text":176,"url":177,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/article-types",{"text":179,"url":180,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/author-guidelines",{"text":182,"url":183,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/editor-guidelines",{"text":185,"url":186,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/publishing-fees",{"text":188,"url":189,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/submission-checklist",{"text":191,"url":192,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/molecular-neuroscience/for-authors/contact-editorial-office",[194,197],{"text":195,"url":196,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":198,"url":199,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[201,204,206],{"text":202,"url":203,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":205,"target":27,"ariaLabel":28},"research-topics",{"text":207,"url":208,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":210,"url":211,"target":77,"ariaLabel":210},"Help center","https://helpcenter.frontiersin.org",{"blocks":213,"socialLinks":267,"copyright":291,"termsAndConditionsUrl":292,"privacyPolicyUrl":293},[214,228,238,252],{"title":215,"links":216},"Guidelines",[217,219,222,225,227],{"text":179,"url":218,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":220,"url":221,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":223,"url":224,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":182,"url":226,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":229,"links":230},"Explore",[231,232,235,237],{"text":202,"url":199,"target":27,"ariaLabel":28},{"text":233,"url":234,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":236,"url":196,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":239,"links":240},"Outreach",[241,244,247,251],{"text":242,"url":92,"target":77,"ariaLabel":243},"Frontiers Forum ","Frontiers Forum website",{"text":245,"url":246,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":248,"url":249,"target":77,"ariaLabel":250},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":253,"links":254},"Connect",[255,256,260,263,266],{"text":210,"url":211,"target":77,"ariaLabel":210},{"text":257,"url":258,"target":77,"ariaLabel":259},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":261,"url":111,"target":27,"ariaLabel":262},"Contact us ","Subscribe to newsletter",{"text":264,"url":265,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[268,276,281,286],{"link":269,"type":272,"color":273,"icon":274,"size":275,"hiddenText":13},{"text":270,"url":271,"target":77,"ariaLabel":270},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":277,"type":272,"color":273,"icon":280,"size":275,"hiddenText":13},{"text":278,"url":279,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":282,"type":272,"color":273,"icon":285,"size":275,"hiddenText":13},{"text":283,"url":284,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":287,"type":272,"color":273,"icon":290,"size":275,"hiddenText":13},{"text":288,"url":289,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":297,"identifier":115,"name":116,"slug":117,"banner":298,"description":395,"mission":396,"palette":397,"impactFactor":398,"citeScore":399,"citations":400,"showTagline":28,"twitter":401},"Journal",[299],{"id":300,"src":301,"name":302,"tags":303,"type":354,"width":355,"height":356,"idHash":357,"archive":358,"brandId":359,"limited":358,"fileSize":360,"isPublic":361,"original":362,"copyright":19,"extension":363,"thumbnails":365,"dateCreated":373,"description":374,"orientation":375,"userCreated":376,"watermarked":358,"dateModified":373,"datePublished":377,"ecsArchiveFiles":378,"propertyOptions":379,"property_Channel":384,"property_Sub-Type":386,"property_Asset_Type":388,"activeOriginalFocusPoint":390,"property_Office_Department":393},"915C603D-8627-48C8-9ADC6859F133F72E","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/webimage-FF824A5C-14ED-4DCD-93CACD22B3645CEB.png","FNMOL_Main Visual_Purple_Website",[304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353],"signal","memory","medical","hormone","rendering","transfer","network","white","tissue","function","electrical","axon","think","impulse","nerve","nervous","brain","bio","receptor","health","system","blue","anatomy","neural","concept","biology","data","intelligence","chemical","loss","science","microscopic","connection","abstract","communication","background","nucleus","synapse","neuron","dendrite","inside","illustration","medicine","3d","cell","human","neurotransmitter","immunological","neurology","cognitive","image",4500,3000,"33456db75c2e9caf",0,"22C10171-81B3-4DA6-99342F272A32E8BB",3650002,1,"https://brand.frontiersin.org/m/33456db75c2e9caf/original/FNMOL_Main-Visual_Purple_Website.jpg",[364],"jpg",{"mini":366,"thul":367,"webimage":301,"Guidelines":368,"WebsiteJpg_XL":369,"WebsiteWebP_L":370,"WebsiteWebP_M":371,"WebsiteWebP_XL":372},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/mini-2DF1B922-ADBF-4B3A-9EDD58E05B5A72E3.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/thul-D2F90508-80E0-452C-AE61AD64775B5DEB.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/6194DC60-82DA-4989-984FDC66CE7BA15C/Guidelines-FNMOL_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/6194DC60-82DA-4989-984FDC66CE7BA15C/WebsiteJpg_XL-FNMOL_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/6194DC60-82DA-4989-984FDC66CE7BA15C/WebsiteWebP_L-FNMOL_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/6194DC60-82DA-4989-984FDC66CE7BA15C/WebsiteWebP_M-FNMOL_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/915C603D-8627-48C8-9ADC6859F133F72E/6194DC60-82DA-4989-984FDC66CE7BA15C/WebsiteWebP_XL-FNMOL_Main Visual_Purple_Website.webp","2022-06-27T10:00:30Z","Receptors sending electrochemical signals. Impulse in human brain on a molecular level. 3d rendering; Shutterstock ID 1210864027; purchase_order: Main Visual; job: ; client: ; other:","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[380,381,382,383],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[385],"frontiersin_org",[387],"Main_Visual",[389],"Photography",{"x":391,"y":392},2250,1500,[394],"Publishing","Part of the most cited neuroscience series, this journal explores and identifies key molecules underlying the structure, design and function of the brain across all levels.","\u003Cp>Frontiers in Molecular Neuroscience is a PubMed Central, Scopus, and SCIE-indexed journal, that explores the brain's molecular structure, design, and function.\u003C/p>\n\n\u003Cp>Frontiers in Molecular Neuroscience is led by Field Chief Editors Robert J. Harvey (University of the Sunshine Coast, Queensland, Australia) and Jochen C. Meier (Technische Universitat Braunschweig, Germany). This multidisciplinary journal seeks to identify how key molecules function and interact to understand the brain's structure, design, and function across all levels. Topics of interest include:\u003C/p>\n\n\u003Cul>\n  \u003Cli>brain disease mechanisms\u003C/li>\n  \u003Cli>coding and non-coding RNA\u003C/li>\n  \u003Cli>methods and model organisms\u003C/li>\n  \u003Cli>molecular mechanisms regulating cellular and dendritic RNA trafficking and translation\u003C/li>\n  \u003Cli>molecular signaling and pathways\u003C/li>\n  \u003Cli>neuroplasticity and development\u003C/li>\n  \u003Cli>pain mechanisms and modulators\u003C/li>\n  \u003Cli>synaptic and cellular proteins.\u003C/li>\n\u003C/ul>\n\n\u003Cp>Frontiers in Molecular Neuroscience is particularly interested in submissions on human brain diseases, and genetically engineered model organisms  such as C. elegans, Drosophila, zebrafish, and rodents  in which alterations in key molecules underlying cellular and synaptic function and plasticity produce defined anatomical, physiological or behavioral changes. Research on genetic alterations in specific neural circuits (e.g., olfactory bulb, motor cortex, cortical layers, hippocampal subfields, cerebellum, brainstem, spinal cord) and compensatory or homeostatic mechanisms are of particular interest.\u003C/p>\n\n\u003Cp>Equally important, the journal encourages submissions that advance the UN's Sustainable Development Goals (SDGs), specifically SDG 3: good health and well-being, promoting our biological understanding of brain health.\u003C/p>\n\n\u003Cp>Manuscripts that focus on clinical practice, genetics, neurological function, cognitive function, and cell proliferation without a clear connection to molecular neuroscience are not suitable for publication in this journal. Similarly, studies on complementary/alternative medicine, e.g., acupuncture/electroacupuncture will not be considered. Studies that do not provide novel insights into the molecular mechanisms underlying neurological processes are also out of scope. For example, research on stem cells or genetic causes of disease without a direct link to molecular neuroscience will not be considered.\u003C/p>\n\n\u003Cp>Frontiers journals require that manuscripts primarily comprising computational studies of public data, must include appropriate validation. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology:~:text=complaints%20and%20allegations.-,Standards%20for%20research%20methodology,-Experiments\">Frontiers Standards for research methodology policy\u003C/a>, for more information. Manuscripts not adhering to these standards will not be considered.\u003Cp>\n\n\u003Cp>Frontiers in Molecular Neuroscience is also committed to advancing research in the field of molecular neuroscience by allowing unrestricted access to articles and communicating scientific knowledge to researchers and the public to enable future scientific breakthroughs.\u003C/p>\n\n\u003Cp>---------\u003C/p>\n\n\u003Cp>Ethics statement\u003C/p>\n\n\u003Cp>All manuscripts submitted toFrontiers in Molecular Neuroscience that have been conducted in human subjects must conform with current regulations and the Declaration of Helsinki. Ethics committee approval and informed patient consent are required for studies involving human subjects. Ethics committee approval is also needed for studies involving animals. Phase I - Phase IV clinical trials submitted for publication inFrontiers in Molecular Neuroscience must have been registered with an appropriate public trials registry at the time or before the first patient enrolment. The information on the clinical trial registration (Unique Identifier and URL) must be included in the abstract. Authors are required to disclose all apparent or potential conflicts of interest according to the ICMJE guidelines and those of Frontiers.\u003C/p>\n\n\u003Cp>Frontiers endeavors to follow the guidelines and best practice recommendations published by the Committee on Publication Ethics (COPE). Authors should refer to theauthor guidelinesfor full details.\u003C/p>\n","purple","4.8","6.7","114113","@FrontNeurosci",{"id":115,"name":116,"slug":117,"abbreviation":403,"isOnline":13,"isOpenForSubmissions":13,"citeScore":404,"impactFactor":405},"fnmol",6.8,3.8,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":295},{"isPublic":13,"allowCompanyUsers":295,"whiteListEmails":408,"enableAllJournals":13,"whiteListJournals":430},[409,410,411,412,413,414,415,416,417,414,418,419,420,421,422,423,424,425,426,427,428,429],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[431,432,433,434,435,436,361,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,451,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":361,"name":361,"availableJournalPages":468,"announcement":472},[203,208,205,469,470,471],"volumes","about","community-reviewers",{"__typename":473,"sys":474,"preHeader":42,"title":476,"description":477,"image":478,"link":500},"Announcement",{"id":475},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[479],{"archive":358,"brandId":359,"copyright":28,"dateCreated":480,"dateModified":481,"datePublished":482,"description":28,"extension":483,"fileSize":485,"height":486,"id":487,"isPublic":358,"limited":358,"name":488,"orientation":375,"original":28,"thumbnails":489,"type":354,"watermarked":358,"width":496,"videoPreviewURLs":497,"tags":498,"textMetaproperties":499,"src":490},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[484],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":490,"thul":491,"mini":492,"WebsiteWebP_L":493,"WebsiteWebP_M":494,"Guidelines":495},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":501,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":504,"isPreviewPage":295,"hasSupplementalData":295,"showCrossmarkWidget":13,"articleTemplate":661,"currentArticlePageMetaInfo":662,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":505,"doi":506,"title":507,"acceptanceDate":508,"receptionDate":509,"publicationDate":510,"lastModifiedDate":511,"isPublished":13,"abstract":512,"researchTopic":28,"articleType":513,"stage":516,"keywords":518,"authors":524,"editors":588,"reviewers":598,"journal":617,"section":624,"impactMetrics":626,"volume":630,"articleVolume":631,"relatedArticles":632,"isPublishedV2":295,"contents":633,"files":636},266403,"10.3389/fnmol.2017.00138","Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy",["Date","2017-04-21T13:41:50.000Z"],["Date","2017-03-13T10:34:21.000Z"],["Date","2017-05-10T00:00:00.000Z"],["Date","2025-11-25T05:33:59.635Z"],"Hereditary ATTR V30M amyloidosis is a lethal autosomal dominant sensorimotor and autonomic neuropathy caused by deposition of aberrant transthyretin (TTR). Immunohistochemical examination of sural nerve biopsies in patients with amyloidotic neuropathy show co-aggregation of TTR with several proteins; including apolipoprotein E, serum amyloid P and components of the complement cascade. Complement activation and macrophages are increasingly recognized to play a crucial role in amyloidogenesis at the tissue bed level. In the current study we test the effect of two C5a receptor agonists and a C5a receptor antagonist (PMX53) on disease phenotype in ATTR V30M mice. Our results indicate that amyloid deposition was significantly reduced following treatment with the C5a receptor agonists, while treatment with the antagonist resulted in a significant increase of amyloid load. Administration of the C5a receptor agonists triggered increased recruitment of phagocytic cells resulting in clearance of amyloid deposits.",{"id":514,"name":515},24,"Original Research",{"id":517,"name":19},18,[519,520,521,522,523],"Amyloidosis","TTR","C5a receptor","Macrophages","amyloid clearance",[525,535,544,550,557,565,573,579],{"id":358,"firstName":526,"middleName":19,"lastName":527,"givenNames":528,"isCorresponding":295,"isProfilePublic":295,"userId":358,"email":-1,"affiliations":529},"Eleni","Fella","Eleni ",[530,533],{"organizationName":531,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},"Neurology Clinic A, The Cyprus Institute of Neurology and Genetics","Nicosia, Cyprus",{"organizationName":534,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},"Cyprus School of Molecular Medicine",{"id":358,"firstName":536,"middleName":19,"lastName":537,"givenNames":538,"isCorresponding":295,"isProfilePublic":295,"userId":358,"email":-1,"affiliations":539},"Kleitos","Sokratous","Kleitos ",[540,542],{"organizationName":541,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},"Electron Microscopy and Molecular Pathology Department, The Cyprus Institute of Neurology and Genetics",{"organizationName":543,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},"Bioinformatics Group, The Cyprus Institute of Neurology and Genetics",{"id":358,"firstName":545,"middleName":19,"lastName":546,"givenNames":547,"isCorresponding":295,"isProfilePublic":295,"userId":358,"email":-1,"affiliations":548},"Revekka","Papacharalambous","Revekka ",[549],{"organizationName":531,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},{"id":358,"firstName":551,"middleName":19,"lastName":552,"givenNames":553,"isCorresponding":295,"isProfilePublic":295,"userId":358,"email":-1,"affiliations":554},"Kyriacos","Kyriacou","Kyriacos ",[555,556],{"organizationName":534,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":541,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},{"id":358,"firstName":558,"middleName":19,"lastName":559,"givenNames":560,"isCorresponding":295,"isProfilePublic":295,"userId":358,"email":-1,"affiliations":561},"Joy","Phillips","Joy ",[562],{"organizationName":563,"countryName":564,"cityName":19,"stateName":19,"zipCode":19},"Donald P. Shiley Bioscience Center, San Diego State University","San Diego, CA, USA",{"id":358,"firstName":566,"middleName":19,"lastName":567,"givenNames":568,"isCorresponding":295,"isProfilePublic":295,"userId":358,"email":-1,"affiliations":569},"Sam","Sanderson","Sam ",[570],{"organizationName":571,"countryName":572,"cityName":19,"stateName":19,"zipCode":19},"Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center","Omaha, NE, USA",{"id":358,"firstName":574,"middleName":19,"lastName":575,"givenNames":576,"isCorresponding":295,"isProfilePublic":295,"userId":358,"email":-1,"affiliations":577},"Elena","Panayiotou","Elena ",[578],{"organizationName":531,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},{"id":580,"firstName":581,"middleName":19,"lastName":582,"givenNames":583,"isCorresponding":13,"isProfilePublic":13,"userId":580,"email":584,"affiliations":585},83140,"Theodoros","Kyriakides","Theodoros ","theodore@cing.ac.cy",[586,587],{"organizationName":531,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":534,"countryName":532,"cityName":19,"stateName":19,"zipCode":19},[589],{"id":590,"firstName":591,"middleName":19,"lastName":592,"givenNames":593,"isCorresponding":295,"isProfilePublic":13,"userId":590,"email":-1,"affiliations":594},75238,"Detlev","Boison","Detlev ",[595],{"organizationName":596,"countryName":597,"cityName":19,"stateName":19,"zipCode":19},"Department of Neurosurgery, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey","United States",[599,608],{"id":600,"firstName":601,"middleName":602,"lastName":603,"givenNames":604,"isCorresponding":295,"isProfilePublic":13,"userId":600,"email":-1,"affiliations":605},82207,"Ursula","S","Sandau","Ursula  S",[606],{"organizationName":607,"countryName":597,"cityName":19,"stateName":19,"zipCode":19},"Oregon Health and Science University",{"id":609,"firstName":610,"middleName":19,"lastName":611,"givenNames":612,"isCorresponding":295,"isProfilePublic":13,"userId":609,"email":-1,"affiliations":613},124888,"David","Blum","David ",[614],{"organizationName":615,"countryName":616,"cityName":19,"stateName":19,"zipCode":19},"INSERM U1172 Centre de Recherche Jean Pierre Aubert","France",{"id":115,"slug":117,"name":116,"shortName":618,"electronicISSN":619,"field":620,"specialtyId":28,"journalSectionPaths":622},"Front. Mol. Neurosci.","1662-5099",{"id":621,"domainId":361},171,[623],{"section":624},{"id":120,"name":121,"slug":122,"specialtyId":625},2473,{"views":627,"downloads":628,"citations":629},6763,1802,8,10,"Volume 10 - 2017",[],{"titleHtml":507,"fullTextHtml":634,"menuHtml":635},"\u003Cdiv class=\"JournalAbstract\">\r\n\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\r\n\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\r\n\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"\r\nEleni Fella,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Eleni Fella\u003Csup>1,2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Kleitos Sokratous,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Kleitos Sokratous\u003Csup>3,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Revekka Papacharalambous\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Revekka Papacharalambous\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Kyriacos Kyriacou,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Kyriacos Kyriacou\u003Csup>2,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Joy Phillips\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Joy Phillips\u003Csup>5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Sam Sanderson\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Sam Sanderson\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Elena Panayiotou&#x;\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Elena Panayiotou\u003Csup>1&#x02020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/83140\" class=\"user-id-83140\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/83140/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Theodoros Kyriakides,*&#x;\">Theodoros Kyriakides\u003C/a>\u003Csup>1,2*&#x02020;\u003C/sup>\u003C/span>\u003C/div>\r\n\u003Cul class=\"notes\">\r\n\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Cyprus School of Molecular Medicine, Nicosia, Cyprus\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Electron Microscopy and Molecular Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Bioinformatics Group, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>Donald P. Shiley Bioscience Center, San Diego State University, San Diego, CA, USA\u003C/li>\r\n\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA\u003C/li>\r\n\u003C/ul> \r\n\u003Cp>Hereditary ATTR V30M amyloidosis is a lethal autosomal dominant sensorimotor and autonomic neuropathy caused by deposition of aberrant transthyretin (TTR). Immunohistochemical examination of sural nerve biopsies in patients with amyloidotic neuropathy show co-aggregation of TTR with several proteins; including apolipoprotein E, serum amyloid P and components of the complement cascade. Complement activation and macrophages are increasingly recognized to play a crucial role in amyloidogenesis at the tissue bed level. In the current study we test the effect of two C5a receptor agonists and a C5a receptor antagonist (PMX53) on disease phenotype in ATTR V30M mice. Our results indicate that amyloid deposition was significantly reduced following treatment with the C5a receptor agonists, while treatment with the antagonist resulted in a significant increase of amyloid load. Administration of the C5a receptor agonists triggered increased recruitment of phagocytic cells resulting in clearance of amyloid deposits.\u003C/p> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"JournalFullText\">\r\n\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\r\n\u003Cp class=\"mb15\">Hereditary ATTR V30M amyloidosis is a life-threatening progressive sensory-motor and autonomic peripheral neuropathy. ATTR V30M amyloidosis is caused by extracellular accumulation of misfolded transthyretin (TTR), subsequently creating insoluble aggregates of amyloid fibrils (\u003Ca href=\"#B50\">Saraiva et al., 1984\u003C/a>). Even though there are more than a 100 mutations causing ATTR amyloidoses, the first discovered and by far the most common is ATTR V30M, which is due to a substitution of a valine with methionine in position 30 (Val30Met) of the TTR protein (\u003Ca href=\"#B2\">Ando et al., 2005\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">There is considerable variability in the age of onset and penetrance of hereditary ATTR V30M in different countries. Epigenetic and genetic factors are believed to contribute to this variability. Complement cascade components have been shown to co-precipitate with amyloid in various forms of amyloidotic neuropathy (\u003Ca href=\"#B21\">Hafer-Macko et al., 2000\u003C/a>). Our group has previously identified polymorphisms in C1q to correlate with age of onset in a Cypriot cohort of ATTR V30M patients suggesting that complement C1q may be a modifier gene (\u003Ca href=\"#B12\">Dardiotis et al., 2009\u003C/a>). We have recently demonstrated that C1q deficient ATTR V30M mice exhibit a 60% increase in amyloid deposition compared to their C1q efficient counterparts (\u003Ca href=\"#B43\">Panayiotou et al., 2017\u003C/a>). C1q has also been shown to modulate beta-amyloid induced complement activation and neuronal loss in Alzheimer&#x02019;s disease (\u003Ca href=\"#B17\">Fonseca et al., 2011\u003C/a>) as well as modulating phagocytosis of soluble pre-amyloid aggregates (\u003Ca href=\"#B46\">Pisalyaput and Tenner, 2008\u003C/a>). A dual role for complement has been proposed, a protective effect from early components of complement (C1q opsonizes foreign material and phagocytes) and a detrimental effect from late components such as C3a and C5a exarcebating neuroinflammation (\u003Ca href=\"#B17\">Fonseca et al., 2011\u003C/a>). Late component C5a is produced following the activation of any of the three pathways of the complement cascade system. The C5 complement system factor is cleaved by C5 convertases producing the C5a and C5b molecules. C5a acts as an anaphylactic molecule by attracting C5a receptor bearing cells including macrophages and neutrophils leading to a pro-inflammatory response (\u003Ca href=\"#B35\">Mathern and Heeger, 2015\u003C/a>). Activation of the C5a receptor in the CNS could have a detrimental role leading to neurotoxicity or a neuroprotective role through phagocytosis (\u003Ca href=\"#B16\">Fonseca et al., 2009\u003C/a>). However, the effects of C5a receptor activation by the C5a anaphylatoxin in ATTRV30M amyloidosis have not been elucidated yet.\u003C/p>\r\n\u003Cp class=\"mb15\">More recently it has been shown that anti-serum amyloid P antibodies admnistered to AA amyloidotic mice resulted in an extensive &#x0201C;complement-dependent, macrophage-derived&#x0201D; response which reduced the amount of amyloid deposition (\u003Ca href=\"#B6\">Bodin et al., 2010\u003C/a>). This observation has been extended successfully in a Phase 1 study in humans (\u003Ca href=\"#B48\">Richards et al., 2015\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb0\">The objective of the current study was to elucidate further the role of the complement in the pathogenesis of ATTR V30M amyloidosis and investigate the possibilty of therapeutically manipulating complement to eliminate amyloid deposit. We have administered two C5a receptor agonists, a full C5a receptor agonist and EP67 (a response-selective C5a receptor agonist deprived of C5a-like anaphylatoxin activity), and a C5a receptor antagonist (PMX53) and examined disease phenotype in ATTR V30M mice after 1 week. We show that treatment with the C5a receptor agonists significantly ameliorated amyloid deposition while C5a receptor antagonist PMX53 exacerbated amyloid deposits. We have also carried out mass spectrometry-based proteomic analysis, comparing the proteome of animals with the highest amount of amyloid and the lowest amount of amyloid. This analysis has shown substantial phagocytic cell activation, as well as the increased expression of proteolytic peptidases accompanying the reduction in amyloid deposition.\u003C/p>\r\n\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials and Methods\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Animals and Tissue Handling\u003C/h3>\r\n\u003Cp class=\"mb15\">The previously published mouse model of ATTR V30M neuropathy (\u003Ca href=\"#B28\">Kohno et al., 1997\u003C/a>) was kindly donated by Dr. M. Saraiva. These animals are knockouts for murine TTR and have been bred to carry the human V30M mutated cDNA in the form of a transgene in a homozygous state (mTTR\u003Csup>&#x02212;/&#x02212;\u003C/sup>hTTR\u003Csup>Met30+/+\u003C/sup>). Real time PCR was used to ensure that all animals included in the experiments had the same copy number of human TTR transgenes. All animals used for the experiments were 13&#x02013;14 months old since at this age amyloid deposits are well established.\u003C/p>\r\n\u003Cp class=\"mb15\">All animals were kept in a regular 12-h light-12 h dark cycle and were given free access to water and food, under SPF conditions. Animals were separated in cages depending on the molecule they were treated with. Four groups of animals were included for study; one group was treated with PMX53 (kindly provided by Cephalon USA), one group with the full C5a receptor agonist molecule (purchased from Anaspec), one group with the modified C5a receptor agonist, EP67 (\u003Ca href=\"#B49\">Sanderson et al., 2012\u003C/a>) and finally there was a control group. Each group was comprised of six animals while the treatment period lasted for 1 week, during which each molecule was added to the animals&#x02019; water source at 20 &#x003BC;g/ml. The control group animals only received water without the addition of any other compound. All animal involving experiments were carried out in accordance to the 86/609/EEC Directive. Also, a project license was obtained from the Cyprus Veterinary Services approving the project and methodology (License Number: CY/EXP/P.L6/2010).\u003C/p>\r\n\u003Cp class=\"mb0\">Mice were anesthetized and then euthanized using Tribromoethanol (Avertin) through IP injection at a dose of 250 mg/Kg. The animals were then exsanguinated via PBS perfusion to reduce the contribution of plasma in tissue measurements. Tissues were processed for immunohistochemistry by carrying out overnight 4% PFA fixation followed by wax embedding or were frozen and kept at &#x02212;80&#x000B0;C for immunoblotting. Amyloid deposition assessment was confined to stomach tissue since this tissue is heavily involved in amyloid deposition at an early age in this particular mouse model of ATTR V30M neuropathy.\u003C/p>\r\n\u003Ch3>Genotyping\u003C/h3>\r\n\u003Cp class=\"mb0\">Animals were genotyped using the PCR method. Primers for the mouse TTR gene (mTTR F 5&#x02032;&#x02013;CTG ACC CAT TTC ACT GAC ATT T&#x02013;3&#x02032; &#x00026; mTTR R 5&#x02032;&#x02013;CAA ATG GGA ACC TGG AAC C&#x02013;3&#x02032;); the human mutated transgene (hMET30 F 5&#x02032;&#x02013;TGCTGATGACACCTGGGAGC&#x02013;3&#x02032; and hMET30 R 5&#x02032;TCAGGTTCCTGGTCACTTCC&#x02013;3&#x02032;) were utilized for screening with annealing temperature at 58&#x000B0;C.\u003C/p>\r\n\u003Ch3>Amyloid Plaque Visualization and Quantification\u003C/h3>\r\n\u003Cp class=\"mb0\">Thioflavin S staining combined with TTR immunofluorescence were used to identify TTR specific amyloid deposits in paraffin sections obtained from stomach tissue. Paraffin sections were deparaffinized and hydrated to distilled water. Sections were then stained with Mayer&#x02019;s hemeatoxylin for 5 min, washed further with distilled water and then stained with aqueous 1% Thioflavin S solution (T1892-25G) for a further 5 min and finally differentiated in 50% ethanol before been rinsed with distilled water and then mounted using the DAKO Fluorescence Mounting Medium (S3023). Thioflavin S positive deposits were further confirmed to be amyloid by Congo Red (Figures \u003Ca href=\"#F1\">1Bi,ii\u003C/a>). Plaques positive for both Thioflavin S and hTTR were measured using the ImageJ software set to measure yellow (570&#x02013;585 nm; Figures \u003Ca href=\"#F1\">1Biii&#x02013;Bvi\u003C/a>). TTR amyloid plaques were measured over the entire area of stomach section, a percentage of the surface area occupied by plaques was calculated and an average percentage obtained over five serial sections.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg\" name=\"figure1\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg\" alt=\"www.frontiersin.org\" id=\"F1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 1. Amyloid deposition: amyloid plaques were quantified through Thioflavin-S staining (A).\u003C/strong> All groups exhibited significant difference from one another, with the PMX53 treated mice having the greatest amount of deposition and the full agonist treated group having the lowest recorded amount. \u003Ci>n\u003C/i> = 6/group, data presented as mean &#x000B1; 1 SD. *\u003Ci>p\u003C/i> &#x0003C; 0.05, **\u003Ci>p\u003C/i> &#x0003C; 0.01, ***\u003Ci>p\u003C/i> &#x0003C; 0.001. \u003Cstrong>(B)\u003C/strong> Amyloid plaque in the stomach that stains with Congo red and exhibits apple green birefringence \u003Cstrong>(Bi,ii)\u003C/strong>. The same plaque stains Thioflavin-S positive \u003Cstrong>(Biii)\u003C/strong> and is composed of human transthyretin (TTR; \u003Cstrong>Biv\u003C/strong>). The area of co-localization of Thioflavin-S and TTR labeling appears yellow \u003Cstrong>(Bv)\u003C/strong> and morphometric measurements are carried out with the ImageJ software \u003Cstrong>(Bvi)\u003C/strong>. Scale bar = 150 &#x003BC;m.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ch3>Serum Elisa Method\u003C/h3>\r\n\u003Cp class=\"mb0\">Serum human TTR was measured using enzyme-linked immunosorbent assay (ELISA) from four animals from each of the four groups. Blood samples were collected, without sacrificing any of the animals, from the orbital sinus in the absence of anticoagulant. The samples were allowed to stand at room temperature for approximately 30 min to coagulate. They were then centrifuged at 3500 rpm for 10 min and the top layer was collected in order to obtain the serum. Samples were diluted 1/50,000 using the supplied mix diluent from the kit used (Abnova TTR Human ELISA Kit KA0495) and the procedure was carried out as outlined by the supplier. Absorbance was measured at 450 nm using a microplate reader.\u003C/p>\r\n\u003Ch3>Western Blots and Densitometry\u003C/h3>\r\n\u003Cp class=\"mb15\">Stomach homogenate (tissue lysed with RIPA buffer and protease inhibitors under sonication) was separated via reducing SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% BSA for 1 h at room temperature. The membranes were then incubated overnight at 4&#x000B0;C with the appropriate primary antibody. Specific antibodies were then visualized using the Super Signal West Femto Maximum Sensitivity Substrate (Thermo Fisher 34095) after incubating with the required HRP conjugated secondary antibody for 1 h at room temperature. Blots were repeated in triplicates and were visualized using the UVP bio-imaging system.\u003C/p>\r\n\u003Cp class=\"mb15\">The antibodies used for immunoblotting were against: BiP (anti-rabbit Santa Cruz sc-13968 1/350), C1q (anti-rabbit Santa Cruz sc-27661 1/100), Caspase-3 (anti-rabbit Enzo Life Sciences ALX-210-806-C100 1/1000), CD68 (anti-rabbit Santa Cruz sc-9139 1/150), CD88 (anti-mouse Santa Cruz sc-53795 1/100), ELANE (anti-rabbit Abcam ab68672 1/1000), F4/80 (anti-rabbit Santa Cruz sc-25830 1/100), IL-36&#x003B3; (anti-goat Santa Cruz sc-168163 1/100), Ly6G (anti-mouse Antibodies online ABIN361224 1/1000) and Properdin (anti-rabbit Santa Cruz sc-68367 1/100). The appropriate HRP conjugated secondary antibodies were used, anti-mouse (Santa Cruz SC-2031 1/5000), anti-rabbit (Santa Cruz SC-2004 1/5000).\u003C/p>\r\n\u003Cp class=\"mb0\">ImageJ was used to carry out densitometry calculations, while all bands were normalized against a GAPDH loading control (Santa Cruz sc-25778 1/1000), while the same reference sample was in all westerns to allow cross-gel comparison).\u003C/p>\r\n\u003Ch3>Immunohistochemistry\u003C/h3>\r\n\u003Cp class=\"mb15\">Paraffin sections from animals&#x02019; stomachs were deparaffinized and hydrated to distilled water. Sections were then blocked with 5% BSA solution in PBS for 1 h at room temperature and then incubated with the appropriate primary antibody overnight at 4&#x000B0;C. The slides were then washed and incubated with the appropriate secondary antibody for 1 h at room temperature. Finally, DAPI staining was used to label the cells&#x02019; nuclei (Sigma Aldrich D9542) before been mounted using the DAKO Fluorescence Mounting Medium (S3023). Pictures were taken using a Zeiss AXIOIMAGER M2 fluorescence microscope.\u003C/p>\r\n\u003Cp class=\"mb0\">The primary antibodies used were against: BiP (anti-rabbit Santa Cruz sc-13968 1/100), Caspase-3 (anti-rabbit Santa Cruz sc-7148 1/500), CD68 (anti-goat Santa Cruz sc-7084 1/50), ELANE (anti-rabbit Abcam ab68672 1/100), Lamp-1 (anti-rabbit Cell signaling 8653 1/800) and human TTR (anti rabbit DAKO A000202 1/500). The appropriate Invitrogen Alexa Fluor 555 and 488 fluorescence secondary antibodies were used, anti-rabbit (A-21428 and A-11008 1/2000) and anti-goat (A-21432 and A-11055 1/2000).\u003C/p>\r\n\u003Ch3>Mass Spectrometry-Based Proteomics\u003C/h3>\r\n\u003Cp class=\"mb0\">Frozen stomach tissue samples from three animals from two groups of animals (full agonist treated and PMX53 treated) were incubated in lysis buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% (v/v) SDS, 1X protease inhibitors) for 30 min on ice, followed by sonication for 30 s (50% pulse) using Model 150VT (Biologics Inc., Virginia, USA). Lysates were clarified by centrifugation at 12,000 rpm for 20 min at 4&#x000B0;C. The supernatant was collected and proteins were precipitated in tenfold excess volume of ice-cold acetone overnight at &#x02212;20&#x000B0;C and subsequently resuspended in urea buffer (8 M urea, 50 mM ammonium bicarbonate). Protein concentration was determined using BCA protein assay. For each sample, 100 &#x003BC;g of protein was transferred to a new tube, reduced with DTT (10 mM final concentration) for 30 min at 60&#x000B0;C and alkylated with iodoacetamide (15 mM final concentration) for 15 min in dark at room temperature followed by fourfold dilution in 50 mM ammonium bicarbonate. Proteins were digested with 2 &#x003BC;g of proteomics grade trypsin (Roche Diagnostics GmbH, Mannheim, Germany) at 37&#x000B0;C for 18 h. Digestion was quenched by addition of TFA to a final concentration of 0.5%. Peptides were desalted and purified using reverse phase solid phase extraction cartridges (Sep-Pak C18, Waters, Vienna, Austria) and eluates were lyophilized using a centrifugal vacuum concentrator. Peptide pellets were re-dissolved in 1% acetonitrile, 0.1% formic acid (mobile phase A) to yield an approximate concentration of 200 ng/&#x003BC;L (determined by NanoDrop measurement at 280 nm). The peptide separation was performed on a Waters nanoAcquity UPLC system (Waters Co., Wilmslow, UK). Peptides were loaded onto a C18 column (Acquity UPLC M-Class, Peptide CSH, 75 &#x003BC;m &#x000D7; 250 mm, 1.7 &#x003BC;m, 130 &#x000C5;) and eluted with a linear gradient from 5% mobile phase B (0.1% formic acid in acetonitrile) to 40% mobile phase B over 175-min. Peptides were analyzed on a Waters Synapt G2Si HDMS instrument (Waters Co., Wilmslow, UK) operated in ion mobility mode using the UDMS\u003Csup>E\u003C/sup> approach (\u003Ca href=\"#B14\">Distler et al., 2014\u003C/a>). Each sample analyzed in triplicate. Raw mass spectrometry data were analyzed using Progenesis QI for proteomics software (version 3.0) and were subjected to protein identification against the SwissProt mouse reference proteome database (version July 2016, 16761 sequences plus human TTR, P02766) using the MS\u003Csup>e\u003C/sup> peptide identification method. The searching parameters used were: trypsin digestion, 1 missed cleavage, FDR &#x0003C;4%. The identifications were refined using the following parameters: score &#x02265;5, hits &#x02265;2, sequence length &#x02265;6, description not containing probable, predictive, potential or putative.\u003C/p>\r\n\u003Ch3>Statistical Analyses\u003C/h3>\r\n\u003Cp class=\"mb0\">Statistical analysis was performed using GraphPad Prism version 5.00 for Windows (GraphPad software, San Diego, CA, USA) where one-way analysis of variance (ANOVA) followed by Tukey&#x02019;s \u003Ci>post hoc\u003C/i> test was carried out. Using this information, graphical charts representing the data were prepared.\u003C/p>\r\n\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\r\n\u003Ch3 class=\"pt0\">Amyloid Deposition in the Stomach\u003C/h3>\r\n\u003Cp class=\"mb0\">Following administration of all three agents for 1 week, all animals were sacrificed (including untreated, age-matched control hTTRV30M animals) and amyloid deposition was examined by combined Thioflavin S staining and TTR immunofluorescence (Figure \u003Ca href=\"#F1\">1A\u003C/a>). There was a 160% increase in amyloid load following the administration of PMX53 for a week when compared to the control hTTRV30M mice. Administration of the C5a receptor agonist EP67 resulted in a 42% decrease in deposited amyloid. Further amyloid reduction was recorded following administration of the full receptor agonist (65%).\u003C/p>\r\n\u003Ch3>hTTR Levels in Serum and Stomach\u003C/h3>\r\n\u003Cp class=\"mb0\">The levels of human V30M TTR were measured in the serum of all mice participating in the study using the ELISA at the end of the treatment period. Our results indicate that the amount of hTTR found in the serum remains unaffected for all four groups (Figure \u003Ca href=\"#F2\">2A\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg\" name=\"figure2\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g002.jpg\" alt=\"www.frontiersin.org\" id=\"F2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 2. Amount of hTTR found in the serum and stomach: (A)\u003C/strong> TTR in the serum was quantified using enzyme-linked immunosorbent assay (ELISA). Results show that no statistical difference in the amount of circulating TTR was recorded between the four groups of mice. \u003Ci>n\u003C/i> = 4/group, data presented as mean &#x000B1; 1 SD. \u003Cstrong>(B)\u003C/strong> hTTR levels in the stomach were measured via immunoblotting. Significant decrease was observed in the mice treated with the two agonist molecules when compared to the untreated control mice. \u003Ci>n\u003C/i> = 6/group. Data presented as mean &#x000B1; 1 SD. Indicative images from each group shown in \u003Cstrong>(Bi&#x02013;iv)\u003C/strong>. *\u003Ci>p\u003C/i> &#x0003C; 0.05, **\u003Ci>p\u003C/i> &#x0003C; 0.01, ***\u003Ci>p\u003C/i> &#x0003C; 0.001.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb0 w100pc float_left mt15\">The amount of pre-fibrillar hTTR was measured in stomach tissue of all animals (Figure \u003Ca href=\"#F2\">2B\u003C/a>). Our results indicated significantly less hTTR between the two groups treated with the agonists and the control animals. The PMX53 group did not significantly differ from the control group.\u003C/p>\r\n\u003Ch3>Phagocytic Cell Markers in Stomach Tissue\u003C/h3>\r\n\u003Cp class=\"mb15\">The PMX53 molecule is a known C5a receptor (CD88) inhibitor, while the other two molecules used are agonists for the receptor. Even though C5a receptors (C5R1, CD88) are ubiquitously expressed on a variety of cells, they are most prominently expressed on the surface of neutrophils and macrophages (\u003Ca href=\"#B40\">Monk et al., 2007\u003C/a>), therefore, identifying markers for these two cell types were used to establish their presence in the experimental animals.\u003C/p>\r\n\u003Cp class=\"mb0\">CD88, the ubiquitous C5a receptor was found to be significantly elevated in both the full agonist and EP67 groups when compared to the control animals, whereas the receptor was severely decreased in the animals treated with PMX53 (Figure \u003Ca href=\"#F3\">3A\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg\" name=\"figure3\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g003.jpg\" alt=\"www.frontiersin.org\" id=\"F3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 3. Expression of phagocytic cell markers in stomach tissue: (A)\u003C/strong> The expression of CD88 was measured by immunoblotting indicating a decrease in the marker in both the untreated group and the group treated with the PMX53 antagonist, while the two groups treated with the agonists exhibited the greatest level of expression. Similar effects were observed with Neutrophil elastase \u003Cstrong>(B)\u003C/strong>, Ly6G \u003Cstrong>(C)\u003C/strong> and IL-36&#x003B3; \u003Cstrong>(D)\u003C/strong>. Immunoblots for the macrophage specific markers F4/80 \u003Cstrong>(E)\u003C/strong> and CD68 \u003Cstrong>(F)\u003C/strong> however indicate their overexpression in the group of mice treated with the modified agonist molecule EP67, while the group treated with the PMX53 antagonist exhibited the lowest levels of expression for both markers. \u003Ci>n\u003C/i> = 6/group data presented as mean &#x000B1; 1 SD. *\u003Ci>p\u003C/i> &#x0003C; 0.05, **\u003Ci>p\u003C/i> &#x0003C; 0.01, ***\u003Ci>p\u003C/i> &#x0003C; 0.001.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Neutrophil elastase (ELANE) and Ly6G are both well characterized markers of neutrophils (\u003Ca href=\"#B57\">Talukdar et al., 2012\u003C/a>; \u003Ca href=\"#B1\">Amsalem et al., 2014\u003C/a>). ELANE is a chymotrypsin like serine proteinase which is mainly secreted by neutrophils during inflammation in order to induce the clearance of bacteria and host tissue (\u003Ca href=\"#B5\">Belaaouaj et al., 2000\u003C/a>). ELANE is also very similar to other immune system cytotoxic serine proteases such as granzymes and cathepsin G (\u003Ca href=\"#B59\">Thomas et al., 2014\u003C/a>). Our results show that ELANE is highest in the group of mice treated with the full agonist molecule, which retains its anaphylactic properties, while it is lower in the group treated with the agonist EP67 which activates C5aR receptors on macrophages but less so on neutrophils (Figure \u003Ca href=\"#F3\">3B\u003C/a>). The PMX53 treated animals were found to express the lowest levels of ELANE even though the change was not statistically significant when compared to the untreated control group.\u003C/p>\r\n\u003Cp class=\"mb15\">Ly6G is s neutrophil specific marker which has been previously used to deplete neutrophils in mice (\u003Ca href=\"#B45\">Pillay et al., 2013\u003C/a>). Our data indicate a similar pattern as with ELANE, where the groups treated with the agonist molecules exhibit the highest level of Ly6G, while the mice treated with the PMX53 antagonist molecule exhibit the lowest amount of Ly6G detected (Figure \u003Ca href=\"#F3\">3C\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Interleukin 36&#x003B3; (IL-36&#x003B3;) has been found to be up-regulated in a number of inflammatory diseases and is believed to be expressed by both neutrophils and macrophages (\u003Ca href=\"#B7\">Bozoyan et al., 2015\u003C/a>; \u003Ca href=\"#B29\">Kovach et al., 2016\u003C/a>; \u003Ca href=\"#B33\">Macleod et al., 2016\u003C/a>). Our results also indicate that IL-36&#x003B3; is highest in the group of mice treated with the full agonist and the lowest in the group treated with the PMX53 molecule (Figure \u003Ca href=\"#F3\">3D\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">The murine F4/80 (EGF-like module-containing mucin-like hormone receptor-like 1, Emr1 homolog) is a well-known marker of murine macrophage populations (\u003Ca href=\"#B3\">Austyn and Gordon, 1981\u003C/a>), while CD68 is found to be expressed on all macrophages (\u003Ca href=\"#B41\">Murray and Wynn, 2011\u003C/a>). The PMX53 treated mice exhibited the lowest levels of both macrophage markers, while both groups of mice treated with the agonist molecules displayed greater expression of the two markers when compared to the untreated control (Figures \u003Ca href=\"#F3\">3E,F\u003C/a>). However, the mice treated with EP67 display the greatest levels of macrophages, even when compared to the group treated with the full agonist.\u003C/p>\r\n\u003Cp class=\"mb0\">Results yielded from the liquid chromatography&#x02014;tandem mass spectrometry (LC-MS/MS) analysis comparison between the group with the highest amyloid deposition (PMX53 treated) and the group with the lowest amount of amyloid (full agonist treated) revealed a number of macrophage and neutrophil related markers which were highly expressed in the animals with the lowest amount of amyloid (Supplementary Table S1).\u003C/p>\r\n\u003Ch3>Immunofluorescence with Neutrophil and Macrophage Markers\u003C/h3>\r\n\u003Cp class=\"mb15\">In order to examine the co-expression of the macrophage and neutrophil markers with the amyloid plaques serial deparaffinized stomach sections were immunostained with antibodies specific for CD68, neutrophil elastase/ELANE, hTTR and Thioflavin-S.\u003C/p>\r\n\u003Cp class=\"mb0\">The untreated group displays minimal co-localization of &#x003B1;-CD68 with the Thioflavin-S/hTTR positive plaques, while there is no co-localization with &#x003B1;-ELANE (Figure \u003Ca href=\"#F4\">4A\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 4\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg\" name=\"figure4\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g004.jpg\" alt=\"www.frontiersin.org\" id=\"F4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 4. Amyloid plaque infiltration by macrophages and neutrophils: serial sections stomach sections from mice representing the four groups of mice were stained with Thioflavin-S, &#x003B1;-TTR, the pan-macrophage marker &#x003B1;-CD68 and the neutrophil marker &#x003B1;-Neutrophil elastase (ELANE).\u003C/strong> Immunofluorescence on the stomach tissue from the untreated mouse indicates the complete absence of neutrophils from the plaque, while there is some co-expression with CD68 \u003Cstrong>(A)\u003C/strong>. A similar pattern was observed with the mouse treated with the PMX53 antagonist molecule \u003Cstrong>(B)\u003C/strong>, while complete co-localization with both CD68 and ELANE was observed in the mouse treated with the full agonist molecule \u003Cstrong>(C)\u003C/strong>. Immunofluorescence on the mouse treated with the modified agonist EP67 however revealed complete plaque co-localization with CD68 and the complete absence of ELANE from the region \u003Cstrong>(D)\u003C/strong>. Scale bar = 75 &#x003BC;m.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">The sections from the mice treated with the C5a antagonist PMX53 exhibit an even lower level of &#x003B1;-CD68 co-localization, probably indicative of the fact that there&#x02019;s a decreased recruitment due to inhibition of the receptor (Figure \u003Ca href=\"#F4\">4B\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb0\">In the group treated with the full agonist there was complete plaque co-localization with both &#x003B1;-CD68 and &#x003B1;-ELANE (Figure \u003Ca href=\"#F4\">4C\u003C/a>). The EP67 treated group however exhibited mainly co-localization with &#x003B1;-CD68 positivity with a much less neutrophil recruitment (Figure \u003Ca href=\"#F4\">4D\u003C/a>).\u003C/p>\r\n\u003Ch3>Complement Markers in Stomach Tissue\u003C/h3>\r\n\u003Cp class=\"mb15\">The complement system has been previously shown to be involved with amyloidogenesis and the pathogenesis of the disease. Therefore, markers for both the classical and alternative complement system were analyzed using immunoblotting.\u003C/p>\r\n\u003Cp class=\"mb0\">The classical complement pathway is initiated through the C1q molecule. C1q itself is produced by peripheral tissue phagocytic cells (\u003Ca href=\"#B44\">Petry et al., 1991\u003C/a>). The group of mice treated with the full agonist molecule express the greatest amount of C1q; even though the mice treated with the EP67 molecule also exhibit elevated amounts of C1q when compared to the untreated control animals. On the contrary, the animals treated with the C5aR inhibitor, PMX53; do not display any significant difference from the control animals (Figure \u003Ca href=\"#F5\">5A\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 5\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg\" name=\"figure5\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g005.jpg\" alt=\"www.frontiersin.org\" id=\"F5\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 5. Expression of complement markers: the expression of the classical complement pathway protein C1q was measured by immunoblotting in stomach tissues of all the animals from the four groups of mice (A).\u003C/strong> The group treated with the full agonist molecule exhibited the highest levels of C1q which was statistically significant when compared to the rest of the groups, while the mice with the modified agonist also exhibited a significant increase when compared to the untreated control group. Similar effects were observed via immunofluorescence. Properdin, the alternative complement pathway marker, also presented an analogous pattern so that the group of mice treated with the two agonists also expressed the greatest amount of the protein \u003Cstrong>(B)\u003C/strong>. \u003Ci>n\u003C/i> = 6/group, data presented as mean &#x000B1; 1 SD. B&#x00026;D Scale bar = 150 &#x003BC;m. *\u003Ci>p\u003C/i> &#x0003C; 0.05, **\u003Ci>p\u003C/i> &#x0003C; 0.01, ***\u003Ci>p\u003C/i> &#x0003C; 0.001.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Properdin (factor P) is a unique positive regulator of complement activation which functions by stabilizing the alternative pathway convertases (\u003Ca href=\"#B53\">Smith et al., 1984\u003C/a>) so that it may be used as an alternative complement pathway marker.\u003C/p>\r\n\u003Cp class=\"mb15\">Our results indicate the greatest amount of properdin in the animals treated with the full agonist, followed by the EP67 treated group (Figure \u003Ca href=\"#F5\">5B\u003C/a>). The PMX53 treated mice express the same amount of properdin as the control group.\u003C/p>\r\n\u003Cp class=\"mb0\">These results were also corroborated through the LC-MS/MS analysis, where the complement cascade proteins, along with properdin, were found to be higher in the group of mice treated with the full agonist molecule when compared to the group of mice treated with the PMX53 molecule (Supplementary Table S1).\u003C/p>\r\n\u003Ch3>Stress and Apoptosis Markers in Stomach Tissue\u003C/h3>\r\n\u003Cp class=\"mb0\">The presence of extracellular amyloid deposits and pre-fibrillar hTTR species have been shown to increase endoplasmic reticulum stress through the activation of the classical unfolded protein response pathways in tissues not specialized in hTTR synthesis (\u003Ca href=\"#B58\">Teixeira et al., 2006\u003C/a>; \u003Ca href=\"#B32\">Macedo et al., 2007\u003C/a>). Our results indicate that the mice treated with PMX53 possess the highest levels of BiP which is in accordance with the high levels of amyloid deposits. The groups treated with the agonists exhibit significantly less amount of BiP than the PMX53 mice even though they do not appear to be lower than the control untreated mice (Figure \u003Ca href=\"#F6\">6A\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 6\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg\" name=\"figure6\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g006.jpg\" alt=\"www.frontiersin.org\" id=\"F6\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 6. Expression of stress markers: the expression of BiP was measured by immunoblotting (A)\u003C/strong> in the stomach tissues of all animals from the four groups. While the animals from the groups treated with the two agonists and the untreated group displayed comparable levels of BiP, the group treated with the PMX53 antagonist exhibited significantly greater amounts of the cellular stress marker. Comparable effects were observed via immunostaining. Similarly, immunoblotting using the apoptotic marker Caspase-3 displayed a significantly increased expression in the group of mice treated with PMX53 \u003Cstrong>(B)\u003C/strong>. \u003Ci>n\u003C/i> = 6/group, data presented as mean &#x000B1; 1 SD. B&#x00026;D Scale bar = 150 mm. *\u003Ci>p\u003C/i> &#x0003C; 0.05, **\u003Ci>p\u003C/i> &#x0003C; 0.01, ***\u003Ci>p\u003C/i> &#x0003C; 0.001.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cp class=\"mb15 w100pc float_left mt15\">Immunostaining of nerve biopsies from hereditary V30M patients carried out with an activated caspase-3 specific antibody has shown that expression of this apoptotic marker increases as the disease progresses (\u003Ca href=\"#B54\">Sousa et al., 2001\u003C/a>). We have also observed a significant increase in Caspase-3 in the group with the highest amyloid load (PMX53 treated) as compared to the other groups, even though no significant difference was recorded between the agonists treated groups and the control group (Figure \u003Ca href=\"#F6\">6B\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb0\">The LC-MS/MS analysis has revealed a great number of ER related stress markers which appear greatly increased in the PMX53 treated group of mice, as well as a number of Caspases and apoptotic markers (Supplementary Table S2).\u003C/p>\r\n\u003Ch3>Lysosomal Marker in Stomach Tissue\u003C/h3>\r\n\u003Cp class=\"mb0\">Lysosomal-associated membrane protein 1 (Lamp-1) is a glycoprotein known to primarily reside across lysosomal membranes (\u003Ca href=\"#B11\">Carlsson and Fukuda, 1989\u003C/a>), also Lamp-1 may be expressed on the cell surface following lysosomal fusion with the cell membrane during phagocytosis (\u003Ca href=\"#B27\">Kima et al., 2000\u003C/a>). During the formation and maturation of the phagosome, Lamp-1 will specifically become localized on the phagosomes (\u003Ca href=\"#B56\">Sugaya et al., 2011\u003C/a>), so that, expression of Lamp-1 signifies the final steps of activated phagocytosis. Serial deparaffinized stomach sections from a mouse treated with the full agonist and EP67 exhibit the complete co-localization of &#x003B1;&#x02013;Lamp-1 with &#x003B1;&#x02013;CD68 and &#x003B1;&#x02013;ELANE. On the contrary, the PMX53 treated mouse does not exhibit any co-localization with ELANE, CD68, or LAMP-1(Figure \u003Ca href=\"#F7\">7A\u003C/a>). On the contrary, sections from an animal treated with PMX53 display no plaque co-localization with Lamp-1 (Figure \u003Ca href=\"#F7\">7B\u003C/a>).\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 7\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg\" name=\"figure7\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g007.jpg\" alt=\"www.frontiersin.org\" id=\"F7\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 7. Amyloid plaque co-localization with the lysosomal marker: immunofluorescence of serial stomach sections from the group treated with the full agonist molecule (A)\u003C/strong> and the PMX53 antagonist \u003Cstrong>(B)\u003C/strong> show the complete co-expression of the amyloid plaque with Lamp-1 \u003Cstrong>(Ai)\u003C/strong> in the mouse treated with the agonist as opposed to the antagonist treated mouse which presents complete absence of the lysosomal marker in the vicinity of the plaque \u003Cstrong>(Bi)\u003C/strong>. Sections were co-stained with Thioflavin-S, a-Lamp-1 and a-CD68 \u003Cstrong>(Ai-iv and Bi-iv)\u003C/strong> and Thioflavin-S, a-hTTR and a-ELANE \u003Cstrong>(Av-viii and Bv-viii)\u003C/strong>. Scale bar = 75 &#x003BC;m.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ch3>Liquid Chromatography&#x02013;Tandem Mass Spectrometry Analysis\u003C/h3>\r\n\u003Cp class=\"mb0\">Considering that the animals treated with the full agonist molecule exhibited the least amount of deposited amyloid, and the animals treated with the PMX53 molecule had the highest amount of amyloid recorded, these two groups were compared using label-free mass spectrometry-based proteomic approach. Overall, a total of 3154 quantifiable proteins were identified. The expression of most of the markers examined using immunoblotting, as well as other related markers, was also confirmed through this technique (Supplementary Tables S1, S2). Furthermore, the data obtained through the LC-MS/MS technique was further analyzed using the Panther tool in order to identify clusters of proteins involved with specific functions in the two extreme groups of mice (\u003Ca href=\"#B60\">Thomas et al., 2003\u003C/a>; \u003Ca href=\"#B38\">Mi et al., 2010\u003C/a>). The most relevant results from this analysis have been summarized in Figure \u003Ca href=\"#F8\">8\u003C/a>, while the specific proteins can be found in Supplementary Tables S3&#x02013;S7. Also, the full list of obtained proteins along with their confidence scores can be found in Supplementary Data Sheet 1. A greater number of proteins involved with macrophage and complement activation were found to be highly expressed in the mice treated with the full agonist molecule. Similarly, a greater number of proteins associated with inflammation mediated by cytokines and chemokines, as well as peptidases were also found in the group treated with the full agonist molecule. However, the animals treated with PMX53 appeared to express a greater number of apoptosis related proteins when compared to the full agonist treated group.\u003C/p>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Cdiv class=\"Imageheaders\">FIGURE 8\u003C/div>\r\n\u003Cdiv class=\"FigureDesc\">\r\n\u003Ca href=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg\" name=\"figure8\" target=\"_blank\">\r\n\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g008.jpg\" alt=\"www.frontiersin.org\" id=\"F8\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\r\n\u003Cp>\u003Cstrong>Figure 8. LC-MS/MS clustering: protein functional clustering was carried out through the Panther tool between the group of mice treated with the full agonist molecule and the PMX53 antagonist.\u003C/strong> The group of mice treated with the full agonist displayed an increase in the expression of markers related with macrophage and complement system activation. Furthermore, an upsurge in the expression of peptidases and factors involved with inflammation was observed. The group treated with the antagonist exhibited a greater expression of caspases and other proteins involved in the apoptosis pathways.\u003C/p>\u003C/div> \r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003Cdiv class=\"DottedLine\">\u003C/div>\r\n\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\r\n\u003Cp class=\"mb15\">Currently there is a variety of approaches, either in the clinic or in clinical trials, for treating ATTR V30M amyloidotic neuropathy; liver transplantation, TTR stabilizers (Tafamidis, Diflunisal), inhibitors of TTR translation (anti-sense oligonucleotides, silencing RNAs), drugs that interfere with amyloid dynamics at the tissue level (doxycycline/TUDCA). There is however an unmet need that arises from the fact that already formed amyloid deposits continue to form foci for further deposition of normal TTR giving rise to further organ damage such as the heart and the kidneys. In addition, amyloidogenesis in certain tissue beds such as the eye and the brain has not yet been effectively addressed partly due to issues of access of the various treatments to the relevant tissue beds. More recently, antibodies against serum amyloid P or in the case of ATTR V30M amyloidosis, a cryptic TTR epitope visible only when TTR is in its monomeric form, are beginning to be explored as possible treatments (\u003Ca href=\"#B48\">Richards et al., 2015\u003C/a>; \u003Ca href=\"#B25\">Hosoi et al., 2016\u003C/a>). Both of these antibodies appear to enhance phagocytosis by macrophages. Complement participation has also been demonstrated with the anti-serum amyloid P antibody \u003Ci>in vivo\u003C/i>. In the current study we provide evidence that amyloid phagocytosis can be modulated by pharmacological manipulation of the C5a receptor and in the absence of any antibodies perhaps offering a more generic and convenient treatment option for the amyloidoses.\u003C/p>\r\n\u003Cp class=\"mb15\">Agonist and antagonists of the C5a receptor molecule are constructed based on the C terminus of the C5a molecule (\u003Ca href=\"#B24\">Higginbottom et al., 2005\u003C/a>). Agonists can be used to activate the C5a receptor bearing cells such as macrophages and neutrophils in order to induce the release of proinflammatory agents, thus activating an inflammatory response (\u003Ca href=\"#B52\">Short et al., 1999\u003C/a>). The C5a molecule is considered an anaphylatoxin based on its propensity to induce mast cell, basophil and neutrophil degranulation (\u003Ca href=\"#B30\">Lee et al., 2008\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">The full agonist molecule of the C5a receptor used here ((N-Methyl-Phe)-Lys-Pro-d-Cha-Cha-d-Arg-CO\u003Csub>2\u003C/sub>H) is a peptide analog of the last six C-terminal residues of the C5a molecule (\u003Ca href=\"#B24\">Higginbottom et al., 2005\u003C/a>). In essence, this molecule retains its anaphylactic activity by not only activating macrophages but also neutrophils. EP67 (Thr-Ser-Phe-Lys-Asp-Met-Pro-(MeLeu)-D-Ala-Arg), a conformationally-restricted decapeptide of the last ten amino acids of the C5a molecule contains an altered structure, which is accommodated by C5a receptors expressed on antigen presenting cells such as macrophages (\u003Ca href=\"#B49\">Sanderson et al., 2012\u003C/a>; \u003Ca href=\"#B22\">Hanke et al., 2013\u003C/a>). The C5a receptor antagonist PMX53 (AcF-[OP(D Cha) WR]) is a small cyclic peptide molecule which binds the C5a receptor suspending its downstream function (\u003Ca href=\"#B61\">Woodruff et al., 2006\u003C/a>; \u003Ca href=\"#B31\">Lobato and Rocha, 2012\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">Our results show that while administering the PMX53 compound results in a 160% increase of fibrillar amyloid deposition (both the full agonist and EP67 result in the decrease of amyloid deposition by 65% and 42%, respectively) following 1 week of oral administration through the animals&#x02019; drinking water. Therefore, inhibition of the C5a receptor (CD88) results in an increase in amyloid deposition, whereas enhancing the action of the receptor induces a considerable decrease. This decrease is even more substantial following the administration of the full agonist molecule which recruits both macrophages and neutrophils (\u003Ca href=\"#B4\">Baik et al., 2014\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">The fact that the amount of circulating hTTR protein in the serum remains unchanged in all four groups is expected since liver production of TTR is not expected to be affected, while the changes in tissue handling of TTR as a result of the administration of the three types of molecules for only a week would be too short to influence serum levels. However, there was a significant decrease in the amount of prefibrillar hTTR detected in the stomach tissue of animals receiving the C5 receptor agonists when compared to control presumably due to increased phagocytosis of prefibrillar hTTR. The PMX53 group mice exhibited no significant rise in prefibrillar hTTR, compared to control, as might be expected due to reduced phagocytosis of prefibrillar hTTR (\u003Ca href=\"#B39\">Misumi et al., 2013\u003C/a>; \u003Ca href=\"#B55\">Suenaga et al., 2016\u003C/a>). This is most likely explained by a shift to a higher rate of amyloid formation driven by higher prefibrillar hTTR.\u003C/p>\r\n\u003Cp class=\"mb15\">The marked decrease in amyloid load observed with the animals treated with the C5a receptor agonists is accompanied by a remarkable increase in neutrophil and macrophage markers. EP67 predominantly targets the macrophage populations, while the full agonist, which also targets neutrophils, produces significantly more IL-36&#x003B3; perhaps indicative of phagocytic capacity (\u003Ca href=\"#B49\">Sanderson et al., 2012\u003C/a>; \u003Ca href=\"#B22\">Hanke et al., 2013\u003C/a>). The extra 23% decrease in amyloid observed in the full agonist treated mice is probably a direct effect of neutrophil activation and recruitment. Immunofluorescence labeling of the plaques shows no co-localization with neutrophils except in mice treated with the full C5a receptor agonist (Figure \u003Ca href=\"#F4\">4C\u003C/a>). Interestingly, this is the group which exemplifies the greatest reduction in amyloid load, indicating a capacity of neutrophils to clear amyloid (\u003Ca href=\"#B4\">Baik et al., 2014\u003C/a>). Moreover, amyloid plaques in animals treated with the two C5a receptor agonists exhibit increased expression of the lysosomal marker Lamp-1, signifying that the recruitment of macrophages and neutrophils does ultimately lead to activated phagocytosis of the amyloid plaque. Additionally, the PMX53 treated group of animals exhibited the lowest expression of both neutrophil and macrophage markers as might be expected due to the inhibition of the C5a receptor (\u003Ca href=\"#B8\">Brennan et al., 2015\u003C/a>; \u003Ca href=\"#B20\">Gupta and Kaplan, 2016\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">The complement pathway is involved in innate immunity and C5a is one of the final effector molecules produced. C5a is imperative in tissue clearance through the recruitment of inflammatory cells. Mice treated with the C5a receptor agonists express a greater amount of C1q than both the control and the PMX53 treated mice. Neutrophils are known to possess C1q receptors which in turn enhance the expression of the CR3 receptor (\u003Ca href=\"#B15\">Eggleton et al., 1994\u003C/a>), an integral part of the innate immune response. Therefore, the significant increase in C1q, observed especially in the group treated with the full C5a receptor agonist, is probably due to the presence of neutrophils. Neutrophils also activate the alternative complement pathway and release C5 fragments, which further amplify the neutrophil pro-inflammatory response, acting in a positive feedback loop (\u003Ca href=\"#B10\">Camous et al., 2011\u003C/a>). Furthermore, macrophages have also been shown to activate the alternative complement pathway by activating C3 (\u003Ca href=\"#B51\">Schorlemmer et al., 1977\u003C/a>), explaining the increase in properdin in the groups treated with the C5a receptor agonists. The PMX53 treated mice however did not appear to produce less properdin than the control group of animals, probably a response to the increased amyloid deposition where several complement components co-localize (\u003Ca href=\"#B47\">Reichwald et al., 2009\u003C/a>). This evidence is also corroborated by the LC-MS/MS analysis, which indicates the massive up-surge of both the classical and alternative complement cascade in relation to the PMX53 treated group (Supplementary Table S1).\u003C/p>\r\n\u003Cp class=\"mb15\">The LC-MS/MS data reveal that a greater number of peptidases, and more specifically serine proteases, become up-regulated in the full agonist treated group when compared to the PMX53 treated animals which exhibit the greatest amyloid load. Evidence from work carried out on amyloid &#x003B2; peptides in Alzheimer&#x02019;s brains, identifies peptidase and protease mediated cleavage as a possible clearance mechanism in the catabolism of amyloid plaques (\u003Ca href=\"#B36\">Matsumoto et al., 1995\u003C/a>; \u003Ca href=\"#B42\">Ogawa et al., 2000\u003C/a>; \u003Ca href=\"#B23\">Hersh, 2003\u003C/a>; \u003Ca href=\"#B34\">Malito et al., 2008\u003C/a>). Neutrophils are known to release a number of serine proteases which induce chemokine and cytokine release as well as proteolytic cleavage (\u003Ca href=\"#B26\">Kessenbrock et al., 2011\u003C/a>; \u003Ca href=\"#B37\">Meyer-Hoffert and Wiedow, 2011\u003C/a>). Furthermore, neutrophil elastase (ELANE), a serine protease secreted by neutrophils has been shown to preferentially activate IL-36 yielding the three by-products IL-36&#x003B1;, IL-36&#x003B2; and IL-36&#x003B3; triggering further inflammatory response. We present data, via immunoblotting and LC-MS/MS analysis demonstrating the significant increase of IL-36&#x003B3; in animals treated with the C5a receptor agonists vs. the animals treated with the PMX53 inhibitor.\u003C/p>\r\n\u003Cp class=\"mb15\">Both apoptosis and cellular stress have been shown to increase along with extracellular TTR amyloid deposition (\u003Ca href=\"#B32\">Macedo et al., 2007\u003C/a>). We observe both by immunoblotting and LC-MS/MS analysis, that the groups of animals treated with the C5a receptor agonists do not have lower levels of apoptosis or cellular stress when compared to the control despite a reduction in amyloid load. This is perhaps partly due to the presence of macrophages and neutrophils \u003Ci>per se\u003C/i> since both are involved in inflammatory pathways which do evoke the ER stress response pathway (\u003Ca href=\"#B18\">Gotoh et al., 2011\u003C/a>). Similarly, macrophages have the ability to release Fas ligands, thus increasing extrinsic-signal triggered apoptosis (\u003Ca href=\"#B9\">Brown and Savill, 1999\u003C/a>) but also the ability to induce chronic inflammation leading to further apoptosis (\u003Ca href=\"#B13\">Diez-Roux and Lang, 1997\u003C/a>; \u003Ca href=\"#B19\">Gregory and Devitt, 2004\u003C/a>).\u003C/p>\r\n\u003Cp class=\"mb15\">In summary our data show that while inhibition of the C5a receptor results in the significant increase of amyloid load, activation of the C5a receptor results in a substantial reduction of amyloid deposits. Measurable effects were seen with only 1 week oral intake and with no visible side-effects on the mice. The full C5a receptor agonist molecule, retaining its full ability to activate neutrophils, had a greater impact in reducing the amyloid load. The long term safety of the of both C5a receptor agonists will need to be assessed in the mouse model whether on a continuous or intermittent basis.\u003C/p>\r\n\u003Cp class=\"mb15\">The role that neutrophils and macrophages may hold in activating amyloid clearance mechanisms also needs to be addressed in the context of other amyloidoses models. It appears that migration towards the plaque may not be determined by the plaque inducing peptide \u003Ci>per se\u003C/i>, but rather on the generic amyloid fibrillar formation since experiments have shown that individual &#x003B1;&#x003B2; monomers do not have the ability to attract peripheral phagocytic cells (\u003Ca href=\"#B4\">Baik et al., 2014\u003C/a>). Therefore, activating the phagocytic immune response through the complement cascade may target generic amyloidoses.\u003C/p>\r\n\u003Cp class=\"mb0\">The therapeutic exploitation of these small molecules as generic treatment in the amyloidoses will no doubt be both more challenging and rewarding.\u003C/p>\r\n\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\r\n\u003Cp class=\"mb0\">EF: data acquisition, data analysis and interpretation. KS: data acquisition and data analysis. RP: sample preparation, data acquisition. KK: study conception, manuscript critical revision. JP and SS: study design, manuscript critical revision. EP: study conception and design, data acquisition, data analysis and interpretation, drafting of manuscript. TK: study conception and design, data interpretation, drafting of manuscript.\u003C/p>\r\n\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Funding\u003C/h2>\r\n\u003Cp class=\"mb0\">This study was funded by the Cyprus Institute of Neurology and Genetics under the Telethon grants (Code: 33173126).\u003C/p>\r\n\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Conflict of Interest Statement\u003C/h2>\r\n\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\r\n\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\r\n\u003Cp class=\"mb0\">We acknowledge Professor Maria Saraiva for kindly donating the mTTR\u003Csup>&#x02212;/&#x02212;\u003C/sup>hMET30\u003Csup>+/+\u003C/sup> transgenic mice.\u003C/p>\r\n\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\r\n\u003Cp class=\"mb0\">The Supplementary Material for this article can be found online at: \u003Ca href=\"http://journal.frontiersin.org/article/10.3389/fnmol.2017.00138/full&#x00023;supplementary-material\">http://journal.frontiersin.org/article/10.3389/fnmol.2017.00138/full&#x00023;supplementary-material\u003C/a>\u003C/p>\r\n\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>References\u003C/h2>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a>Amsalem, H., Kwan, M., Hazan, A., Zhang, J., Jones, R. L., Whittle, W., et al. (2014). Identification of a novel neutrophil population: proangiogenic granulocytes in second-trimester human decidua. \u003Ci>J. Immunol.\u003C/i> 193, 3070&#x02013;3079. doi: 10.4049/jimmunol.1303117\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25135830\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4049/jimmunol.1303117\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Identification+of+a+novel+neutrophil+population%3A+proangiogenic+granulocytes+in+second-trimester+human+decidua&#x00026;author=Amsalem+H.&#x00026;author=Kwan+M.&#x00026;author=Hazan+A.&#x00026;author=Zhang+J.&#x00026;author=Jones+R.+L.&#x00026;author=Whittle+W.&#x00026;+&#x00026;publication_year=2014&#x00026;journal=J.+Immunol.&#x00026;volume=193&#x00026;pages=3070-3079\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a>Ando, Y., Nakamura, M., and Araki, S. (2005). Transthyretin-related familial amyloidotic polyneuropathy. \u003Ci>Arch. Neurol.\u003C/i> 62, 1057&#x02013;1062. doi: 10.1001/archneur.62.7.1057\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16009758\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/archneur.62.7.1057\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Transthyretin-related+familial+amyloidotic+polyneuropathy&#x00026;author=Ando+Y.&#x00026;author=Nakamura+M.&#x00026;author=Araki+S.&#x00026;publication_year=2005&#x00026;journal=Arch.+Neurol.&#x00026;volume=62&#x00026;pages=1057-1062\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a>Austyn, J. M., and Gordon, S. (1981). F4/80, a monoclonal antibody directed specifically against the mouse macrophage. \u003Ci>Eur. J. Immunol.\u003C/i> 11, 805&#x02013;815. doi: 10.1002/eji.1830111013\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=7308288\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/eji.1830111013\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=F4%2F80,+a+monoclonal+antibody+directed+specifically+against+the+mouse+macrophage&#x00026;author=Austyn+J.+M.&#x00026;author=Gordon+S.&#x00026;publication_year=1981&#x00026;journal=Eur.+J.+Immunol.&#x00026;volume=11&#x00026;pages=805-815\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a>Baik, S. H., Cha, M. Y., Hyun, Y. M., Cho, H., Hamza, B., Kim, D. K., et al. (2014). Migration of neutrophils targeting amyloid plaques in Alzheimer&#x02019;s disease mouse model. \u003Ci>Neurobiol. Aging\u003C/i> 35, 1286&#x02013;1292. doi: 10.1016/j.neurobiolaging.2014.01.003\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24485508\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.neurobiolaging.2014.01.003\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Migration+of+neutrophils+targeting+amyloid+plaques+in+Alzheimer's+disease+mouse+model&#x00026;author=Baik+S.+H.&#x00026;author=Cha+M.+Y.&#x00026;author=Hyun+Y.+M.&#x00026;author=Cho+H.&#x00026;author=Hamza+B.&#x00026;author=Kim+D.+K.&#x00026;+&#x00026;publication_year=2014&#x00026;journal=Neurobiol.+Aging&#x00026;volume=35&#x00026;pages=1286-1292\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a>Belaaouaj, A., Kim, K. S., and Shapiro, S. D. (2000). Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. \u003Ci>Science\u003C/i> 289, 1185&#x02013;1188. doi: 10.1126/science.289.5482.1185\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=10947984\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1126/science.289.5482.1185\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Degradation+of+outer+membrane+protein+A+in+Escherichia+coli+killing+by+neutrophil+elastase&#x00026;author=Belaaouaj+A.&#x00026;author=Kim+K.+S.&#x00026;author=Shapiro+S.+D.&#x00026;publication_year=2000&#x00026;journal=Science&#x00026;volume=289&#x00026;pages=1185-1188\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a>Bodin, K., Ellmerich, S., Kahan, M. C., Tennent, G. A., Loesch, A., Gilbertson, J. A., et al. (2010). Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. \u003Ci>Nature\u003C/i> 468, 93&#x02013;97. doi: 10.1038/nature09494\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20962779\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature09494\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Antibodies+to+human+serum+amyloid+P+component+eliminate+visceral+amyloid+deposits&#x00026;author=Bodin+K.&#x00026;author=Ellmerich+S.&#x00026;author=Kahan+M.+C.&#x00026;author=Tennent+G.+A.&#x00026;author=Loesch+A.&#x00026;author=Gilbertson+J.+A.&#x00026;+&#x00026;publication_year=2010&#x00026;journal=Nature&#x00026;volume=468&#x00026;pages=93-97\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a>Bozoyan, L., Dumas, A., Patenaude, A., and Valli&#x000E9;res, L. (2015). Interleukin-36&#x003B3; is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis. \u003Ci>J. Neuroinflammation\u003C/i> 12:173. doi: 10.1186/s12974-015-0392-7\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26377915\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12974-015-0392-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Interleukin-36&#x003B3;+is+expressed+by+neutrophils+and+can+activate+microglia,+but+has+no+role+in+experimental+autoimmune+encephalomyelitis&#x00026;author=Bozoyan+L.&#x00026;author=Dumas+A.&#x00026;author=Patenaude+A.&#x00026;author=Valli&#x000E9;res+L.&#x00026;publication_year=2015&#x00026;journal=J.+Neuroinflammation&#x00026;volume=12&#x00026;pages=173\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a>Brennan, F. H., Gordon, R., Lao, H. W., Biggins, P. J., Taylor, S. M., Franklin, R. J., et al. (2015). The complement receptor c5ar controls acute inflammation and astrogliosis following spinal cord injury. \u003Ci>J. Neurosci.\u003C/i> 35, 6517&#x02013;6531. doi: 10.1523/JNEUROSCI.5218-14.2015\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25904802\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1523/JNEUROSCI.5218-14.2015\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=The+complement+receptor+c5ar+controls+acute+inflammation+and+astrogliosis+following+spinal+cord+injury&#x00026;author=Brennan+F.+H.&#x00026;author=Gordon+R.&#x00026;author=Lao+H.+W.&#x00026;author=Biggins+P.+J.&#x00026;author=Taylor+S.+M.&#x00026;author=Franklin+R.+J.&#x00026;+&#x00026;publication_year=2015&#x00026;journal=J.+Neurosci.&#x00026;volume=35&#x00026;pages=6517-6531\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a>Brown, S. B., and Savill, J. (1999). Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. \u003Ci>J. Immunol.\u003C/i> 162, 480&#x02013;485. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9886423\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Phagocytosis+triggers+macrophage+release+of+Fas+ligand+and+induces+apoptosis+of+bystander+leukocytes&#x00026;author=Brown+S.+B.&#x00026;author=Savill+J.&#x00026;publication_year=1999&#x00026;journal=J.+Immunol.&#x00026;volume=162&#x00026;pages=480-485\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a>Camous, L., Roumenina, L., Bigot, S., Brachemi, S., Fr&#x000E9;meaux-Bacchi, V., Lesavre, P., et al. (2011). Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. \u003Ci>Blood\u003C/i> 117, 1340&#x02013;1349. doi: 10.1182/blood-2010-05-283564\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21063021\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1182/blood-2010-05-283564\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Complement+alternative+pathway+acts+as+a+positive+feedback+amplification+of+neutrophil+activation&#x00026;author=Camous+L.&#x00026;author=Roumenina+L.&#x00026;author=Bigot+S.&#x00026;author=Brachemi+S.&#x00026;author=Fr&#x000E9;meaux-Bacchi+V.&#x00026;author=Lesavre+P.&#x00026;+&#x00026;publication_year=2011&#x00026;journal=Blood&#x00026;volume=117&#x00026;pages=1340-1349\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a>Carlsson, S. R., and Fukuda, M. (1989). Structure of human lysosomal membrane glycoprotein 1. Assignment of disulfide bonds and visualization of its domain arrangement. \u003Ci>J. Biol. Chem.\u003C/i> 264, 20526&#x02013;20531. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=2584229\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Structure+of+human+lysosomal+membrane+glycoprotein+1.+Assignment+of+disulfide+bonds+and+visualization+of+its+domain+arrangement&#x00026;author=Carlsson+S.+R.&#x00026;author=Fukuda+M.&#x00026;publication_year=1989&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=264&#x00026;pages=20526-20531\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a>Dardiotis, E., Koutsou, P., Zamba-Papanicolaou, E., Vonta, I., Hadjivassiliou, M., Hadjigeorgiou, G., et al. (2009). Complement C1Q polymorphisms modulate onset in familial amyloidotic polyneuropathy TTR Val30Met. \u003Ci>J. Neurol. Sci.\u003C/i> 284, 158&#x02013;162. doi: 10.1016/j.jns.2009.05.018\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19493541\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.jns.2009.05.018\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Complement+C1Q+polymorphisms+modulate+onset+in+familial+amyloidotic+polyneuropathy+TTR+Val30Met&#x00026;author=Dardiotis+E.&#x00026;author=Koutsou+P.&#x00026;author=Zamba-Papanicolaou+E.&#x00026;author=Vonta+I.&#x00026;author=Hadjivassiliou+M.&#x00026;author=Hadjigeorgiou+G.&#x00026;+&#x00026;publication_year=2009&#x00026;journal=J.+Neurol.+Sci.&#x00026;volume=284&#x00026;pages=158-162\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a>Diez-Roux, G., and Lang, R. A. (1997). Macrophages induce apoptosis in normal cells \u003Ci>in vivo\u003C/i>. \u003Ci>Development\u003C/i> 124, 3633&#x02013;3638. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9342055\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Macrophages+induce+apoptosis+in+normal+cells+in+vivo&#x00026;author=Diez-Roux+G.&#x00026;author=Lang+R.+A.&#x00026;publication_year=1997&#x00026;journal=Development&#x00026;volume=124&#x00026;pages=3633-3638\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a>Distler, U., Kuharev, J., Navarro, P., Levin, Y., Schild, H., and Tenzer, S. (2014). Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. \u003Ci>Nat. Methods\u003C/i> 11, 167&#x02013;170. doi: 10.1038/nmeth.2767\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24336358\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nmeth.2767\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Drift+time-specific+collision+energies+enable+deep-coverage+data-independent+acquisition+proteomics&#x00026;author=Distler+U.&#x00026;author=Kuharev+J.&#x00026;author=Navarro+P.&#x00026;author=Levin+Y.&#x00026;author=Schild+H.&#x00026;author=Tenzer+S.&#x00026;publication_year=2014&#x00026;journal=Nat.+Methods&#x00026;volume=11&#x00026;pages=167-170\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a>Eggleton, P., Ghebrehiwet, B., Coburn, J. P., Sastry, K. N., Zaner, K. S., and Tauber, A. I. (1994). Characterization of the human neutrophil C1q receptor and functional effects of free ligand on activated neutrophils. \u003Ci>Blood\u003C/i> 84, 1640&#x02013;1649. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=8068954\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Characterization+of+the+human+neutrophil+C1q+receptor+and+functional+effects+of+free+ligand+on+activated+neutrophils&#x00026;author=Eggleton+P.&#x00026;author=Ghebrehiwet+B.&#x00026;author=Coburn+J.+P.&#x00026;author=Sastry+K.+N.&#x00026;author=Zaner+K.+S.&#x00026;author=Tauber+A.+I.&#x00026;publication_year=1994&#x00026;journal=Blood&#x00026;volume=84&#x00026;pages=1640-1649\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a>Fonseca, M. I., Ager, R. R., Chu, S. H., Yazan, O., Sanderson, S. D., LaFerla, F. M., et al. (2009). Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer&#x02019;s disease. \u003Ci>J. Immunol.\u003C/i> 183, 1375&#x02013;1383. doi: 10.4049/jimmunol.0901005\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19561098\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4049/jimmunol.0901005\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Treatment+with+a+C5aR+antagonist+decreases+pathology+and+enhances+behavioral+performance+in+murine+models+of+Alzheimer's+disease&#x00026;author=Fonseca+M.+I.&#x00026;author=Ager+R.+R.&#x00026;author=Chu+S.+H.&#x00026;author=Yazan+O.&#x00026;author=Sanderson+S.+D.&#x00026;author=LaFerla+F.+M.&#x00026;+&#x00026;publication_year=2009&#x00026;journal=J.+Immunol.&#x00026;volume=183&#x00026;pages=1375-1383\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a>Fonseca, M. I., Chu, S. H., Berci, A. M., Benoit, M. E., Peters, D. G., Kimura, Y., et al. (2011). Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer&#x02019;s disease. \u003Ci>J. Neuroinflammation\u003C/i> 8:4. doi: 10.1186/1742-2094-8-4\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21235806\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1742-2094-8-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Contribution+of+complement+activation+pathways+to+neuropathology+differs+among+mouse+models+of+Alzheimer's+disease&#x00026;author=Fonseca+M.+I.&#x00026;author=Chu+S.+H.&#x00026;author=Berci+A.+M.&#x00026;author=Benoit+M.+E.&#x00026;author=Peters+D.+G.&#x00026;author=Kimura+Y.&#x00026;+&#x00026;publication_year=2011&#x00026;journal=J.+Neuroinflammation&#x00026;volume=8&#x00026;pages=4\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a>Gotoh, T., Endo, M., and Oike, Y. (2011). Endoplasmic reticulum stress-related inflammation and cardiovascular diseases. \u003Ci>Int. J. Inflam.\u003C/i> 2011:259462. doi: 10.4061/2011/259462\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21755026\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4061/2011/259462\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Endoplasmic+reticulum+stress-related+inflammation+and+cardiovascular+diseases&#x00026;author=Gotoh+T.&#x00026;author=Endo+M.&#x00026;author=Oike+Y.&#x00026;publication_year=2011&#x00026;journal=Int.+J.+Inflam.&#x00026;volume=2011&#x00026;pages=259462\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a>Gregory, C. D., and Devitt, A. (2004). The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? \u003Ci>Immunology\u003C/i> 113, 1&#x02013;14. doi: 10.1111/j.1365-2567.2004.01959.x\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=15312130\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1365-2567.2004.01959.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=The+macrophage+and+the+apoptotic+cell%3A+an+innate+immune+interaction+viewed+simplistically%3F&#x00026;author=Gregory+C.+D.&#x00026;author=Devitt+A.&#x00026;publication_year=2004&#x00026;journal=Immunology&#x00026;volume=113&#x00026;pages=1-14\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a>Gupta, S., and Kaplan, M. J. (2016). The role of neutrophils and NETosis in autoimmune and renal diseases. \u003Ci>Nat. Rev. Nephrol.\u003C/i> 12, 402&#x02013;413. doi: 10.1038/nrneph.2016.71\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27241241\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrneph.2016.71\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=The+role+of+neutrophils+and+NETosis+in+autoimmune+and+renal+diseases&#x00026;author=Gupta+S.&#x00026;author=Kaplan+M.+J.&#x00026;publication_year=2016&#x00026;journal=Nat.+Rev.+Nephrol.&#x00026;volume=12&#x00026;pages=402-413\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a>Hafer-Macko, C. E., Dyck, P. J., and Koski, C. L. (2000). Complement activation in acquired and hereditary amyloid neuropathy. \u003Ci>J. Peripher. Nerv. Syst.\u003C/i> 5, 131&#x02013;139. doi: 10.1046/j.1529-8027.2000.00018.x\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11442169\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1046/j.1529-8027.2000.00018.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Complement+activation+in+acquired+and+hereditary+amyloid+neuropathy&#x00026;author=Hafer-Macko+C.+E.&#x00026;author=Dyck+P.+J.&#x00026;author=Koski+C.+L.&#x00026;publication_year=2000&#x00026;journal=J.+Peripher.+Nerv.+Syst.&#x00026;volume=5&#x00026;pages=131-139\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a>Hanke, M. L., Heim, C. E., Angle, A., Sanderson, S. D., and Kielian, T. (2013). Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. \u003Ci>J. Immunol.\u003C/i> 190, 2159&#x02013;2168. doi: 10.4049/jimmunol.1202348\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=23365077\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4049/jimmunol.1202348\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Targeting+macrophage+activation+for+the+prevention+and+treatment+of+Staphylococcus+aureus+biofilm+infections&#x00026;author=Hanke+M.+L.&#x00026;author=Heim+C.+E.&#x00026;author=Angle+A.&#x00026;author=Sanderson+S.+D.&#x00026;author=Kielian+T.&#x00026;publication_year=2013&#x00026;journal=J.+Immunol.&#x00026;volume=190&#x00026;pages=2159-2168\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a>Hersh, L. B. (2003). Peptidases, proteases and amyloid &#x003B2;-peptide catabolism. \u003Ci>Curr. Pharm. Des.\u003C/i> 9, 449&#x02013;454. doi: 10.2174/1381612033391676\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=12570808\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.2174/1381612033391676\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Peptidases,+proteases+and+amyloid+&#x003B2;-peptide+catabolism&#x00026;author=Hersh+L.+B.&#x00026;publication_year=2003&#x00026;journal=Curr.+Pharm.+Des.&#x00026;volume=9&#x00026;pages=449-454\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a>Higginbottom, A., Cain, S. A., Woodruff, T. M., Proctor, L. M., Madala, P. K., Tyndall, J. D., et al. (2005). Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site. \u003Ci>J. Biol. Chem.\u003C/i> 280, 17831&#x02013;17840. doi: 10.1074/jbc.M410797200\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=15661745\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1074/jbc.M410797200\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Comparative+agonist%2Fantagonist+responses+in+mutant+human+C5a+receptors+define+the+ligand+binding+site&#x00026;author=Higginbottom+A.&#x00026;author=Cain+S.+A.&#x00026;author=Woodruff+T.+M.&#x00026;author=Proctor+L.+M.&#x00026;author=Madala+P.+K.&#x00026;author=Tyndall+J.+D.&#x00026;+&#x00026;publication_year=2005&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=280&#x00026;pages=17831-17840\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a>Hosoi, A., Su, Y., Torikai, M., Jono, H., Ishikawa, D., Soejima, K., et al. (2016). Novel antibody for the treatment of transthyretin amyloidosis. \u003Ci>J. Biol. Chem.\u003C/i> 291, 25096&#x02013;25105. doi: 10.1074/jbc.M116.738138\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27758856\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1074/jbc.M116.738138\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Novel+antibody+for+the+treatment+of+transthyretin+amyloidosis&#x00026;author=Hosoi+A.&#x00026;author=Su+Y.&#x00026;author=Torikai+M.&#x00026;author=Jono+H.&#x00026;author=Ishikawa+D.&#x00026;author=Soejima+K.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=291&#x00026;pages=25096-25105\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a>Kessenbrock, K., Dau, T., and Jenne, D. E. (2011). Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. \u003Ci>J. Mol. Med.\u003C/i> 89, 23&#x02013;28. doi: 10.1007/s00109-010-0677-3\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20809089\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00109-010-0677-3\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Tailor-made+inflammation%3A+how+neutrophil+serine+proteases+modulate+the+inflammatory+response&#x00026;author=Kessenbrock+K.&#x00026;author=Dau+T.&#x00026;author=Jenne+D.+E.&#x00026;publication_year=2011&#x00026;journal=J.+Mol.+Med.&#x00026;volume=89&#x00026;pages=23-28\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a>Kima, P. E., Burleigh, B., and Andrews, N. W. (2000). Surface-targeted lysosomal membrane glycoprotein-1 (Lamp-1) enhances lysosome exocytosis and cell invasion by Trypanosoma cruzi. \u003Ci>Cell. Microbiol.\u003C/i> 2, 477&#x02013;486. doi: 10.1046/j.1462-5822.2000.00071.x\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11207602\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1046/j.1462-5822.2000.00071.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Surface-targeted+lysosomal+membrane+glycoprotein-1+(Lamp-1)+enhances+lysosome+exocytosis+and+cell+invasion+by+Trypanosoma+cruzi&#x00026;author=Kima+P.+E.&#x00026;author=Burleigh+B.&#x00026;author=Andrews+N.+W.&#x00026;publication_year=2000&#x00026;journal=Cell.+Microbiol.&#x00026;volume=2&#x00026;pages=477-486\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a>Kohno, K., Palha, J. A., Miyakawa, K., Saraiva, M. J., Ito, S., Mabuchi, T., et al. (1997). Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. \u003Ci>Am. J. Pathol.\u003C/i> 150, 1497&#x02013;1508. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=9095004\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Analysis+of+amyloid+deposition+in+a+transgenic+mouse+model+of+homozygous+familial+amyloidotic+polyneuropathy&#x00026;author=Kohno+K.&#x00026;author=Palha+J.+A.&#x00026;author=Miyakawa+K.&#x00026;author=Saraiva+M.+J.&#x00026;author=Ito+S.&#x00026;author=Mabuchi+T.&#x00026;+&#x00026;publication_year=1997&#x00026;journal=Am.+J.+Pathol.&#x00026;volume=150&#x00026;pages=1497-1508\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a>Kovach, M. A., Singer, B. H., Newstead, M. W., Zeng, X., Moore, T. A., White, E. S., et al. (2016). IL-36&#x003B3; is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components. \u003Ci>J. Leukoc. Biol.\u003C/i> 100, 413&#x02013;421. doi: 10.1189/jlb.4A0315-087R\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26864267\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1189/jlb.4A0315-087R\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=IL-36&#x003B3;+is+secreted+in+microparticles+and+exosomes+by+lung+macrophages+in+response+to+bacteria+and+bacterial+components&#x00026;author=Kovach+M.+A.&#x00026;author=Singer+B.+H.&#x00026;author=Newstead+M.+W.&#x00026;author=Zeng+X.&#x00026;author=Moore+T.+A.&#x00026;author=White+E.+S.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=J.+Leukoc.+Biol.&#x00026;volume=100&#x00026;pages=413-421\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a>Lee, H., Whitfeld, P. L., and Mackay, C. R. (2008). Receptors for complement C5a. \u003Ci>Immunol. Cell Biol.\u003C/i> 86, 153&#x02013;160. doi: 10.1038/sj.icb.7100166\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18227853\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.icb.7100166\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Receptors+for+complement+C5a&#x00026;author=Lee+H.&#x00026;author=Whitfeld+P.+L.&#x00026;author=Mackay+C.+R.&#x00026;publication_year=2008&#x00026;journal=Immunol.+Cell+Biol.&#x00026;volume=86&#x00026;pages=153-160\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a>Lobato, L., and Rocha, A. (2012). Transthyretin amyloidosis and the kidney. \u003Ci>Clin. J. Am. Soc. Nephrol.\u003C/i> 7, 1337&#x02013;1346. doi: 10.2215/CJN.08720811\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22537653\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.2215/CJN.08720811\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Transthyretin+amyloidosis+and+the+kidney&#x00026;author=Lobato+L.&#x00026;author=Rocha+A.&#x00026;publication_year=2012&#x00026;journal=Clin.+J.+Am.+Soc.+Nephrol.&#x00026;volume=7&#x00026;pages=1337-1346\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a>Macedo, B., Batista, A. R., do Amaral, J. B., and Saraiva, M. J. (2007). Biomarkers in the assessment of therapies for familial amyloidotic polyneuropathy. \u003Ci>Mol. Med.\u003C/i> 13, 584&#x02013;591. doi: 10.2119/2007-00068.Macedo\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=17932549\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.2119/2007-00068.Macedo\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Biomarkers+in+the+assessment+of+therapies+for+familial+amyloidotic+polyneuropathy&#x00026;author=Macedo+B.&#x00026;author=Batista+A.+R.&#x00026;author=do+Amaral+J.+B.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2007&#x00026;journal=Mol.+Med.&#x00026;volume=13&#x00026;pages=584-591\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a>Macleod, T., Doble, R., McGonagle, D., Wasson, C. W., Alase, A., Stacey, M., et al. (2016). Neutrophil Elastase-mediated proteolysis activates the anti-inflammatory cytokine IL-36 Receptor antagonist. \u003Ci>Sci. Rep.\u003C/i> 6:24880. doi: 10.1038/srep24880\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27101808\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/srep24880\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Neutrophil+Elastase-mediated+proteolysis+activates+the+anti-inflammatory+cytokine+IL-36+Receptor+antagonist&#x00026;author=Macleod+T.&#x00026;author=Doble+R.&#x00026;author=McGonagle+D.&#x00026;author=Wasson+C.+W.&#x00026;author=Alase+A.&#x00026;author=Stacey+M.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=Sci.+Rep.&#x00026;volume=6&#x00026;pages=24880\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a>Malito, E., Hulse, R. E., and Tang, W. J. (2008). Amyloid &#x003B2;-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. \u003Ci>Cell. Mol. Life Sci.\u003C/i> 65, 2574&#x02013;2585. doi: 10.1007/s00018-008-8112-4\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=18470479\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00018-008-8112-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Amyloid+&#x003B2;-degrading+cryptidases%3A+insulin+degrading+enzyme,+presequence+peptidase,+and+neprilysin&#x00026;author=Malito+E.&#x00026;author=Hulse+R.+E.&#x00026;author=Tang+W.+J.&#x00026;publication_year=2008&#x00026;journal=Cell.+Mol.+Life+Sci.&#x00026;volume=65&#x00026;pages=2574-2585\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a>Mathern, D. R., and Heeger, P. S. (2015). Molecules great and small: the complement system. \u003Ci>Clin. J. Am. Soc. Nephrol.\u003C/i> 10, 1636&#x02013;1650. doi: 10.2215/CJN.06230614\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=25568220\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.2215/CJN.06230614\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Molecules+great+and+small%3A+the+complement+system&#x00026;author=Mathern+D.+R.&#x00026;author=Heeger+P.+S.&#x00026;publication_year=2015&#x00026;journal=Clin.+J.+Am.+Soc.+Nephrol.&#x00026;volume=10&#x00026;pages=1636-1650\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a>Matsumoto, A., Matsumoto, R., Baba, H., and Fujiwara, Y. (1995). A serine protease in Alzheimer&#x02019;s disease cells cleaves a 16K-peptide with flanking residues upstream to &#x003B2;-amyloid-N-terminus as natural substrate. \u003Ci>Neurosci. Lett.\u003C/i> 195, 171&#x02013;174. doi: 10.1016/0304-3940(95)11810-j\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=8584202\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/0304-3940(95)11810-j\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=A+serine+protease+in+Alzheimer's+disease+cells+cleaves+a+16K-peptide+with+flanking+residues+upstream+to+&#x003B2;-amyloid-N-terminus+as+natural+substrate&#x00026;author=Matsumoto+A.&#x00026;author=Matsumoto+R.&#x00026;author=Baba+H.&#x00026;author=Fujiwara+Y.&#x00026;publication_year=1995&#x00026;journal=Neurosci.+Lett.&#x00026;volume=195&#x00026;pages=171-174\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a>Meyer-Hoffert, U., and Wiedow, O. (2011). Neutrophil serine proteases: mediators of innate immune responses. \u003Ci>Curr. Opin. Hematol.\u003C/i> 18, 19&#x02013;24. doi: 10.1097/MOH.0b013e32834115d1\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21042214\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1097/MOH.0b013e32834115d1\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Neutrophil+serine+proteases%3A+mediators+of+innate+immune+responses&#x00026;author=Meyer-Hoffert+U.&#x00026;author=Wiedow+O.&#x00026;publication_year=2011&#x00026;journal=Curr.+Opin.+Hematol.&#x00026;volume=18&#x00026;pages=19-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a>Mi, H., Dong, Q., Muruganujan, A., Gaudet, P., Lewis, S., and Thomas, P. D. (2010). PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. \u003Ci>Nucleic Acids Res.\u003C/i> 38, D204&#x02013;D210. doi: 10.1093/nar/gkp1019\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=20015972\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkp1019\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=PANTHER+version+7%3A+improved+phylogenetic+trees,+orthologs+and+collaboration+with+the+Gene+Ontology+Consortium&#x00026;author=Mi+H.&#x00026;author=Dong+Q.&#x00026;author=Muruganujan+A.&#x00026;author=Gaudet+P.&#x00026;author=Lewis+S.&#x00026;author=Thomas+P.+D.&#x00026;publication_year=2010&#x00026;journal=Nucleic+Acids+Res.&#x00026;volume=38&#x00026;pages=D204-D210\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a>Misumi, Y., Ando, Y., Gon&#x000E7;alves, N. P., and Saraiva, M. J. (2013). Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis. \u003Ci>Lab. Invest.\u003C/i> 93, 911&#x02013;920. doi: 10.1038/labinvest.2013.83\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=23817086\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/labinvest.2013.83\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Fibroblasts+endocytose+and+degrade+transthyretin+aggregates+in+transthyretin-related+amyloidosis&#x00026;author=Misumi+Y.&#x00026;author=Ando+Y.&#x00026;author=Gon&#x000E7;alves+N.+P.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2013&#x00026;journal=Lab.+Invest.&#x00026;volume=93&#x00026;pages=911-920\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a>Monk, P. N., Scola, A. M., Madala, P., and Fairlie, D. P. (2007). Function, structure and therapeutic potential of complement C5a receptors. \u003Ci>Br. J. Pharmacol.\u003C/i> 152, 429&#x02013;448. doi: 10.1038/sj.bjp.0707332\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=17603557\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.bjp.0707332\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Function,+structure+and+therapeutic+potential+of+complement+C5a+receptors&#x00026;author=Monk+P.+N.&#x00026;author=Scola+A.+M.&#x00026;author=Madala+P.&#x00026;author=Fairlie+D.+P.&#x00026;publication_year=2007&#x00026;journal=Br.+J.+Pharmacol.&#x00026;volume=152&#x00026;pages=429-448\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a>Murray, P. J., and Wynn, T. A. (2011). Protective and pathogenic functions of macrophage subsets. \u003Ci>Nat. Rev. Immunol.\u003C/i> 11, 723&#x02013;737. doi: 10.1038/nri3073\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21997792\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nri3073\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Protective+and+pathogenic+functions+of+macrophage+subsets&#x00026;author=Murray+P.+J.&#x00026;author=Wynn+T.+A.&#x00026;publication_year=2011&#x00026;journal=Nat.+Rev.+Immunol.&#x00026;volume=11&#x00026;pages=723-737\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a>Ogawa, K., Yamada, T., Tsujioka, Y., Taguchi, J., Takahashi, M., Tsuboi, Y., et al. (2000). Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease. \u003Ci>Psychiatry Clin. Neurosci.\u003C/i> 54, 419&#x02013;426. doi: 10.1046/j.1440-1819.2000.00731.x\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=10997858\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1046/j.1440-1819.2000.00731.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Localization+of+a+novel+type+trypsin-like+serine+protease,+neurosin,+in+brain+tissues+of+Alzheimer's+disease+and+Parkinson's+disease&#x00026;author=Ogawa+K.&#x00026;author=Yamada+T.&#x00026;author=Tsujioka+Y.&#x00026;author=Taguchi+J.&#x00026;author=Takahashi+M.&#x00026;author=Tsuboi+Y.&#x00026;+&#x00026;publication_year=2000&#x00026;journal=Psychiatry+Clin.+Neurosci.&#x00026;volume=54&#x00026;pages=419-426\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a>Panayiotou, E., Fella, E., Papacharalambous, R., Malas, S., Saraiva, M. J., and Kyriakides, T. (2017). C1q ablation exacerbates amyloid deposition: a study in a transgenic mouse model of ATTRV30M amyloid neuropathy. \u003Ci>PLoS One\u003C/i> 12:e0175767. doi: 10.1371/journal.pone.0175767\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=28407005\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0175767\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=C1q+ablation+exacerbates+amyloid+deposition%3A+a+study+in+a+transgenic+mouse+model+of+ATTRV30M+amyloid+neuropathy&#x00026;author=Panayiotou+E.&#x00026;author=Fella+E.&#x00026;author=Papacharalambous+R.&#x00026;author=Malas+S.&#x00026;author=Saraiva+M.+J.&#x00026;author=Kyriakides+T.&#x00026;publication_year=2017&#x00026;journal=PLoS+One&#x00026;volume=12&#x00026;pages=e0175767\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a>Petry, F., Reid, K. B., and Loos, M. (1991). Gene expression of the A- and B-chain of mouse C1q in different tissues and the characterization of the recombinant A-chain. \u003Ci>J. Immunol.\u003C/i> 147, 3988&#x02013;3993. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=1940381\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Gene+expression+of+the+A-+and+B-chain+of+mouse+C1q+in+different+tissues+and+the+characterization+of+the+recombinant+A-chain&#x00026;author=Petry+F.&#x00026;author=Reid+K.+B.&#x00026;author=Loos+M.&#x00026;publication_year=1991&#x00026;journal=J.+Immunol.&#x00026;volume=147&#x00026;pages=3988-3993\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a>Pillay, J., Tak, T., Kamp, V. M., and Koenderman, L. (2013). Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. \u003Ci>Cell Mol. Life Sci.\u003C/i> 70, 3813&#x02013;3827. doi: 10.1007/s00018-013-1286-4\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=23423530\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00018-013-1286-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Immune+suppression+by+neutrophils+and+granulocytic+myeloid-derived+suppressor+cells%3A+similarities+and+differences&#x00026;author=Pillay+J.&#x00026;author=Tak+T.&#x00026;author=Kamp+V.+M.&#x00026;author=Koenderman+L.&#x00026;publication_year=2013&#x00026;journal=Cell+Mol.+Life+Sci.&#x00026;volume=70&#x00026;pages=3813-3827\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a>Pisalyaput, K., and Tenner, A. J. (2008). Complement component C1q inhibits &#x003B2;-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. \u003Ci>J. Neurochem.\u003C/i> 104, 696&#x02013;707. doi: 10.1111/j.1471-4159.2007.05012.x\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=17986223\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/j.1471-4159.2007.05012.x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Complement+component+C1q+inhibits+&#x003B2;-amyloid-+and+serum+amyloid+P-induced+neurotoxicity+via+caspase-+and+calpain-independent+mechanisms&#x00026;author=Pisalyaput+K.&#x00026;author=Tenner+A.+J.&#x00026;publication_year=2008&#x00026;journal=J.+Neurochem.&#x00026;volume=104&#x00026;pages=696-707\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a>Reichwald, J., Danner, S., Wiederhold, K. H., and Staufenbiel, M. (2009). Expression of complement system components during aging and amyloid deposition in APP transgenic mice. \u003Ci>J. Neuroinflammation\u003C/i> 6:35. doi: 10.1186/1742-2094-6-35\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=19917141\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1742-2094-6-35\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Expression+of+complement+system+components+during+aging+and+amyloid+deposition+in+APP+transgenic+mice&#x00026;author=Reichwald+J.&#x00026;author=Danner+S.&#x00026;author=Wiederhold+K.+H.&#x00026;author=Staufenbiel+M.&#x00026;publication_year=2009&#x00026;journal=J.+Neuroinflammation&#x00026;volume=6&#x00026;pages=35\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a>Richards, D. B., Cookson, L. M., Berges, A. C., Barton, S. V., Lane, T., Ritter, J. M., et al. (2015). Therapeutic clearance of amyloid by antibodies to serum amyloid P component. \u003Ci>N. Engl. J. Med.\u003C/i> 373, 1106&#x02013;1114. doi: 10.1056/NEJMoa1504942\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=26176329\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa1504942\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Therapeutic+clearance+of+amyloid+by+antibodies+to+serum+amyloid+P+component&#x00026;author=Richards+D.+B.&#x00026;author=Cookson+L.+M.&#x00026;author=Berges+A.+C.&#x00026;author=Barton+S.+V.&#x00026;author=Lane+T.&#x00026;author=Ritter+J.+M.&#x00026;+&#x00026;publication_year=2015&#x00026;journal=N.+Engl.+J.+Med.&#x00026;volume=373&#x00026;pages=1106-1114\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a>Sanderson, S. D., Thoman, M. L., Kis, K., Virts, E. L., Herrera, E. B., Widmann, S., et al. (2012). Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a. \u003Ci>PLoS One\u003C/i> 7:e40303. doi: 10.1371/journal.pone.0040303\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22792270\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0040303\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Innate+immune+induction+and+influenza+protection+elicited+by+a+response-selective+agonist+of+human+C5a&#x00026;author=Sanderson+S.+D.&#x00026;author=Thoman+M.+L.&#x00026;author=Kis+K.&#x00026;author=Virts+E.+L.&#x00026;author=Herrera+E.+B.&#x00026;author=Widmann+S.&#x00026;+&#x00026;publication_year=2012&#x00026;journal=PLoS+One&#x00026;volume=7&#x00026;pages=e40303\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a>Saraiva, M. J., Birken, S., Costa, P. P., and Goodman, D. S. (1984). Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. \u003Ci>J. Clin. Invest.\u003C/i> 74, 104&#x02013;119. doi: 10.1172/jci111390\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=6736244\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1172/jci111390\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Amyloid+fibril+protein+in+familial+amyloidotic+polyneuropathy,+Portuguese+type&#x00026;author=Saraiva+M.+J.&#x00026;author=Birken+S.&#x00026;author=Costa+P.+P.&#x00026;author=Goodman+D.+S.&#x00026;publication_year=1984&#x00026;journal=J.+Clin.+Invest.&#x00026;volume=74&#x00026;pages=104-119\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a>Schorlemmer, H. U., Bitter-Suermann, D., and Allison, A. C. (1977). Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. \u003Ci>Immunology\u003C/i> 32, 929&#x02013;940. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=328387\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Complement+activation+by+the+alternative+pathway+and+macrophage+enzyme+secretion+in+the+pathogenesis+of+chronic+inflammation&#x00026;author=Schorlemmer+H.+U.&#x00026;author=Bitter-Suermann+D.&#x00026;author=Allison+A.+C.&#x00026;publication_year=1977&#x00026;journal=Immunology&#x00026;volume=32&#x00026;pages=929-940\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a>Short, A. J., Paczkowski, N. J., Vogen, S. M., Sanderson, S. D., and Taylor, S. M. (1999). Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat. \u003Ci>Br. J. Pharmacol.\u003C/i> 128, 511&#x02013;514. doi: 10.1038/sj.bjp.0702847\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=10516626\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.bjp.0702847\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Response-selective+C5a+agonists%3A+differential+effects+on+neutropenia+and+hypotension+in+the+rat&#x00026;author=Short+A.+J.&#x00026;author=Paczkowski+N.+J.&#x00026;author=Vogen+S.+M.&#x00026;author=Sanderson+S.+D.&#x00026;author=Taylor+S.+M.&#x00026;publication_year=1999&#x00026;journal=Br.+J.+Pharmacol.&#x00026;volume=128&#x00026;pages=511-514\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a>Smith, C. A., Pangburn, M. K., Vogel, C. W., and M&#x000FC;ller-Eberhard, H. J. (1984). Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. \u003Ci>J. Biol. Chem.\u003C/i> 259, 4582&#x02013;4588. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=6707020\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Molecular+architecture+of+human+properdin,+a+positive+regulator+of+the+alternative+pathway+of+complement&#x00026;author=Smith+C.+A.&#x00026;author=Pangburn+M.+K.&#x00026;author=Vogel+C.+W.&#x00026;author=M&#x000FC;ller-Eberhard+H.+J.&#x00026;publication_year=1984&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=259&#x00026;pages=4582-4588\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a>Sousa, M. M., Du Yan, S., Fernandes, R., Guimaraes, A., Stern, D., and Saraiva, M. J. (2001). Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. \u003Ci>J. Neurosci.\u003C/i> 21, 7576&#x02013;7586. \u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=11567048\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Familial+amyloid+polyneuropathy%3A+receptor+for+advanced+glycation+end+products-dependent+triggering+of+neuronal+inflammatory+and+apoptotic+pathways&#x00026;author=Sousa+M.+M.&#x00026;author=Du+Yan+S.&#x00026;author=Fernandes+R.&#x00026;author=Guimaraes+A.&#x00026;author=Stern+D.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2001&#x00026;journal=J.+Neurosci.&#x00026;volume=21&#x00026;pages=7576-7586\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a>Suenaga, G., Ikeda, T., Komohara, Y., Takamatsu, K., Kakuma, T., Tasaki, M., et al. (2016). Involvement of macrophages in the pathogenesis of familial amyloid polyneuropathy and efficacy of human ips cell-derived macrophages in its treatment. \u003Ci>PLoS One\u003C/i> 11:e0163944. doi: 10.1371/journal.pone.0163944\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=27695122\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1371/journal.pone.0163944\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Involvement+of+macrophages+in+the+pathogenesis+of+familial+amyloid+polyneuropathy+and+efficacy+of+human+ips+cell-derived+macrophages+in+its+treatment&#x00026;author=Suenaga+G.&#x00026;author=Ikeda+T.&#x00026;author=Komohara+Y.&#x00026;author=Takamatsu+K.&#x00026;author=Kakuma+T.&#x00026;author=Tasaki+M.&#x00026;+&#x00026;publication_year=2016&#x00026;journal=PLoS+One&#x00026;volume=11&#x00026;pages=e0163944\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a>Sugaya, K., Seto, S., Tsujimura, K., and Koide, Y. (2011). Mobility of late endosomal and lysosomal markers on phagosomes analyzed by fluorescence recovery after photobleaching. \u003Ci>Biochem. Biophys. Res. Commun.\u003C/i> 410, 371&#x02013;375. doi: 10.1016/j.bbrc.2011.06.023\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=21683685\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.bbrc.2011.06.023\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Mobility+of+late+endosomal+and+lysosomal+markers+on+phagosomes+analyzed+by+fluorescence+recovery+after+photobleaching&#x00026;author=Sugaya+K.&#x00026;author=Seto+S.&#x00026;author=Tsujimura+K.&#x00026;author=Koide+Y.&#x00026;publication_year=2011&#x00026;journal=Biochem.+Biophys.+Res.+Commun.&#x00026;volume=410&#x00026;pages=371-375\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a>Talukdar, S., Oh, D. Y., Bandyopadhyay, G., Li, D., Xu, J., McNelis, J., et al. (2012). Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. \u003Ci>Nat. Med.\u003C/i> 18, 1407&#x02013;1412. doi: 10.1038/nm.2885\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=22863787\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nm.2885\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Neutrophils+mediate+insulin+resistance+in+mice+fed+a+high-fat+diet+through+secreted+elastase&#x00026;author=Talukdar+S.&#x00026;author=Oh+D.+Y.&#x00026;author=Bandyopadhyay+G.&#x00026;author=Li+D.&#x00026;author=Xu+J.&#x00026;author=McNelis+J.&#x00026;+&#x00026;publication_year=2012&#x00026;journal=Nat.+Med.&#x00026;volume=18&#x00026;pages=1407-1412\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B58\" id=\"B58\">\u003C/a>Teixeira, P. F., Cerca, F., Santos, S. D., and Saraiva, M. J. (2006). Endoplasmic reticulum stress associated with extracellular aggregates. \u003Ci>J. Biol. Chem.\u003C/i> 281, 21998&#x02013;22003. doi: 10.1074/jbc.M602302200\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16751191\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1074/jbc.M602302200\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Endoplasmic+reticulum+stress+associated+with+extracellular+aggregates&#x00026;author=Teixeira+P.+F.&#x00026;author=Cerca+F.&#x00026;author=Santos+S.+D.&#x00026;author=Saraiva+M.+J.&#x00026;publication_year=2006&#x00026;journal=J.+Biol.+Chem.&#x00026;volume=281&#x00026;pages=21998-22003\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B60\" id=\"B60\">\u003C/a>Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., et al. (2003). PANTHER: a library of protein families and subfamilies indexed by function. \u003Ci>Genome Res.\u003C/i> 13, 2129&#x02013;2141. doi: 10.1101/gr.772403\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=12952881\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1101/gr.772403\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=PANTHER%3A+a+library+of+protein+families+and+subfamilies+indexed+by+function&#x00026;author=Thomas+P.+D.&#x00026;author=Campbell+M.+J.&#x00026;author=Kejariwal+A.&#x00026;author=Mi+H.&#x00026;author=Karlak+B.&#x00026;author=Daverman+R.&#x00026;+&#x00026;publication_year=2003&#x00026;journal=Genome+Res.&#x00026;volume=13&#x00026;pages=2129-2141\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B59\" id=\"B59\">\u003C/a>Thomas, M. P., Whangbo, J., McCrossan, G., Deutsch, A. J., Martinod, K., Walch, M., et al. (2014). Leukocyte protease binding to nucleic acids promotes nuclear localization and cleavage of nucleic acid binding proteins. \u003Ci>J. Immunol.\u003C/i> 192, 5390&#x02013;5397. doi: 10.4049/jimmunol.1303296\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=24771851\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4049/jimmunol.1303296\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Leukocyte+protease+binding+to+nucleic+acids+promotes+nuclear+localization+and+cleavage+of+nucleic+acid+binding+proteins&#x00026;author=Thomas+M.+P.&#x00026;author=Whangbo+J.&#x00026;author=McCrossan+G.&#x00026;author=Deutsch+A.+J.&#x00026;author=Martinod+K.&#x00026;author=Walch+M.&#x00026;+&#x00026;publication_year=2014&#x00026;journal=J.+Immunol.&#x00026;volume=192&#x00026;pages=5390-5397\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003Cdiv class=\"References\">\r\n\u003Cp class=\"ReferencesCopy1\">\u003Ca name=\"B61\" id=\"B61\">\u003C/a>Woodruff, T. M., Crane, J. W., Proctor, L. M., Buller, K. M., Shek, A. B., de Vos, K., et al. (2006). Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. \u003Ci>FASEB J.\u003C/i> 20, 1407&#x02013;1417. doi: 10.1096/fj.05-5814com\u003C/p>\r\n\u003Cp class=\"ReferencesCopy2\">\u003Ca href=\"http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&#x00026;Cmd=ShowDetailView&#x00026;TermToSearch=16816116\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1096/fj.05-5814com\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?title=Therapeutic+activity+of+C5a+receptor+antagonists+in+a+rat+model+of+neurodegeneration&#x00026;author=Woodruff+T.+M.&#x00026;author=Crane+J.+W.&#x00026;author=Proctor+L.+M.&#x00026;author=Buller+K.+M.&#x00026;author=Shek+A.+B.&#x00026;author=de+Vos+K.&#x00026;+&#x00026;publication_year=2006&#x00026;journal=FASEB+J.&#x00026;volume=20&#x00026;pages=1407-1417\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\r\n\u003C/div>\r\n\u003C/div>\r\n\u003Cdiv class=\"thinLineM20\">\u003C/div>\r\n\u003Cdiv class=\"AbstractSummary\">\r\n\u003Cp>\u003Cspan>Keywords:\u003C/span> amyloidosis, TTR, C5a receptor, macrophages, amyloid clearance\u003C/p> \r\n\u003Cp>\u003Cspan>Citation:\u003C/span> Fella E, Sokratous K, Papacharalambous R, Kyriakou K, Phillips J, Sanderson S, Panayiotou E and Kyriakides T (2017) Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy. Front. Mol. Neurosci. 10:138. doi: 10.3389/fnmol.2017.00138\u003C/p>\r\n\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 13 March 2017; \u003Cspan>Accepted:\u003C/span> 21 April 2017;\u003Cbr> \u003Cspan>Published:\u003C/span> 10 May 2017.\u003C/p>\r\n\u003Cdiv>\u003Cp>Edited by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/75238/overview\">Detlev Boison\u003C/a>, Legacy Health, USA\u003C/div>\r\n\u003Cdiv>\u003Cp>Reviewed by:\u003C/p> \u003Ca href=\"http://loop.frontiersin.org/people/82207/overview\">Ursula Susan Sandau\u003C/a>, Oregon Health &#x00026; Science University, USA\u003Cbr> \u003Ca href=\"http://loop.frontiersin.org/people/124888/overview\">David Blum\u003C/a>, Institut National de la Sant&#x000E9; et de la Recherche M&#x000E9;dicale (INSERM), France\u003C/div>\r\n\u003Cp>\u003Cspan>Copyright\u003C/span> &#x000A9; 2017 Fella, Sokratous, Papacharalambous, Kyriakou, Phillips, Sanderson, Panayiotou and Kyriakides. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\r\n\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Theodoros Kyriakides, \u003Ca id=\"encmail\">dGhlb2RvcmVAY2luZy5hYy5jeQ==\u003C/a>\u003C/p>\r\n\u003Cp>\u003Cspan>\u003Csup>&#x02020;\u003C/sup>\u003C/span> These authors have contributed equally to this work.\u003C/p>\r\n\u003Cdiv class=\"clear\">\u003C/div>\r\n\u003C/div>","\u003Cul class=\"flyoutJournal\">\r\n\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h3\">Materials and Methods\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h6\">Author Contributions\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h7\">Funding\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h8\">Conflict of Interest Statement\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h9\">Acknowledgments\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h10\">Supplementary Material\u003C/a>\u003C/li>\r\n\u003Cli>\u003Ca href=\"#h11\">References\u003C/a>\u003C/li>\r\n\u003C/ul>",[637,642,648,651,657],{"name":638,"fileServerPackageEntryId":19,"fileServerId":639,"fileServerVersionNumber":361,"type":640},"EPUB.epub","266403/epub",{"code":641,"name":641},"EPUB",{"name":643,"fileServerPackageEntryId":644,"fileServerId":645,"fileServerVersionNumber":361,"type":646},"fnmol-10-00138.pdf","fnmol-10-00138/fnmol-10-00138.pdf","266403/pubmed-zip",{"code":647,"name":647},"PDF",{"name":643,"fileServerPackageEntryId":19,"fileServerId":649,"fileServerVersionNumber":361,"type":650},"266403/publishers-proof/pdf",{"code":647,"name":647},{"name":652,"fileServerPackageEntryId":653,"fileServerId":645,"fileServerVersionNumber":361,"type":654},"fnmol-10-00138.xml","fnmol-10-00138/fnmol-10-00138.xml",{"code":655,"name":656},"NLM_XML","XML",{"name":658,"fileServerPackageEntryId":19,"fileServerId":659,"fileServerVersionNumber":361,"type":660},"Provisional PDF.pdf","266403/provisional-pdf",{"code":647,"name":647},"v3",{"title":663,"link":664,"meta":668,"script":790},"Frontiers | Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy",[665],{"rel":666,"href":667},"canonical","https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/full",[669,672,675,677,680,684,687,691,694,697,700,702,704,706,708,710,713,716,718,721,723,725,728,731,734,737,740,744,748,751,754,757,759,762,765,768,771,774,777,780,782,785,787],{"hid":670,"property":670,"name":670,"content":671},"description","Hereditary ATTR V30M amyloidosis is a lethal autosomal dominant sensorimotor and autonomic neuropathy caused by deposition of aberrant transthyretin (TTR). I...",{"hid":673,"property":673,"name":674,"content":663},"og:title","title",{"hid":676,"property":676,"name":670,"content":671},"og:description",{"hid":678,"name":678,"content":679},"keywords","Amyloidosis,TTR,C5a receptor,Macrophages,amyloid clearance",{"hid":681,"property":681,"name":682,"content":683},"og:site_name","site_name","Frontiers",{"hid":685,"property":685,"name":354,"content":686},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/266403/fnmol-10-00138-HTML/image_m/fnmol-10-00138-g001.jpg",{"hid":688,"property":688,"name":689,"content":690},"og:type","type","article",{"hid":692,"property":692,"name":693,"content":667},"og:url","url",{"hid":695,"name":695,"content":696},"twitter:card","summary_large_image",{"hid":698,"name":698,"content":699},"citation_volume","10",{"hid":701,"name":701,"content":116},"citation_journal_title",{"hid":703,"name":703,"content":683},"citation_publisher",{"hid":705,"name":705,"content":618},"citation_journal_abbrev",{"hid":707,"name":707,"content":619},"citation_issn",{"hid":709,"name":709,"content":506},"citation_doi",{"hid":711,"name":711,"content":712},"citation_firstpage","266403",{"hid":714,"name":714,"content":715},"citation_language","English",{"hid":717,"name":717,"content":507},"citation_title",{"hid":719,"name":719,"content":720},"citation_keywords","Amyloidosis; TTR; C5a receptor; Macrophages; amyloid clearance",{"hid":722,"name":722,"content":512},"citation_abstract",{"hid":724,"name":724,"content":515},"citation_article_type",{"hid":726,"name":726,"content":727},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/pdf",{"hid":729,"name":729,"content":730},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2017.00138/xml",{"hid":732,"name":732,"content":733},"citation_fulltext_world_readable","yes",{"hid":735,"name":735,"content":736},"citation_online_date","2017/04/21",{"hid":738,"name":738,"content":739},"citation_publication_date","2017/05/10",{"hid":741,"name":742,"content":743},"citation_author_0","citation_author","Fella, Eleni ",{"hid":745,"name":746,"content":747},"citation_author_institution_0","citation_author_institution","Neurology Clinic A, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus",{"hid":749,"name":742,"content":750},"citation_author_1","Sokratous, Kleitos ",{"hid":752,"name":746,"content":753},"citation_author_institution_1","Electron Microscopy and Molecular Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus",{"hid":755,"name":742,"content":756},"citation_author_2","Papacharalambous, Revekka ",{"hid":758,"name":746,"content":747},"citation_author_institution_2",{"hid":760,"name":742,"content":761},"citation_author_3","Kyriacou, Kyriacos ",{"hid":763,"name":746,"content":764},"citation_author_institution_3","Cyprus School of Molecular Medicine, Nicosia, Cyprus",{"hid":766,"name":742,"content":767},"citation_author_4","Phillips, Joy ",{"hid":769,"name":746,"content":770},"citation_author_institution_4","Donald P. Shiley Bioscience Center, San Diego State University, San Diego, CA, USA",{"hid":772,"name":742,"content":773},"citation_author_5","Sanderson, Sam ",{"hid":775,"name":746,"content":776},"citation_author_institution_5","Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA",{"hid":778,"name":742,"content":779},"citation_author_6","Panayiotou, Elena ",{"hid":781,"name":746,"content":747},"citation_author_institution_6",{"hid":783,"name":742,"content":784},"citation_author_7","Kyriakides, Theodoros ",{"hid":786,"name":746,"content":747},"citation_author_institution_7",{"hid":788,"name":788,"content":789},"dc.identifier","doi:10.3389/fnmol.2017.00138",[791,794,796,798,800],{"src":792,"body":13,"type":793,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":795,"body":13,"type":793,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":797,"body":13,"type":793,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":799,"body":13,"type":793,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fnmol.2017.00138?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":801,"body":13,"type":793,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":803,"articleHubArticlesList":804,"canJournalHasArticleHub":295,"articleDoiList":805},{},[],[],{"title":19,"image":-1,"breadcrumbs":807,"linksCollection":808,"metricsCollection":810},[],{"total":358,"items":809},[],{"total":358,"items":811},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fnmol.2017.00138?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>